<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Darbepoetin for the anaemia of chronic kidney disease - Palmer, SC - 2014 | Cochrane Library</title> <meta content="Darbepoetin for the anaemia of chronic kidney disease - Palmer, SC - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009297.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Darbepoetin for the anaemia of chronic kidney disease - Palmer, SC - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009297.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009297.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Darbepoetin for the anaemia of chronic kidney disease" name="citation_title"/> <meta content="Suetonia C Palmer" name="citation_author"/> <meta content="University of Otago Christchurch" name="citation_author_institution"/> <meta content="Valeria Saglimbene" name="citation_author"/> <meta content="Mario Negri Sud Consortium" name="citation_author_institution"/> <meta content="Jonathan C Craig" name="citation_author"/> <meta content="The University of Sydney" name="citation_author_institution"/> <meta content="Sankar D Navaneethan" name="citation_author"/> <meta content="Glickman Urological and Kidney Institute, Cleveland Clinic" name="citation_author_institution"/> <meta content="Giovanni FM Strippoli" name="citation_author"/> <meta content="strippoli@negrisud.it" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD009297.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/03/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009297.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009297.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009297.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anemia [*drug therapy, etiology]; Darbepoetin alfa; Epoetin Alfa; Erythropoietin [*analogs &amp; derivatives, therapeutic use]; Hematinics [*therapeutic use]; Kidney Transplantation; Polyethylene Glycols [therapeutic use]; Randomized Controlled Trials as Topic; Recombinant Proteins [therapeutic use]; Renal Insufficiency, Chronic [*complications]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009297.pub2&amp;doi=10.1002/14651858.CD009297.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="nnwvukoo";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009297\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009297\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009297.pub2",title:"Darbepoetin for the anaemia of chronic kidney disease",firstPublishedDate:"Mar 31, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009297.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009297.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009297.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009297.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009297.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009297.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009297.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009297.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009297.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009297.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3840 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009297.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/full#CD009297-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/full#CD009297-sec-0081"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/full#CD009297-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/full#CD009297-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/full#CD009297-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/full#CD009297-sec-0048"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/full#CD009297-sec-0075"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/appendices#CD009297-sec-0086"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/table_n/CD009297StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/table_n/CD009297StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Darbepoetin for the anaemia of chronic kidney disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/information#CD009297-cr-0002">Suetonia C Palmer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/information#CD009297-cr-0003">Valeria Saglimbene</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/information#CD009297-cr-0004">Jonathan C Craig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/information#CD009297-cr-0005">Sankar D Navaneethan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009297.pub2/information#CD009297-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Giovanni FM Strippoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/information/en#CD009297-sec-0092">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 March 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009297.pub2">https://doi.org/10.1002/14651858.CD009297.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009297-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009297-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009297-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009297-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009297-abs-0002">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009297-abs-0001" lang="en"> <section id="CD009297-sec-0001"> <h3 class="title" id="CD009297-sec-0001">Background</h3> <p>Erythropoiesis‐stimulating agents are used to treat anaemia in people with chronic kidney disease (CKD). Several agents are available including epoetin alfa or beta as well as agents with a longer duration of action, darbepoetin alfa and methoxy polyethylene glycol‐epoetin beta. </p> </section> <section id="CD009297-sec-0002"> <h3 class="title" id="CD009297-sec-0002">Objectives</h3> <p>To assess the benefits and harms of darbepoetin alfa to treat anaemia in adults and children with CKD (stages 3 to 5, 5D, and kidney transplant recipients). </p> </section> <section id="CD009297-sec-0003"> <h3 class="title" id="CD009297-sec-0003">Search methods</h3> <p>We searched the Cochrane Renal Group's Specialised Register (to 13 January 2014) through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE and EMBASE. </p> </section> <section id="CD009297-sec-0004"> <h3 class="title" id="CD009297-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials of any darbepoetin alfa treatment of at least three months duration in adults or children with CKD (any stage). </p> </section> <section id="CD009297-sec-0005"> <h3 class="title" id="CD009297-sec-0005">Data collection and analysis</h3> <p>Data were extracted by two independent investigators. Patient‐centred outcomes (need for blood transfusion, iron therapy, progression of kidney disease, total and cardiovascular mortality, cardiovascular events, cancer, hypertension, seizures, and health‐related quality of life) and other outcomes (haemoglobin levels) were assessed using random effects meta‐analysis. We calculated risk ratios for dichotomous outcomes and mean differences for continuous outcomes, both with 95% confidence intervals. </p> </section> <section id="CD009297-sec-0006"> <h3 class="title" id="CD009297-sec-0006">Main results</h3> <p>We identified 32 studies comprising 9414 participants; 21 studies in 8328 participants could be included in our meta‐analyses. One study (4038 participants) compared darbepoetin alfa to placebo, 16 studies (2955 participants) compared darbepoetin alfa to epoetin alfa or beta, four studies (1198 participants) compared darbepoetin alfa to methoxy polyethylene glycol‐epoetin beta, three studies (420 participants) compared more frequent with less frequent darbepoetin alfa administration and four studies (303 participants) compared intravenous with subcutaneous darbepoetin alfa administration. </p> <p>In a single large study, darbepoetin alfa reduced the need for blood transfusion and iron therapy compared with placebo in adults with CKD stage 3 to 5, but had little or no effect on survival, increased risks of hypertension, and had uncertain effects on quality of life. Data comparing darbepoetin alfa with epoetin alfa or beta or methoxy polyethylene glycol‐epoetin beta were sparse and inconclusive. Comparisons of differing dosing schedules and routes of administration were compared in small numbers of participants and studies. Evidence for treatment effects of darbepoetin alfa were particularly limited for children with CKD, adults with CKD stage 5D, and recipients of a kidney transplant. </p> <p>Studies included in this review were generally at high or unclear risk of bias for all items (random sequence generation, allocation concealment, incomplete outcome data, blinding of participants and personnel, blinding of outcome assessment, selective outcome reporting, intention to treat analysis and other sources of bias). One large study comparing darbepoetin alfa with placebo was at low risk of bias for most items assessed. </p> </section> <section id="CD009297-sec-0007"> <h3 class="title" id="CD009297-sec-0007">Authors' conclusions</h3> <p>Data suggest that darbepoetin alfa effectively reduces need for blood transfusions in adults with CKD stage 3 to 5, but has little or no effect on mortality or quality of life. The effects of darbepoetin alfa in adults with CKD stage 5D and kidney transplant recipients and children with CKD remain uncertain as do the relative benefits and harms of darbepoetin alfa compared with other ESAs (epoetin alfa or beta and methoxy polyethylene glycol‐epoetin beta). </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009297-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009297-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009297-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009297-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009297-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009297-abs-0004" lang="en"> <h3>Darbepoetin alfa to treat anaemia in people with chronic kidney disease</h3> <p>People who have chronic kidney disease (CKD) frequently experience anaemia. Several different medicines that treat anaemia are available including darbepoetin alfa. </p> <p>We investigated whether darbepoetin alfa might have different effects in people with CKD compared to placebo or no treatment, or similar other treatment options called epoetin or methoxy polyethylene glycol‐epoetin beta, and whether differing ways of administering darbepoetin (route and frequency of treatment) might have different benefits and harms for people who have CKD. </p> <p>While darbepoetin alfa reduced the need for patients to have blood transfusions to treat severe anaemia, darbepoetin alfa had little or no effect on survival or chances of needing dialysis therapy and their overall quality of life. </p> <p>There were not enough studies comparing darbepoetin alfa with other similar treatment options to provide sufficient information to guide clinical decision‐making about choosing which medicine is best for an individual patient. </p> <p>Little information was available about darbepoetin treatment for children who have CKD and adults who have received a kidney transplant or those treated with dialysis. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009297-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009297-sec-0081"></div> <h3 class="title" id="CD009297-sec-0082">Implications for practice</h3> <section id="CD009297-sec-0082"> <p>Currently, available data dominated by a single study suggest that darbepoetin alfa reduces the need for blood transfusion therapy but may increase risks of hypertension and does not clinically improve quality of life or survival in adults with diabetes and CKD stage 3 to 5. On the basis of this review, it remains unclear whether specific classes of ESAs (darbepoetin alfa, epoetin or methoxy polyethylene glycol‐epoetin beta) have differing effectiveness and safety when treating anaemia in people with CKD and especially for children with CKD and adult recipients of a kidney transplant. </p> </section> <h3 class="title" id="CD009297-sec-0083">Implications for research</h3> <section id="CD009297-sec-0083"> <p>The relative effectiveness and safety of different types of erythropoietin‐stimulating agents (darbepoetin alfa, epoetin, and methoxy polyethylene glycol‐epoetin beta) remain uncertain due to a lack of directly comparative studies measuring patient‐relevant outcomes. Given that additional comparative studies of darbepoetin alfa are unlikely and that a large number of studies of anaemia treatment are already available, a network meta‐analysis of RCTs would allow the integration of direct treatment comparisons within studies and indirect treatment comparisons between studies and provide information about the relative benefits and harms of different ESAs (epoetin, darbepoetin alfa, and methoxy polyethylene glycol‐epoetin beta) when treating anaemia in chronic disease. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009297-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009297-sec-0022"></div> <section id="CD009297-sec-0023"> <h3 class="title" id="CD009297-sec-0023">Description of the condition</h3> <p>Anaemia is common in individuals with chronic kidney disease (CKD) largely due to reduced erythropoietin production, iron deficiency, and a shortened red blood cell life span. The observation that anaemia in CKD is associated with fatigue and impaired quality of life (<a href="./references#CD009297-bbs2-0079" title="FinkelsteinFO , StoryK , FiranekC , MendelssohnD , BarreP , TakanoT , et al. Health‐related quality of life and hemoglobin levels in chronic kidney disease patients. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):33‐8. [MEDLINE: 18987300] ">Finkelstein 2009</a>; <a href="./references#CD009297-bbs2-0081" title="GersonA , HwangW , FiorenzaJ , BarthK , KaskelF , WeissL , et al. Anemia and health‐related quality of life in adolescents with chronic kidney disease. American Journal of Kidney Diseases2004;44(6):1017‐23. [MEDLINE: 15558522] ">Gerson 2004</a>), cardiac injury, and premature death (<a href="./references#CD009297-bbs2-0075" title="AstorBC , CoreshJ , HeissG , PettittD , SarnakMJ . Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. American Heart Journal2006;151(2):492‐500. [MEDLINE: 16442920] ">Astor 2006</a>; <a href="./references#CD009297-bbs2-0082" title="GlassockRJ , Pecoits‐FilhoR , BarberatoSH . Left ventricular mass in chronic kidney disease and ESRD. Clinical Journal of The American Society of Nephrology: CJASN2009;4 Suppl 1:S79‐91. [MEDLINE: 19996010] ">Glassock 2009</a>; <a href="./references#CD009297-bbs2-0088" title="LevinA , ThompsonCR , EthierJ , CarlisleEJ , TobeS , MendelssohnD , et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. American Journal of Kidney Diseases1999;34(1):125‐34. [MEDLINE: 10401026] ">Levin 1999</a>; <a href="./references#CD009297-bbs2-0090" title="LocatelliF , PisoniRL , CombeC , BommerJ , AndreucciVE , PieraL , et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology Dialysis Transplantation2004;19(1):121‐32. [MEDLINE: 14671047] ">Locatelli 2004a</a>), together with the desire to avoid treatment with red cell transfusions has resulted in the routine practice of correcting anaemia with recombinant human erythropoietin and iron supplementation. Recombinant human erythropoietin (epoetin alfa or beta) stimulates bone marrow erythrocyte production and is administered 2 to 3 times each week either into the vein (intravenous, IV) or beneath the skin (subcutaneous, SC). </p> </section> <section id="CD009297-sec-0024"> <h3 class="title" id="CD009297-sec-0024">Description of the intervention</h3> <p>To simplify anaemia management by reducing the frequency of administration, erythropoiesis‐stimulating agents (ESAs) including darbepoetin alfa and methoxy polyethylene glycol‐epoetin beta have been developed and can be administered less often (once every one to two weeks for darbepoetin alfa and monthly for methoxy polyethylene glycol‐epoetin beta) than epoetin. Because of its increased sialic acid‐containing carbohydrate content, darbepoetin alfa has a longer (three‐fold) terminal half‐life in animal models and in humans (<a href="./references#CD009297-bbs2-0044" title="MacdougallIC , GraySJ , ElstonO , BreenC , JenkinsB , BrowneJ , et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. Journal of the American Society of Nephrology1999;10(11):2392‐5. [MEDLINE: 10541299] MacdougallIC , GraySJ , McEvoyO , BreenC , JenkinsB , BrowneJ , et al. Comparison of the pharmacokinetics of novel erythropoiesis stimulating protein (NESP) and epoetin alfa (rhEPO) in dialysis patients [abstract no: A1233]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):268A. [CENTRAL: CN‐00446519] ">Macdougall 1999</a>) when compared with epoetin alfa or beta. Clinical studies have shown that darbepoetin alfa is effective for achieving and maintaining target haemoglobin (Hb) levels in CKD patients (<a href="./references#CD009297-bbs2-0089" title="LocatelliF , OlivaresJ , WalkerR , WilkieM , the European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced frequency compared with recombinant human erythropoietin (r‐HuEPO) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):283A. [CENTRAL: CN‐00626023] ">Locatelli 2000</a>; <a href="./references#CD009297-bbs2-0091" title="MacdougallIC . Novel erythropoiesis stimulating protein. Seminars in Nephrology2000;20(4):375‐81. [MEDLINE: 10928340] ">Macdougall 2000</a>; <a href="./references#CD009297-bbs2-0045" title="MacdougallIC . Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in ESRD patients [abstract]. 37th Congress. European Renal Association. European Dialysis and Transplantation Association. European Kidney Research Organisation; 2000 Sept 17‐20; Nice, France. 2000:237. [CENTRAL: CN‐00461229] MacdougallIC . Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in ESRD patients [abstract]. Nephrology Dialysis Transplantation2000;15(9):A160. MacdougallIC , MatchamJ , GraySJ , NESP 960245/246 Study Group. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrology Dialysis Transplantation2003;18(3):576‐81. [MEDLINE: 12584282] MacdougallIC , UK NESP Study Group. Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):258A‐9A. [CENTRAL: CN‐00446518] ">Macdougall 2003</a>; <a href="./references#CD009297-bbs2-0095" title="PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] ">Pfeffer 2009</a>). </p> </section> <section id="CD009297-sec-0025"> <h3 class="title" id="CD009297-sec-0025">How the intervention might work</h3> <p>Clinical practice guidelines for ESAs to treat anaemia due to CKD were issued in 2001; European Best Practice Guidelines (EBPG) for anaemia management recommended the use of darbepoetin alfa or epoetin alfa or beta in all CKD patients (<a href="./references#CD009297-bbs2-0078" title="LocatelliF , AljamaP , BaranyP , CanaudB , CarreraF , EckardtKU , et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrology Dialysis Transplantation2004;19 Suppl 2:ii1‐47. [MEDLINE: 15206425] ">EBPG 2004</a>; <a href="./references#CD009297-bbs2-0092" title="AljamaP , BommerJ , CanaudB , CarreraF , EckardtKU , HorlWH , et al. Practical guidelines for the use of NESP in treating renal anaemia. Nephrology Dialysis Transplantation2001;16 Suppl 3:22‐8. [MEDLINE: 11402087] ">NESP 2001</a>). An update of the National Kidney Foundation‐Kidney Disease Outcomes and Quality initiative (NKF‐KDOQI) guidelines on anaemia management in 2006 did not suggest any specific epoetin type when treating CKD patients (<a href="./references#CD009297-bbs2-0087" title="KDOQI. National Kidney Foundation. Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Adults. American Journal of Kidney Diseases2006;47(5 Suppl 3):S16‐85. [MEDLINE: 16678661] ">KDOQI 2006</a>) and recommended darbepoetin alfa or epoetin alfa or beta to manage the symptoms of anaemia. Clinical studies dating back to 1998 have now consistently shown that targeting near‐normal Hb levels using ESAs is associated with increased risks of stroke and hypertension, without improving survival, quality of life, or reducing cardiovascular events (<a href="./references#CD009297-bbs2-0076" title="BesarabA , BoltonWK , BrowneJK , EgrieJC , NissensonAR , OkamotoDM , et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine1998;339(9):584‐90. [MEDLINE: 9718377] ">Besarab 1998</a>; <a href="./references#CD009297-bbs2-0077" title="DruekeTB , LocatelliF , ClyneN , EckardtKU , MacdougallIC , TsakirisD , et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine2006;355(20):2071‐84. [MEDLINE: 17108342] ">Drueke 2006</a>; <a href="./references#CD009297-bbs2-0095" title="PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] ">Pfeffer 2009</a>; <a href="./references#CD009297-bbs2-0097" title="SinghAK , SzczechL , TangKL , BarnhartH , SappS , WolfsonM , et al. Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine2006;355(20):2085‐98. [MEDLINE: 17108343] ">Singh 2006</a>), although direct comparative studies between differing epoetins are lacking. </p> <p>Guidelines for anaemia management in CKD recently published by the Kidney Disease: Improving global Outcomes (KDIGO) group in 2012 (<a href="./references#CD009297-bbs2-0086" title="Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International ‐ Supplement2012;2:279‐335. ">KDIGO 2012</a>) now recommend balancing the potential benefits from ESAs (e.g. reducing blood transfusions and anaemia‐related symptoms) against the risks for harm (e.g. stroke, dialysis vascular access loss, and hypertension). KDIGO guidelines also recommend that the choice of specific epoetin (including darbepoetin alfa) is based on pharmacokinetic information, safety data, clinical outcome data, cost and availability, and that decisions about the relative benefits and harms of differing ESAs (epoetin, darbepoetin and methoxy polyethylene glycol‐epoetin beta) are currently based on very low quality evidence. </p> </section> <section id="CD009297-sec-0026"> <h3 class="title" id="CD009297-sec-0026">Why it is important to do this review</h3> <p>Previous meta‐analyses relating to the management of anaemia with epoetins in CKD have focused on either the Hb targets or have included all epoetin agents in their analyses (<a href="./references#CD009297-bbs2-0080" title="GandraSR , FinkelsteinFO , BennettAV , LewisEF , BrazgT , MartinML . Impact of erythropoiesis‐stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. American Journal of Kidney Diseases2010;55(3):519‐34. [MEDLINE: 20031287] ">Gandra 2010</a>; <a href="./references#CD009297-bbs2-0085" title="JohansenKL , FinkelsteinFO , RevickiDA , GitlinM , EvansC , MayneTJ . Systematic review and meta‐analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis‐stimulating agents. American Journal of Kidney Diseases2010;55(3):535‐48. [MEDLINE: 20133033] ">Johansen 2010</a>; <a href="./references#CD009297-bbs2-0093" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , TonelliM , GargAX , et al. Meta‐analysis: erythropoiesis‐stimulating agents in patients with chronic kidney disease. Annals of Internal Medicine2010;153(1):23‐33. [MEDLINE: 20439566] ">Palmer 2010</a>; <a href="./references#CD009297-bbs2-0094" title="ParfreyPS , LauveM , Latremouille‐ViauD , LefebvreP . Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta‐analysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(4):755‐62. [MEDLINE: 19339417] ">Parfrey 2009</a>; <a href="./references#CD009297-bbs2-0096" title="PhrommintikulA , HaasSJ , ElsikM , KrumH . Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta‐analysis. Lancet2007;369(9559):381‐8. [MEDLINE: 17276778] ">Phrommintikul 2007</a>; <a href="./references#CD009297-bbs2-0098" title="StrippoliGF , NavaneethanSD , CraigJC , PalmerSP . Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD003967.pub2] ">Strippoli 2006</a>). To date, no systematic review of randomised controlled trials (RCTs) has evaluated the relative benefits and harms of darbepoetin alfa directly compared with placebo or other epoetins when treating the anaemia of CKD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009297-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009297-sec-0027"></div> <p>To assess the benefits and harms of darbepoetin alfa to treat anaemia in people with CKD (stages 3 to 5, and 5D, and kidney transplant recipients). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009297-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009297-sec-0028"></div> <section id="CD009297-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009297-sec-0030"> <h4 class="title">Types of studies</h4> <p>All RCTs and quasi‐RCTs (studies in which the allocation of treatment is not truly random, such as allocation by birth date, alternation, hospital number, or other predictable methods) of darbepoetin alpha alone or in combination with other non‐randomised co‐interventions (e.g. iron supplementation, or red cell transfusion) in individuals with anaemia and CKD (ESA‐naive patients and conversion from other ESAs) were included. The first period of randomised cross‐over studies was also considered. Studies were considered without language restriction. Studies were of at least three months in duration. </p> </section> <section id="CD009297-sec-0031"> <h4 class="title">Types of participants</h4> <p> <ul id="CD009297-list-0001"> <li> <p>Individuals with stage 3, 4, and 5 CKD (including patients on dialysis) as defined by the NKF‐KDOQI guidelines. </p> <ul id="CD009297-list-0002"> <li> <p>Stage 3: glomerular filtration rate (GFR) 30 to 59 mL/min/1.73 m²</p> </li> <li> <p>Stage 4: GFR 16 to 29 mL/min/1.73 m²</p> </li> <li> <p>Stage 5: GFR &lt; 15 mL/min/1.73 m²</p> </li> <li> <p>Stage 5D: GFR &lt; 15 mL/min/1.73 m² (treated with dialysis)</p> </li> </ul> </li> <li> <p>Kidney transplant recipients</p> </li> <li> <p>Adults and children</p> </li> </ul> </p> </section> <section id="CD009297-sec-0032"> <h4 class="title">Types of interventions</h4> <p>Studies of darbepoetin alfa by any route (SC or IV) or dose, compared with epoetin alfa or beta, methoxy polyethylene glycol‐epoetin beta, placebo, or no treatment were included. </p> <p>The following comparisons were considered for inclusion.</p> <p> <ul id="CD009297-list-0003"> <li> <p>Darbepoetin alfa versus placebo or no treatment</p> </li> <li> <p>Darbepoetin alfa versus epoetin alfa or beta</p> </li> <li> <p>Darbepoetin alfa versus methoxy polyethylene glycol‐epoetin beta</p> </li> <li> <p>Darbepoetin alfa (IV versus SC)</p> </li> <li> <p>Darbepoetin alfa with different strategies of administration (e.g. using higher versus lower doses, targeting higher versus lower Hb levels) and different dosing regimens (frequent versus extended dosing regimens) </p> </li> </ul> </p> </section> <section id="CD009297-sec-0033"> <h4 class="title">Types of outcome measures</h4> <p> <ul id="CD009297-list-0004"> <li> <p>Achieving and maintaining Hb levels as recommended by the NKF‐KDOQI guidelines. The following parameters were analysed for each planned treatment comparison. </p> <ul id="CD009297-list-0005"> <li> <p>Number of individuals achieving the recommended Hb levels during the study period</p> </li> <li> <p>Time to achieve a Hb concentration of 11 g/dL (days)</p> </li> <li> <p>Mean change in Hb (mg/dL) and haematocrit (HCT) values (%) at the end of treatment period </p> </li> <li> <p>Number of blood transfusions during the study period</p> </li> <li> <p>Number of individuals requiring one or more red cell transfusions.</p> </li> <li> <p>Number of individuals requiring iron supplementation during the study period</p> </li> <li> <p>Number of patients who exceed a Hb concentration of 12 g/dL or more on one or more occasions during the study period </p> </li> <li> <p>Number of patients who fall below or exceed the therapeutic Hb target range of the included studies (e.g. 11 to 12 g/dL) </p> </li> </ul> </li> <li> <p>Progression of CKD in patients not yet requiring renal replacement therapy (RRT: haemodialysis, peritoneal dialysis or kidney transplantation). </p> <ul id="CD009297-list-0006"> <li> <p>End of treatment GFR (mL/min/1.73 m²)</p> </li> <li> <p>Change in GFR (mL/min/1.73 m²) based on Modification of Diet in Renal Disease (MDRD) equation or other estimating equations (eGFR), as reported in the studies </p> </li> <li> <p>Number of patients with doubling of serum creatinine or who develop CKD defined as GFR &lt; 60 mL/min/1.73 m² </p> </li> <li> <p>Progression of CKD to end‐stage kidney disease (ESKD) requiring RRT</p> </li> </ul> </li> <li> <p>Clinical outcomes</p> <ul id="CD009297-list-0007"> <li> <p>Cardiovascular events: non‐fatal myocardial infarction; fatal or non‐fatal myocardial infarction; non‐fatal stroke; fatal or non‐fatal stroke; need for revascularization procedures (any vascular ‐ coronary artery, carotid artery, peripheral vascular) </p> </li> <li> <p>Hospital admissions: number of individuals who are hospitalised one or more times/number of individuals at risk, or mean number of days of hospitalisation/number of days at risk </p> </li> <li> <p>Cardiovascular mortality</p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Vascular access thrombosis: number of individuals with one or more episodes of thrombosis; number of individuals with one or more episodes of requiring surgical intervention for vascular access (loss of unassisted patency) </p> </li> <li> <p>Cancer: onset of new documented cancer, or as defined by the investigators</p> </li> </ul> </li> <li> <p>Quality of life</p> <ul id="CD009297-list-0008"> <li> <p>End of treatment scores obtained using validated tools such as 36‐item Short Form General Health Survey questionnaire (SF‐36) and Kidney Disease Quality of Life (KDQOL) tool or others as mentioned in the studies. We will assess the studies for evidence of selective reporting of outcomes, reviewing study protocols where necessary. If studies report quality of life outcomes using heterogeneous outcomes, we will tabulate these outcomes when meta‐analysis is not possible. </p> </li> </ul> </li> <li> <p>Adverse events</p> <ul id="CD009297-list-0009"> <li> <p>Seizures</p> </li> <li> <p>Hyperkalaemia</p> </li> <li> <p>Vascular access thrombosis</p> </li> <li> <p>Hypertension (one or more hypertensive events requiring additional antihypertensive medication or as defined by the investigators; end of treatment blood pressure) </p> </li> <li> <p>Injection site‐related events (e.g. lipodystrophy, burning sensation)</p> </li> </ul> </li> </ul> </p> </section> </section> <section id="CD009297-sec-0034"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009297-sec-0035"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Renal Group's Specialised Register (up to 13 January 2014) through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. </p> <p>The Cochrane Renal Group’s Specialised Register contains studies identified from:</p> <p> <ol id="CD009297-list-0010"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of renal‐related journals and the proceedings of major renal conferences;</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected renal journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Renal Group</a>. </p> <p>See <a href="./appendices#CD009297-sec-0087">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD009297-sec-0036"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD009297-list-0011"> <li> <p>Reference lists of clinical practice guidelines, review articles and relevant studies.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD009297-sec-0037"> <h3 class="title" id="CD009297-sec-0037">Data collection and analysis</h3> <section id="CD009297-sec-0038"> <h4 class="title">Selection of studies</h4> <p>The search strategy was used to obtain citations that were relevant to this review. The titles and abstracts of all retrieved citations were screened by two or more independent authors who discarded citations that were not applicable. All citations for studies and reviews that might have reported relevant data or information on available studies were retained initially. The same authors independently assessed the full text of these citations to determine which report studies that satisfied the inclusion criteria. Reasons for exclusion from the review at this stage were recorded. </p> </section> <section id="CD009297-sec-0039"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions these data were used. Any discrepancy between published versions was highlighted. Disagreements during the study identification and data extraction process were resolved in consultation with the other authors. </p> </section> <section id="CD009297-sec-0040"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were assessed independently by two authors using the risk of bias assessment tool (<a href="./references#CD009297-bbs2-0084" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (<i>see</i><a href="./appendices#CD009297-sec-0088">Appendix 2</a>). </p> <p> <ul id="CD009297-list-0012"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)? </p> <ul id="CD009297-list-0013"> <li> <p>Participants and personnel</p> </li> <li> <p>Outcome assessors</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD009297-sec-0041"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (all‐cause mortality, doubling of serum creatinine, progression to ESKD, adverse effects of treatment, number of patients who were hospitalised) results were expressed as risk ratios (RR) together with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (change in mean Hb and HCT values, blood pressure, change in GFR, days of hospitalisation), the mean difference (MD) was used. </p> </section> <section id="CD009297-sec-0042"> <h4 class="title">Dealing with missing data</h4> <p>Any further information required from the original author was requested by written correspondence (e.g. emailing or writing to corresponding author) and any relevant information obtained in this manner was included in the review. Evaluation of important numerical data such as screened and randomised patients as well as intention‐to‐treat, as‐treated and per‐protocol populations were carefully performed. Attrition rates (e.g. drop‐outs, losses to follow‐up and withdrawals) were investigated. Issues of missing data and imputation methods (e.g. last‐observation‐carried‐forward) were critically appraised (<a href="./references#CD009297-bbs2-0084" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) where possible. </p> </section> <section id="CD009297-sec-0043"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi² test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<a href="./references#CD009297-bbs2-0083" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I² values of 25%, 50% and 75% corresponded to low, medium and high levels of heterogeneity. </p> </section> <section id="CD009297-sec-0044"> <h4 class="title">Assessment of reporting biases</h4> <p>Insufficient data were available to generate funnel plots to assess for the potential existence of small study bias (<a href="./references#CD009297-bbs2-0084" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD009297-sec-0045"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model but the fixed‐effect model was also analysed to ensure robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD009297-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses were prespecified to explore possible sources of heterogeneity (e.g. participants, treatments and study quality). Heterogeneity among participants could be related to age, stage of CKD and modalities of dialysis used. Heterogeneity in interventions could be related to dose and duration of darbepoetin alpha treatment, route of administration and the use of iron supplements. Prespecified subgroup analyses included: </p> <p> <ul id="CD009297-list-0014"> <li> <p>CKD stage: stages 3 to 5 versus stage 5D</p> </li> <li> <p>Study design: darbepoetin alfa compared to epoetin alfa versus darbepoetin alfa compared to placebo or no treatment. </p> </li> <li> <p>Baseline Hb: ≥ 11 g/dL versus<i>&lt;</i> 11 g/dL </p> </li> <li> <p>Baseline age: ≥ 60 years versus<i>&lt;</i> 60 years </p> </li> <li> <p>Proportion with cardiovascular disease: ≥ 70% versus &lt; 70%</p> </li> <li> <p>Proportion with diabetes mellitus: ≥ 25% versus &lt; 25%</p> </li> <li> <p>Proportion with hypertension: ≥ 70% versus &lt; 70%</p> </li> <li> <p>Duration of intervention: &lt; 5 months, 5 to 12 months, 1 to 2 years, &gt; 2 years</p> </li> <li> <p>Risks of bias items: allocation concealment, selective reporting</p> </li> <li> <p>Number of participants: &lt; 500, ≥ 500</p> </li> <li> <p>Paediatric versus adult participants.</p> </li> </ul> </p> </section> <section id="CD009297-sec-0047"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analyses in order to explore the influence of the following factors on effect size, although insufficient data were available to complete such analyses. </p> <p> <ul id="CD009297-list-0015"> <li> <p>Repeating the analysis excluding unpublished studies.</p> </li> <li> <p>Repeating the analysis taking account of risk of bias items, as specified above.</p> </li> <li> <p>Repeating the analysis excluding any very long or large studies to establish how much they dominate the results. </p> </li> <li> <p>Repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), and country. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009297-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009297-sec-0048"></div> <section id="CD009297-sec-0049"> <h3 class="title">Description of studies</h3> <section id="CD009297-sec-0050"> <h4 class="title">Results of the search</h4> <p>Our search of the Cochrane Renal Group's Specialised Register), Clinicaltrials.gov and the ICTRP retrieved 162 reports. We excluded 14 records on title and abstract review as they did not report a RCT, did not evaluate an appropriate intervention, were a commentary or editorial, or were of insufficient duration (<a href="#CD009297-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009297-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow chart showing number of reports retrieved by database searching and the number of studies included in this review" data-id="CD009297-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow chart showing number of reports retrieved by database searching and the number of studies included in this review </p> </div> </div> </div> <p>We examined 148 reports in detail and excluded 34 reports (22 studies) for the following reasons. </p> <p> <ol id="CD009297-list-0016"> <li> <p>They did not report a RCT (10 studies; 14 reports) (<a href="./references#CD009297-bbs2-0033" title="AkizawaT , KoshikawaS , IwasakiM , KRN321 A08 Study Group. Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients. Therapeutic Apheresis &amp; Dialysis2007;11(3):220‐6. [MEDLINE: 17498005] ">Akizawa 2007b</a>; <a href="./references#CD009297-bbs2-0035" title="CarreraF , AnunciadaAI , NogueiraC , SilvaJG . Comparison of HB levels in dialysis patients receiving three‐times weekly rHuepo switched to once‐weekly darbepoetin alfa: results of a randomized study [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):164. [CENTRAL: CN‐00444694] ">Carrera 2003</a>; <a href="./references#CD009297-bbs2-0036" title="ChenHH , TarngDC , LeeKF , WuCY , ChenYC . Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease. Journal of Nephrology2008;21(4):543‐9. [MEDLINE: 18651544] ">Chen 2008</a>; <a href="./references#CD009297-bbs2-0038" title="DerayG . Dosing darbepoetin alfa continued. American Journal of Kidney Diseases2003;41(6):1334‐5. [MEDLINE: 12776288] ">Deray 2003</a>; <a href="./references#CD009297-bbs2-0039" title="DisneyA , JerseyPD , KirklandG , ManthaM , CharlesworthJA , GallagherM , et al. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, open‐label, Australian study. Nephrology2007;12(1):95‐101. [MEDLINE: 17295668] ">Disney 2007</a>; <a href="./references#CD009297-bbs2-0045" title="MacdougallIC . Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in ESRD patients [abstract]. 37th Congress. European Renal Association. European Dialysis and Transplantation Association. European Kidney Research Organisation; 2000 Sept 17‐20; Nice, France. 2000:237. [CENTRAL: CN‐00461229] MacdougallIC . Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in ESRD patients [abstract]. Nephrology Dialysis Transplantation2000;15(9):A160. MacdougallIC , MatchamJ , GraySJ , NESP 960245/246 Study Group. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrology Dialysis Transplantation2003;18(3):576‐81. [MEDLINE: 12584282] MacdougallIC , UK NESP Study Group. Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):258A‐9A. [CENTRAL: CN‐00446518] ">Macdougall 2003</a>; <a href="./references#CD009297-bbs2-0046" title="MannJ , KesslerM , VillaG , Martinez‐CastelaoA , Feldt‐RasmussenB , CruzJ , et al. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. Clinical Nephrology2007;67(3):140‐8. ">Mann 2007</a>; <a href="./references#CD009297-bbs2-0048" title="MurtaghH , BrownJH , MaxwellAP . Experience with novel erythropoiesis stimulating protein (NESP) in the treatment of anaemia in haemodialysis patients [abstract]. Irish Journal of Medical Science2000;169(4):321. [CENTRAL: CN‐00740599] ">Murtagh 2000</a>; <a href="./references#CD009297-bbs2-0049" title="PaganiniEP , LathamD , AbdulhadiM . Practical considerations of recombinant human erythropoietin therapy. American Journal of Kidney Diseases1989;14(2 Suppl 1):19‐25. ">Paganini 1989</a>; <a href="./references#CD009297-bbs2-0053" title="AlexanderM , KewalramaniR , AgodoaI , GlobeD . Association of anemia correction with health related quality of life in patients not on dialysis. Current Medical Research &amp; Opinion2007;23(12):2997‐3008. [MEDLINE: 17958944] ThadhaniR , CheriyanR , BrennerR , FordJ , PowersK , RahmanSN . Treatment of anemia with ARANESP (darbepoetin alfa) improves health related quality of life (HRQOL) in patients with chronic kidney disease (CKD) [abstract]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):637A. [CENTRAL: CN‐00447983] ">Thadhani 2002</a>) </p> </li> <li> <p>They did not report an appropriate intervention (four studies, seven reports) (<a href="./references#CD009297-bbs2-0034" title="ArganiH , OssarehS , TabibanS , GanjiMR , NafarM , AbdiE , et al. PDpoietin in comparison with Eprex in treatment of anemic patients on hemodialysis. Iranian journal of Kidney Diseases2009;3(3):145‐50. [MEDLINE: 19617663] ">Argani 2009</a>; <a href="./references#CD009297-bbs2-0042" title="LamasJM , AlonsoM , SastreF , Garcia‐TrioG , SaavedraJ , PalomaresL . Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements‐‐a randomized study. Nephrology Dialysis Transplantation2006;21(10):2851‐8. [MEDLINE: 16822792] ">Lamas 2006</a>; <a href="./references#CD009297-bbs2-0047" title="McMahonLP , ChesterK , WalkerRG . Effects of different dialysis membranes on serum concentrations of epoetin alfa, darbepoetin alfa, enoxaparin and iron sucrose during dialysis [abstract no: P109]. Nephrology2004;9(Suppl 1):A28. [CENTRAL: CN‐00509348] ">McMahon 2004</a>; <a href="./references#CD009297-bbs2-0051" title="PrattR . Pharmacokinetics of erythropoietin by a human cell line (Epoetin I): subcutaneous vs intravenous dosing in patients with chronic kidney disease [abstract no: 1137]. Haematologica2006;91(Suppl 1):414. [CENTRAL: CN‐00716122] PrattRD . Epoetin delta for the treatment of anemia in patients with CKD not requiring hemodialysis [abstract no: TH‐PO378]. Journal of the American Society of Nephrology2006;17(Abstracts):187A. [CENTRAL: CN‐00765050] PrattRD , DowellJ . Pharmacokinetics of epoetin delta: a new erythropoietin produced by gene‐activation in a human cell line [abstract no: TH‐PO377]. Journal of the American Society of Nephrology2006;17(Abstracts):187A. [CENTRAL: CN‐00644158] SmithWB , DowellJA , PrattRD . Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Clinical Therapeutics2007;29(7):1368‐80. [MEDLINE: 17825688] ">Smith 2007</a>) </p> </li> <li> <p>Theey were of insufficient duration (eight studies; 13 reports) (<a href="./references#CD009297-bbs2-0037" title="RogerSD , SuranyiMG , WalkerRG , DisneyA , IsbelNM , KairaitisL , et al. A randomised, cross‐over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease. Current Medical Research &amp; Opinion2008;24(8):2181‐7. [MEDLINE: 18565240] SuranyiM , WalkerR , DisneyA , IsbelN , KairaitisL , PollockC , et al. Subcutaneous neoRecormon (epoetin beta) is associated with less injection site pain than aranesp (darbepoetin alfa) in patients with chronic kidney disease [abstract no: PUB475]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):934A. [CENTRAL: CN‐00740565] ">COMFORT Study 2007</a>; <a href="./references#CD009297-bbs2-0040" title="IinoY , HiramatsuM , AkizawaT , KoshikawaS , KRN321 Study Group. Subcutaneous (SC) administration of darbepoetin alfa (KRN321) on CAPD patients. Study for pharmacokinetics and safety [abstract no: PUB401]. Journal of the American Society of Nephrology2003;14(Nov):860A. [CENTRAL: CN‐00740536] ">Iino 2003</a>; <a href="./references#CD009297-bbs2-0041" title="KawanishiH , IwasakiM , AkizawaT , KoshikawaS , KRN321 Study Group. Dose‐finding and long‐term studies of intravenous KRN321 (darbepoetin alfa) in chronic renal failure patients (CRF) on hemodialysis (HD) in Japan [abstract no: SA‐PO943]. Journal of the American Society of Nephrology2005;16:763A. [CENTRAL: CN‐00740571] ">Kawanishi 2005</a>; <a href="./references#CD009297-bbs2-0043" title="LernerG , KaleAS , WaradyBA , JabsK , BunchmanTE , HeatheringtonA , et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatric Nephrology2002;17(11):933‐7. [MEDLINE: 12432437] ">Lerner 2002</a>; <a href="./references#CD009297-bbs2-0044" title="MacdougallIC , GraySJ , ElstonO , BreenC , JenkinsB , BrowneJ , et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. Journal of the American Society of Nephrology1999;10(11):2392‐5. [MEDLINE: 10541299] MacdougallIC , GraySJ , McEvoyO , BreenC , JenkinsB , BrowneJ , et al. Comparison of the pharmacokinetics of novel erythropoiesis stimulating protein (NESP) and epoetin alfa (rhEPO) in dialysis patients [abstract no: A1233]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):268A. [CENTRAL: CN‐00446519] ">Macdougall 1999</a>; <a href="./references#CD009297-bbs2-0052" title="StPeterWL , LewisMJ , MacresMG . Pain comparison after subcutaneous administration of single‐dose formulation versus multidose formulation of epogen in hemodialysis patients. American Journal of Kidney Diseases1998;32(3):470‐4. [MEDLINE: 9740164] ">St Peter 1998</a>; <a href="./references#CD009297-bbs2-0054" title="TsubakiharaY , IinoY , AkizawaT , KosikawaS , KRN321 Study Group. Pharmacokinetics and safety of subcutaneous (SC) administration of KRN321 (darbepoetin alfa) in predialysis chronic kidney disease (CKD) patients [abstract no: SU‐PO781]. Journal of the American Society of Nephrology2003;14(Nov):706A. [CENTRAL: CN‐00740543] ">Tsubakihara 2003</a>; <a href="./references#CD009297-bbs2-0054" title="TsubakiharaY , IinoY , AkizawaT , KosikawaS , KRN321 Study Group. Pharmacokinetics and safety of subcutaneous (SC) administration of KRN321 (darbepoetin alfa) in predialysis chronic kidney disease (CKD) patients [abstract no: SU‐PO781]. Journal of the American Society of Nephrology2003;14(Nov):706A. [CENTRAL: CN‐00740543] ">Tsubakihara 2003</a>). </p> </li> </ol> </p> <p>We identified 13 ongoing studies (<a href="./references#CD009297-bbs2-0062" title="BesarabA , CanaudB , deFranciscoAL , KerrP , LocatelliF , LokCE , et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology2006;17(Abstracts):896A. [CENTRAL: CN‐00740564] ">Besarab 2006</a>; <a href="./references#CD009297-bbs2-0063" title="DediR . Randomised controlled trial of maintaining low serum ferritin levels in patients receiving darbepoetin (Aranesp®). controlled‐trials.com/ISRCTN89787518 (accessed 3 January 2014). ">ISRCTN89787518</a>; <a href="./references#CD009297-bbs2-0064" title="ItoT . The effect of darbepoetin for renal anemia and iron kinetics in chronic kidney disease (CKD) patients. apps.who.int/trialsearch/Trial.aspx?TrialID=JPRN‐UMIN000005068 (accessed 3 January 2014). ">Ito 2011</a>; <a href="./references#CD009297-bbs2-0065" title="NCT00121602 . Randomized, double‐blind, equivalence study of the efficacy of darbepoetin alfa manufactured by serum free bioreactor technology and darbepoetin alfa manufactured by roller‐bottle technology for the treatment of anemia in patients with chronic kidney disease receiving hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00121602 (accessed 3 January 2014). ">NCT00121602</a>; <a href="./references#CD009297-bbs2-0066" title="NCT00436748 . A multi‐center, double‐blind, randomized study evaluating de novo weekly and once every two week darbepoetin alfa dosing for the correction of anemia in pediatric subjects with chronic kidney disease receiving and not receiving dialysis. www.clinicaltrials.gov/ct2/show/NCT00436748 (accessed 3 January 2014). ">NCT00436748</a>; <a href="./references#CD009297-bbs2-0067" title="NCT00442702 . An open‐label, randomized, multi‐center, parallel group non‐inferiority study of subcutaneous injections of RO0503821 given once monthly vs. darbepoetin alfa given according to local label in patients with chronic kidney disease who are not on dialysis. www.clinicaltrials.gov/show/NCT00442702 (accessed 3 January 2014). ">NCT00442702</a>; <a href="./references#CD009297-bbs2-0068" title="NCT00559273 . An open‐label, randomized, multicenter, parallel‐group study to demonstrate correction of anemia using once every 4 weeks subcutaneous injections of Mircera in patients with chronic kidney disease who are not on dialysis. www.clinicaltrials.gov/ct2/show/NCT00559273 (accessed 3 January 2014). ">NCT00559273</a>; <a href="./references#CD009297-bbs2-0069" title="NCT00605345 . An open label randomised controlled study to compare the efficacy, safety and tolerability of once‐monthly administration of subcutaneous mircera versus darbepoetin alfa for the maintenance of haemoglobin levels in renal transplant recipients with chronic renal anaemia. www.clinicaltrials.gov/ct2/show/NCT00605345 (accessed 16 January 2014). ">NCT00605345</a>; <a href="./references#CD009297-bbs2-0070" title="NCT00717821 . A randomized, controlled, open label, french multicenter parallel group study to compare the hemoglobin maintenance with once monthly administration of mircera versus epoetin beta or darbepoetin alfa in patients with chronic kidney disease on hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00717821 (accessed 3 January 2014). ">NCT00717821</a>; <a href="./references#CD009297-bbs2-0071" title="NCT00773513 . A randomized, open label study to assess all‐cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with Mircera or reference ESAs. www.clinicaltrials.gov/ct2/show/NCT00773513 (accessed 3 January 2014). ">NCT00773513</a>; <a href="./references#CD009297-bbs2-0072" title="NCT00925587 . A multicenter, randomised, double‐blind study comparing de novo once monthly and once every 2 week darbepoetin alfa dosing for the correction of anemia in subjects with chronic kidney disease not receiving dialysis. www.clinicaltrials.gov/ct2/show/NCT00925587 (accessed 3 January 2014). ">NCT00925587</a>; <a href="./references#CD009297-bbs2-0073" title="NCT01306409 . Neocytolysis in the treatment of renal anemia with erythropoieses stimulating agents. www.clinicaltrials.gov/ct2/show/NCT01306409 (accessed 3 January 2014). ">NCT01306409</a>; <a href="./references#CD009297-bbs2-0074" title="NCT00364845 . A randomised single‐blind study to improve health‐related quality of life as measured by the SF‐36 vitality score by correcting anemia with aranesp (darbepoetin alfa) in the elderly. www.clinicaltrials.gov/ct2/show/NCT00364845 (accessed 3 January 2014). ">STIMULATE Study 2011</a>) and seven studies (10 reports) are awaiting classification (insufficient information to include or exclude) (<a href="./references#CD009297-bbs2-0055" title="Martinez‐CastelaoA . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in chronic kidney disease (CKD) patients with low incidence of Hb values outside the target range [abstract no: OSu057]. NDT Plus2010;3(Suppl 3):iii298. [EMBASE: 70484207] RogerS . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa [abstract no: 202]. Nephrology2010;15(Suppl 4):79‐80. [EMBASE: 70467206] RogerSD . C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa weekly (QW) or once every 2 weeks (Q2W) [abstract no: Sa535]. NDT Plus2010;3(Suppl 3):iii219‐iii220. [EMBASE: 70484001] RogerSD , LocatelliF , WoitasRP , LavilleM , TobeSW , ProvenzanoR , et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrology Dialysis Transplantation2011;26(12):3980‐6. [MEDLINE: 21505096] ">CORDATUS Study 2011</a>; <a href="./references#CD009297-bbs2-0056" title="ForniV , BianchiG , OgnaA , SalvadeI , VuistinerP , BurnierM , et al. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrology2013;14(1):157. [MEDLINE: 23870287] ">Forni 2013</a>; <a href="./references#CD009297-bbs2-0057" title="GurevichA , YampolskiyA , TimokhovskayaG , TangH , PoluK , DuliegeAM . Efficacy and tolerability of once‐monthly Hematide (peginesatide) in patients who are undergoing chronic hemodialysis and not on ESA treatment [abstract no: Sa510]. NDT Plus2010;3(Suppl 3):iii209‐iii210. [EMBASE: 70483976] ">Gurevich 2010</a>; <a href="./references#CD009297-bbs2-0058" title="MartinezF , MamzerM , PilleboutE , TricotL , LegendreC , ThervetE . Comparison between 2 erythropeitic regimens during the initial period after renal transplantation [abstract no: PUB195]. Journal of the American Society of Nephrology2006;17(Abstracts):857A. [CENTRAL: CN‐00774106] ">Martinez 2006</a>; <a href="./references#CD009297-bbs2-0059" title="PatelM , ThimonsDG , WinstonJL , LangholffW , McGowanT . An open‐label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting. Journal of the American Medical Directors Association2012;13(3):244‐8. [MEDLINE: 21450214] ">Patel 2012</a>; <a href="./references#CD009297-bbs2-0060" title="MacdougallIC , ProvenzanoR , SharmaA , SpinowitzBS , SchmidtRJ , PergolaPE , et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. New England Journal of Medicine2013;368(4):320‐32. [MEDLINE: 23343062] ">PEARL 1 2013</a>; <a href="./references#CD009297-bbs2-0061" title="MacdougallIC , ProvenzanoR , SharmaA , SpinowitzBS , SchmidtRJ , PergolaPE , et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. New England Journal of Medicine2013;368(4):320‐32. [MEDLINE: 23343062] ">PEARL 2 2013</a>). These will be assessed in a future update of this review. </p> </section> <section id="CD009297-sec-0051"> <h4 class="title">Included studies</h4> <p>We identified 32 eligible studies (91 reports; 9414 participants) evaluating darbepoetin alfa (<a href="./references#CD009297-bbs2-0001" title="AarupM , BryndumJ , DieperinkH , JoffeP . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrology Dialysis Transplantation2006;21(5):1312‐6. [MEDLINE: 16396971] AarupM , BryndumJ , JoffeP , DieperinkH . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of Aranesp® (darbepoetin alfa) [abstract no: PUB278]. Journal of the American Society of Nephrology2004;15(Oct):821A. [CENTRAL: CN‐00583657] ">Aarup 2004</a>; <a href="./references#CD009297-bbs2-0002" title="AkizawaT , GejyoF , NishiS , IinoY , WatanabeY , SuzukiM , et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Therapeutic Apheresis &amp; Dialysis2011;15(5):431‐40. [MEDLINE: 21974695] AkizawaT , TsubakiharaY . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the efficacy [abstract no: SU‐PO804]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00740554] TsubakiharaY , AkizawaT . High target hemoglobin with erythropoiesis stimulating agent (ESA) in chronic kidney disease (CKD) slows the occurrence rate of events related to decline of renal function [abstract no: SA‐FC341]. Journal of the American Society of Nephrology2009;20:79A. [CENTRAL: CN‐00793981] TsubakiharaY , AkizawaT . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the safety [abstract no: SU‐PO818]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):765A. [CENTRAL: CN‐00740542] ">Akizawa 2011</a>; <a href="./references#CD009297-bbs2-0003" title="AllonM , KleinmanAK , WalczykM , KaupkeC , MaroniBJ , HeatheringtonA , et al. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time‐and dose‐linear [abstract no: A1308]. Journal of the American Society of Nephrology2000;11(Sept):248A. [CENTRAL: CN‐00626053] AllonM , KleinmanK , WalczykM , KaupkeC , Messer‐MannL , OlsonK , et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clinical Pharmacology &amp; Therapeutics2002;72(5):546‐55. [MEDLINE: 12426518] ">Allon 2002</a>; <a href="./references#CD009297-bbs2-0004" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , DeAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00644214] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009297-bbs2-0005" title="BommerJ , AsmusG , WenningM , BommerG . A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study. Nephrology Dialysis Transplantation2008;23(12):4002‐8. [MEDLINE: 18676350] BommerJ , AsmusH , BommerG , WenningM . Efficacy of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: W‐PO40135]. Nephrology2005;10(Suppl 1):A315. [CENTRAL: CN‐00602087] BommerJ , AssmusH , BommerG , WenningM . Comparison of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: F‐PO499]. Journal of the American Society of Nephrology2004;15(Oct):176A. [CENTRAL: CN‐00583725] BommerJ , WenningM , BommerG . Comparison of IV or SC darbepoetin in hemodialysis patients [abstract no: F‐PO676]. Journal of the American Society of Nephrology2005;16:482A. [CENTRAL: CN‐00583778] ">Bommer 2004</a>; <a href="./references#CD009297-bbs2-0006" title="CervelliMJ , DisneyAPS , GrayN , McDonaldSP . Randomised, single blinded, cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients [abstract]. Nephrology2004;9(Suppl 1):A28. [CENTRAL: CN‐00509125] CervelliMJ , GrayN , McDonaldS , GentgallMG , DisneyAP . Randomized cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology2005;10(2):129‐35. [MEDLINE: 15877671] ">Cervelli 2005</a>; <a href="./references#CD009297-bbs2-0007" title="ChazotC , DumoulinA , AngKS , PaulGJ , BernardC , Conference Medicale Group. Haemodialysis patients under subcutaneous recombinant human erythropoietin can be directly switched to intravenous Aranesp® [abstract no: F‐PO682]. Journal of the American Society of Nephrology2005;16:483A. [CENTRAL: CN‐00740583] ChazotC , TerratJC , AngK , GassiaJP , ChedidK , MauriceF , et al. Intravenous darbepoetin A maintains hemoglobin level in hemodialysis patients converting from subcutaneous recombinant human erythropoietin. [abstract no: F‐PO501]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00583168] ChazotC , TerratJC , DumoulinA , AngKS , GassiaJP , ChedidK , et al. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa. Annals of Pharmacotherapy2009;43(2):228‐34. [MEDLINE: 19407262] ">Chazot 2009</a>; <a href="./references#CD009297-bbs2-0008" title="CoyneDW , LingBN , TotoR , McDermott‐VitakAD , TrotmanML , JacksonL . Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant‐human erythropoietin (R‐HUEPO) [abstract no:1380]. Journal of the American Society of Nephrology2000;11(Sept):263A. [CENTRAL: CN‐00583382] ">Coyne 2000</a>; <a href="./references#CD009297-bbs2-0009" title="CoyneD , ZeigR , BenzR , BernsJ , VarmaN , NakanishiA , et al. A randomized, double‐blind study comparing darbepoetin alfa and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American (AA) subjects with chronic kidney disease (CKD) receiving hemodialysis (HD) [abstract no:TH‐PO365]. Journal of the American Society of Nephrology2006;17(Abstracts):184A. [CENTRAL: CN‐00740574] NCT00111995 . A randomized, double‐blind study comparing Aranesp© (darbepoetin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American subjects with chronic renal failure (CRF) receiving hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00111995 (accessed 16 January 2014). ">Coyne 2006a</a>; <a href="./references#CD009297-bbs2-0010" title="HirakataH , GejyoF , SuzukiM , SaitoA , LinoY , WatanabeY , et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health‐related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO204]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00740524] HirakataH , TsubakiharaY , GejyoF , NishiS , IinoY , WatanabeY , et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre‐dialysis Japanese chronic kidney disease patients. Clinical &amp; Experimental Nephrology2010;14(1):28‐35. [MEDLINE: 19763743] InagumaD , TsubakiharaY , HirakataH , HiroeM , HadaY , AkizawaT , et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi352. [CENTRAL: CN‐00740573] SuzukiM , HadaY , AkaishiM , HiroeM , AonumaK , TsubakiharaY , et al. Effects of anemia correction by erythropoiesis‐stimulating agents on cardiovascular function in non‐dialysis patients with chronic kidney disease. International Heart Journal2012;53(4):238‐43. [MEDLINE: 22878802] ">Hirakata 2010</a>; <a href="./references#CD009297-bbs2-0011" title="HoriK , TsujimotoY , OhmoriH , NakamuraH , SugaA , IwasakiM , et al. Randomized, double‐blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no:F‐PO502]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00740529] ">Hori 2004</a>; <a href="./references#CD009297-bbs2-0012" title="IwasakiT , KimataN , SugiO , SawaraY , JinnaiH , KikuchiK , et al. Difference in reactivity became more evident by changing of the erythropoiesis‐stimulating agent (ESA) [abstract no: PUB462]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):914A. [CENTRAL: CN‐00792600] ">Iwasaki 2008</a>; <a href="./references#CD009297-bbs2-0013" title="KimCD , ParkSH , KimDJ , DoJY , ShinSK , KimBS , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in hemodialysis patient [abstract no: TH‐PO370]. Journal of the American Society of Nephrology2006;17(Abstracts):185A. [CENTRAL: CN‐00740537] KimCD , ParkSH , KimDJ , ParkJW , DoJY , ShinSK , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. Nephrology2009;14(5):482‐7. [MEDLINE: 19298639] ">Kim 2009a</a>; <a href="./references#CD009297-bbs2-0014" title="KwanBC , LeungC , SzetoC , LiPK . Efficacy of bi‐weekly versus monthly subcutaneous darbepoetin‐alpha for the maintenance treatment of anemia in peritoneal dialysis patients ‐ an open‐label randomized study [abstract no:SA‐PO805]. Journal of the American Society of Nephrology2005;16:732A. [CENTRAL: CN‐00740570] ">Kwan 2005</a>; <a href="./references#CD009297-bbs2-0015" title="LiWY , ChuTS , HuangJW , WuMS , WuKD . Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. Journal of the Formosan Medical Association2008;107(11):843‐50. [MEDLINE: 18971153] ">Li 2008</a>; <a href="./references#CD009297-bbs2-0016" title="JohnsonDW , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (darbepoetin alpha) corrects anaemia of early chronic kidney disease (CKD) at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) [abstract no: P156]. Nephrology2002;7(Suppl 3):A40. [CENTRAL: CN‐00794721] LocatelliF , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) corrects anemia of chronic renal insufficiency (CRI) at a reduced dose frequency compared with rHuEPO [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00671771] LocatelliF , OlivaresJ , WalkerR , WilkieM , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant‐human erythropoietin (r‐HuEPO) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):283A. [CENTRAL: CN‐00626023] LocatelliF , OlivaresJ , WalkerR , WilkieM , JenkinsB , DeweyC , et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International2001;60(2):741‐7. [MEDLINE: 11473657] ">Locatelli 2001</a>; <a href="./references#CD009297-bbs2-0017" title="LocatelliF , BacksW , delPinoMD , deMartinA , GuillaumeB , VikydalR , et al. Control of anaemia with Aranesp®: haemoglobin stability achieved with fewer patients requiring dose adjustments after switching to Aranesp® every 2‐weeks [abstract no: SP411]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv152. [CENTRAL: CN‐00740593] LocatelliF , VillaG , BacksW , delPinoMD . A phase 3, multicentre, randomised, double‐blind, non‐inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) inpatients on haemodialysis (HD) [abstract no: MP181]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v260. [CENTRAL: CN‐00740588] LocatelliF , VillaG , BacksW , delPinoMD . Aranesp® (darbepoetin alfa) maintains hemoglobin (Hb) levels in hemodialysis (HD) patients at extended dosing intervals regardless of previous recombinant human erythropoietin (rHuEPO) dosing frequency [abstract no: PUB254]. Journal of the American Society of Nephrology2004;15(Oct):816A. [CENTRAL: CN‐00740589] ">Locatelli 2004</a>; <a href="./references#CD009297-bbs2-0018" title="LocatelliF , VillaG , MessaP , FilippiniA , CannellaG , DeFerrariG , et al. Efficacy and safety of once‐weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. Journal of Nephrology2008;21(3):412‐20. [MEDLINE: 18587731] ">Locatelli 2008</a>; <a href="./references#CD009297-bbs2-0019" title="InagumaD , NagayaH , HamaguchiK , TatematsuM , SuzukiS , KurataK . Intravenous darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in Japanese patients on hemodialysis [abstract no: TH‐PO741]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):275A. [CENTRAL: CN‐00740572] NagayaH , InagumaD , KitagawaA , MurataM , KamimuraY , HamaguchiK , et al. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. Clinical &amp; Experimental Nephrology2010;14(2):158‐63. [MEDLINE: 19967423] ">Nagaya 2010</a>; <a href="./references#CD009297-bbs2-0020" title="NissensonA , KrishnanM , LiuW , McCaryL , Stehman‐BreenC , MixC . Hemoglobin (Hb) variability does not differ between hemodialysis (HD) patients treated with epoetin alfa and darbepoetin alfa [abstract no: TH‐PO360]. Journal of the American Society of Nephrology2006;17(Abstracts):183A. [CENTRAL: CN‐00740539] NissensonAR . Dosing darbepoetin alfa. American Journal of Kidney Diseases2002;40(4):872. [MEDLINE: 12324929] NissensonAR , SwanSK , LindbergJS , SorokaSD , BeateyR , WangC , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases2002;40(1):110‐8. [MEDLINE: 12087568] NissensonAR , SwanSK , LindbergJS , SorokaSD , McDermott‐VitakAD , WangC , et al. Novel Erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r‐HuEPO when administered once weekly [abstract no: A1326]. Journal of the American Society of Nephrology2000;11(Sept):252A. [CENTRAL: CN‐00794722] NissensonAR , US/Canadian NESP 980117 Study Group. Once weekly IV novel erythropoiesis stimulating protein (NESP) effectively maintains Hb in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00446969] ">Nissenson 2002</a>; <a href="./references#CD009297-bbs2-0021" title="CarreraF . CERA vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009297-bbs2-0022" title="SmythJS , MarshallW , AshfieldL , EliasL , McGinnS . Conversion from subcutaneous to intravenous erythropoietin analogues is cost neutral: results of a six month pilot study [abstract no: PUB246]. Journal of the American Society of Nephrology2004;15(Oct):814A‐5A. [CENTRAL: CN‐00792440] ">Smyth 2004</a>; <a href="./references#CD009297-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>; <a href="./references#CD009297-bbs2-0024" title="SvarstadE , ForslundT . Nurse assisted nine months darbepoetin (D) treatment with fix dose and variable dosing interval in an outpatient clinic is cost effective in predialytic CKD patients [abstract no: SU‐PO800]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00740562] ">Svarstad 2007</a>; <a href="./references#CD009297-bbs2-0025" title="TessitoreN , MantovaniW , BedognaV , LossR , MelilliE , PoliA , et al. Cost analysis of switching from epoetin alfa to darbepoetin alfa in chronic hemodialysis patients (HD Pts): a long‐term, randomized, open‐label, cross‐over, pilot study [abstract no: SA‐PO2645]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):706A. [CENTRAL: CN‐00740545] ">Tessitore 2008</a>; <a href="./references#CD009297-bbs2-0026" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: 27]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of CERA once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4. ">TIVOLI Study 2011</a>; <a href="./references#CD009297-bbs2-0027" title="TolmanC , RichardsonD , BartlettC , WillE . A randomised study of weekly subcutaneous Aranesp and Neorecormon in a large unselected haemodialysis cohort, managed with computer assisted anaemia algorithms [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:229‐30. [CENTRAL: CN‐00509514] TolmanC , RichardsonD , BartlettC , WillE . Application of computer assisted anaemia management algorithms in haemodialysis patients produces predictable haemoglobin outcomes regardless of the erythropoietic agent or frequency of administration: results of a randomised study [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:110. [CENTRAL: CN‐00509513] TolmanC , RichardsonD , BartlettC , WillE . Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision‐support system: a randomized clinical study. Journal of the American Society of Nephrology2005;16(5):1463‐70. [MEDLINE: 15788469] TolmanC , RichardsonD , BartlettC , WillEJ . Dose conversion ratio (DCR) from subcutaneous epoetin‐B (EPO) to weekly darbepoetin‐A (DA) is dependent on baseline sensitivity: results from a randomised study [abstract no: SA‐PO461]. Journal of the American Society of Nephrology2004;15(Oct):404A. [CENTRAL: CN‐00583282] WestRM , HarrisK , GilthorpeMS , TolmanC , WillEJ . Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. Journal of the American Society of Nephrology2007;18(8):2371‐6. [MEDLINE: 17625113] ">Tolman 2005</a>; <a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>; <a href="./references#CD009297-bbs2-0029" title="CanaudB . Darbepoetin alfa dose requirements for IV and SC administration are equivalent in anaemic dialysis patients [abstract no: M319]. Nephrology Dialysis Transplantation2002;17(Suppl 1):137. [CENTRAL: CN‐00550478] KerrPG , HarrisD , HawleyC , WalkerR , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains haemoglobin in ESRD patients with administered once weekly or once every other week [abstract no: 181]. Nephrology2000;5(3):A112. [CENTRAL: CN‐00509271] VanrenterghemY , BaranyP , MannJ , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (hgb) in ESRD patients when administered once weekly or once every other week [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):270A. [CENTRAL: CN‐00583820] VanrenterghemY , BaranyP , MannJF , KerrPG , WilsonJ , BakerNF , et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International2002;62(6):2167‐75. [MEDLINE: 12427142] ">Vanrenterghem 2002</a>; <a href="./references#CD009297-bbs2-0030" title="WaradyBA , ArarMY , LernerG , NakanishiAM , Stehman‐BreenC . Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatric Nephrology2006;21(8):1144‐52. [MEDLINE: 16724235] ">Warady 2006</a>; <a href="./references#CD009297-bbs2-0031" title="WatanabeY , GejyoF , ShigematsuT , IinoY , HosoyaT , ShojiT , et al. KRN321 (darbepoetin alfa) administered once every other week (Q2W) and once every four weeks (Q4W) in predialysis chronic renal failure (CRF) patients in Japan [abstract no: SU‐PO053]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00740541] ">Watanabe 2004</a>; <a href="./references#CD009297-bbs2-0032" title="YoonSY , BangBK , KimSG , HanDC , HwangSD , ParkJS , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of renal anemia in hemodialysis patients [abstract no: MP271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:322. [CENTRAL: CN‐00509573] ">Yoon 2004</a>). </p> <p>Twenty one studies (8328 participants) were included in our meta‐analyses (<a href="./references#CD009297-bbs2-0001" title="AarupM , BryndumJ , DieperinkH , JoffeP . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrology Dialysis Transplantation2006;21(5):1312‐6. [MEDLINE: 16396971] AarupM , BryndumJ , JoffeP , DieperinkH . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of Aranesp® (darbepoetin alfa) [abstract no: PUB278]. Journal of the American Society of Nephrology2004;15(Oct):821A. [CENTRAL: CN‐00583657] ">Aarup 2004</a>; <a href="./references#CD009297-bbs2-0002" title="AkizawaT , GejyoF , NishiS , IinoY , WatanabeY , SuzukiM , et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Therapeutic Apheresis &amp; Dialysis2011;15(5):431‐40. [MEDLINE: 21974695] AkizawaT , TsubakiharaY . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the efficacy [abstract no: SU‐PO804]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00740554] TsubakiharaY , AkizawaT . High target hemoglobin with erythropoiesis stimulating agent (ESA) in chronic kidney disease (CKD) slows the occurrence rate of events related to decline of renal function [abstract no: SA‐FC341]. Journal of the American Society of Nephrology2009;20:79A. [CENTRAL: CN‐00793981] TsubakiharaY , AkizawaT . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the safety [abstract no: SU‐PO818]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):765A. [CENTRAL: CN‐00740542] ">Akizawa 2011</a>; <a href="./references#CD009297-bbs2-0004" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , DeAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00644214] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009297-bbs2-0005" title="BommerJ , AsmusG , WenningM , BommerG . A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study. Nephrology Dialysis Transplantation2008;23(12):4002‐8. [MEDLINE: 18676350] BommerJ , AsmusH , BommerG , WenningM . Efficacy of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: W‐PO40135]. Nephrology2005;10(Suppl 1):A315. [CENTRAL: CN‐00602087] BommerJ , AssmusH , BommerG , WenningM . Comparison of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: F‐PO499]. Journal of the American Society of Nephrology2004;15(Oct):176A. [CENTRAL: CN‐00583725] BommerJ , WenningM , BommerG . Comparison of IV or SC darbepoetin in hemodialysis patients [abstract no: F‐PO676]. Journal of the American Society of Nephrology2005;16:482A. [CENTRAL: CN‐00583778] ">Bommer 2004</a>; <a href="./references#CD009297-bbs2-0007" title="ChazotC , DumoulinA , AngKS , PaulGJ , BernardC , Conference Medicale Group. Haemodialysis patients under subcutaneous recombinant human erythropoietin can be directly switched to intravenous Aranesp® [abstract no: F‐PO682]. Journal of the American Society of Nephrology2005;16:483A. [CENTRAL: CN‐00740583] ChazotC , TerratJC , AngK , GassiaJP , ChedidK , MauriceF , et al. Intravenous darbepoetin A maintains hemoglobin level in hemodialysis patients converting from subcutaneous recombinant human erythropoietin. [abstract no: F‐PO501]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00583168] ChazotC , TerratJC , DumoulinA , AngKS , GassiaJP , ChedidK , et al. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa. Annals of Pharmacotherapy2009;43(2):228‐34. [MEDLINE: 19407262] ">Chazot 2009</a>; <a href="./references#CD009297-bbs2-0009" title="CoyneD , ZeigR , BenzR , BernsJ , VarmaN , NakanishiA , et al. A randomized, double‐blind study comparing darbepoetin alfa and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American (AA) subjects with chronic kidney disease (CKD) receiving hemodialysis (HD) [abstract no:TH‐PO365]. Journal of the American Society of Nephrology2006;17(Abstracts):184A. [CENTRAL: CN‐00740574] NCT00111995 . A randomized, double‐blind study comparing Aranesp© (darbepoetin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American subjects with chronic renal failure (CRF) receiving hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00111995 (accessed 16 January 2014). ">Coyne 2006a</a>; <a href="./references#CD009297-bbs2-0010" title="HirakataH , GejyoF , SuzukiM , SaitoA , LinoY , WatanabeY , et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health‐related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO204]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00740524] HirakataH , TsubakiharaY , GejyoF , NishiS , IinoY , WatanabeY , et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre‐dialysis Japanese chronic kidney disease patients. Clinical &amp; Experimental Nephrology2010;14(1):28‐35. [MEDLINE: 19763743] InagumaD , TsubakiharaY , HirakataH , HiroeM , HadaY , AkizawaT , et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi352. [CENTRAL: CN‐00740573] SuzukiM , HadaY , AkaishiM , HiroeM , AonumaK , TsubakiharaY , et al. Effects of anemia correction by erythropoiesis‐stimulating agents on cardiovascular function in non‐dialysis patients with chronic kidney disease. International Heart Journal2012;53(4):238‐43. [MEDLINE: 22878802] ">Hirakata 2010</a>; <a href="./references#CD009297-bbs2-0011" title="HoriK , TsujimotoY , OhmoriH , NakamuraH , SugaA , IwasakiM , et al. Randomized, double‐blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no:F‐PO502]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00740529] ">Hori 2004</a>; <a href="./references#CD009297-bbs2-0013" title="KimCD , ParkSH , KimDJ , DoJY , ShinSK , KimBS , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in hemodialysis patient [abstract no: TH‐PO370]. Journal of the American Society of Nephrology2006;17(Abstracts):185A. [CENTRAL: CN‐00740537] KimCD , ParkSH , KimDJ , ParkJW , DoJY , ShinSK , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. Nephrology2009;14(5):482‐7. [MEDLINE: 19298639] ">Kim 2009a</a>; <a href="./references#CD009297-bbs2-0014" title="KwanBC , LeungC , SzetoC , LiPK . Efficacy of bi‐weekly versus monthly subcutaneous darbepoetin‐alpha for the maintenance treatment of anemia in peritoneal dialysis patients ‐ an open‐label randomized study [abstract no:SA‐PO805]. Journal of the American Society of Nephrology2005;16:732A. [CENTRAL: CN‐00740570] ">Kwan 2005</a>; <a href="./references#CD009297-bbs2-0016" title="JohnsonDW , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (darbepoetin alpha) corrects anaemia of early chronic kidney disease (CKD) at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) [abstract no: P156]. Nephrology2002;7(Suppl 3):A40. [CENTRAL: CN‐00794721] LocatelliF , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) corrects anemia of chronic renal insufficiency (CRI) at a reduced dose frequency compared with rHuEPO [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00671771] LocatelliF , OlivaresJ , WalkerR , WilkieM , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant‐human erythropoietin (r‐HuEPO) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):283A. [CENTRAL: CN‐00626023] LocatelliF , OlivaresJ , WalkerR , WilkieM , JenkinsB , DeweyC , et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International2001;60(2):741‐7. [MEDLINE: 11473657] ">Locatelli 2001</a>; <a href="./references#CD009297-bbs2-0019" title="InagumaD , NagayaH , HamaguchiK , TatematsuM , SuzukiS , KurataK . Intravenous darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in Japanese patients on hemodialysis [abstract no: TH‐PO741]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):275A. [CENTRAL: CN‐00740572] NagayaH , InagumaD , KitagawaA , MurataM , KamimuraY , HamaguchiK , et al. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. Clinical &amp; Experimental Nephrology2010;14(2):158‐63. [MEDLINE: 19967423] ">Nagaya 2010</a>; <a href="./references#CD009297-bbs2-0020" title="NissensonA , KrishnanM , LiuW , McCaryL , Stehman‐BreenC , MixC . Hemoglobin (Hb) variability does not differ between hemodialysis (HD) patients treated with epoetin alfa and darbepoetin alfa [abstract no: TH‐PO360]. Journal of the American Society of Nephrology2006;17(Abstracts):183A. [CENTRAL: CN‐00740539] NissensonAR . Dosing darbepoetin alfa. American Journal of Kidney Diseases2002;40(4):872. [MEDLINE: 12324929] NissensonAR , SwanSK , LindbergJS , SorokaSD , BeateyR , WangC , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases2002;40(1):110‐8. [MEDLINE: 12087568] NissensonAR , SwanSK , LindbergJS , SorokaSD , McDermott‐VitakAD , WangC , et al. Novel Erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r‐HuEPO when administered once weekly [abstract no: A1326]. Journal of the American Society of Nephrology2000;11(Sept):252A. [CENTRAL: CN‐00794722] NissensonAR , US/Canadian NESP 980117 Study Group. Once weekly IV novel erythropoiesis stimulating protein (NESP) effectively maintains Hb in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00446969] ">Nissenson 2002</a>; <a href="./references#CD009297-bbs2-0021" title="CarreraF . CERA vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009297-bbs2-0022" title="SmythJS , MarshallW , AshfieldL , EliasL , McGinnS . Conversion from subcutaneous to intravenous erythropoietin analogues is cost neutral: results of a six month pilot study [abstract no: PUB246]. Journal of the American Society of Nephrology2004;15(Oct):814A‐5A. [CENTRAL: CN‐00792440] ">Smyth 2004</a>; <a href="./references#CD009297-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>; <a href="./references#CD009297-bbs2-0026" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: 27]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of CERA once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4. ">TIVOLI Study 2011</a>; <a href="./references#CD009297-bbs2-0027" title="TolmanC , RichardsonD , BartlettC , WillE . A randomised study of weekly subcutaneous Aranesp and Neorecormon in a large unselected haemodialysis cohort, managed with computer assisted anaemia algorithms [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:229‐30. [CENTRAL: CN‐00509514] TolmanC , RichardsonD , BartlettC , WillE . Application of computer assisted anaemia management algorithms in haemodialysis patients produces predictable haemoglobin outcomes regardless of the erythropoietic agent or frequency of administration: results of a randomised study [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:110. [CENTRAL: CN‐00509513] TolmanC , RichardsonD , BartlettC , WillE . Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision‐support system: a randomized clinical study. Journal of the American Society of Nephrology2005;16(5):1463‐70. [MEDLINE: 15788469] TolmanC , RichardsonD , BartlettC , WillEJ . Dose conversion ratio (DCR) from subcutaneous epoetin‐B (EPO) to weekly darbepoetin‐A (DA) is dependent on baseline sensitivity: results from a randomised study [abstract no: SA‐PO461]. Journal of the American Society of Nephrology2004;15(Oct):404A. [CENTRAL: CN‐00583282] WestRM , HarrisK , GilthorpeMS , TolmanC , WillEJ . Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. Journal of the American Society of Nephrology2007;18(8):2371‐6. [MEDLINE: 17625113] ">Tolman 2005</a>; <a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>; <a href="./references#CD009297-bbs2-0029" title="CanaudB . Darbepoetin alfa dose requirements for IV and SC administration are equivalent in anaemic dialysis patients [abstract no: M319]. Nephrology Dialysis Transplantation2002;17(Suppl 1):137. [CENTRAL: CN‐00550478] KerrPG , HarrisD , HawleyC , WalkerR , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains haemoglobin in ESRD patients with administered once weekly or once every other week [abstract no: 181]. Nephrology2000;5(3):A112. [CENTRAL: CN‐00509271] VanrenterghemY , BaranyP , MannJ , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (hgb) in ESRD patients when administered once weekly or once every other week [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):270A. [CENTRAL: CN‐00583820] VanrenterghemY , BaranyP , MannJF , KerrPG , WilsonJ , BakerNF , et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International2002;62(6):2167‐75. [MEDLINE: 12427142] ">Vanrenterghem 2002</a>; <a href="./references#CD009297-bbs2-0030" title="WaradyBA , ArarMY , LernerG , NakanishiAM , Stehman‐BreenC . Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatric Nephrology2006;21(8):1144‐52. [MEDLINE: 16724235] ">Warady 2006</a>). </p> <section id="CD009297-sec-0052"> <h5 class="title">Darbepoetin alfa versus placebo or no treatment</h5> <p>We identified a single large study that compared darbepoetin alfa with placebo in 4038 participants who had type 2 diabetes and CKD stages 3 and 4 (eGFR 20 to 60 mL/min/1.73 m²) (<a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>) that could be included in our meta‐analyses. The treatment algorithm was designed to adjust the dose in the darbepoetin alfa arm to maintain the Hb level at approximately 13.0 g/dL. In the placebo arm, darbepoetin alfa was administered when the Hb level was &lt; 9.0 g/dL. The primary end points were the composite outcomes of death or a cardiovascular event (nonfatal myocardial infarction, congestive heart failure, stroke, or hospitalisation for myocardial ischaemia) and of death or ESKD. Median follow‐up duration was 29.1 months. Data comparing darbepoetin alfa with placebo were not available for patients with CKD stage 5 and 5D, kidney transplant recipients, or children with any stage of CKD. </p> </section> <section id="CD009297-sec-0053"> <h5 class="title">Darbepoetin alfa versus epoetin alfa or beta</h5> <p>Sixteen studies compared darbepoetin alfa with epoetin alfa or beta in 2955 participants (range 30 to 522 participants) (<a href="./references#CD009297-bbs2-0002" title="AkizawaT , GejyoF , NishiS , IinoY , WatanabeY , SuzukiM , et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Therapeutic Apheresis &amp; Dialysis2011;15(5):431‐40. [MEDLINE: 21974695] AkizawaT , TsubakiharaY . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the efficacy [abstract no: SU‐PO804]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00740554] TsubakiharaY , AkizawaT . High target hemoglobin with erythropoiesis stimulating agent (ESA) in chronic kidney disease (CKD) slows the occurrence rate of events related to decline of renal function [abstract no: SA‐FC341]. Journal of the American Society of Nephrology2009;20:79A. [CENTRAL: CN‐00793981] TsubakiharaY , AkizawaT . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the safety [abstract no: SU‐PO818]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):765A. [CENTRAL: CN‐00740542] ">Akizawa 2011</a>; <a href="./references#CD009297-bbs2-0003" title="AllonM , KleinmanAK , WalczykM , KaupkeC , MaroniBJ , HeatheringtonA , et al. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time‐and dose‐linear [abstract no: A1308]. Journal of the American Society of Nephrology2000;11(Sept):248A. [CENTRAL: CN‐00626053] AllonM , KleinmanK , WalczykM , KaupkeC , Messer‐MannL , OlsonK , et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clinical Pharmacology &amp; Therapeutics2002;72(5):546‐55. [MEDLINE: 12426518] ">Allon 2002</a>; <a href="./references#CD009297-bbs2-0008" title="CoyneDW , LingBN , TotoR , McDermott‐VitakAD , TrotmanML , JacksonL . Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant‐human erythropoietin (R‐HUEPO) [abstract no:1380]. Journal of the American Society of Nephrology2000;11(Sept):263A. [CENTRAL: CN‐00583382] ">Coyne 2000</a>; <a href="./references#CD009297-bbs2-0009" title="CoyneD , ZeigR , BenzR , BernsJ , VarmaN , NakanishiA , et al. A randomized, double‐blind study comparing darbepoetin alfa and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American (AA) subjects with chronic kidney disease (CKD) receiving hemodialysis (HD) [abstract no:TH‐PO365]. Journal of the American Society of Nephrology2006;17(Abstracts):184A. [CENTRAL: CN‐00740574] NCT00111995 . A randomized, double‐blind study comparing Aranesp© (darbepoetin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American subjects with chronic renal failure (CRF) receiving hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00111995 (accessed 16 January 2014). ">Coyne 2006a</a>; <a href="./references#CD009297-bbs2-0010" title="HirakataH , GejyoF , SuzukiM , SaitoA , LinoY , WatanabeY , et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health‐related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO204]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00740524] HirakataH , TsubakiharaY , GejyoF , NishiS , IinoY , WatanabeY , et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre‐dialysis Japanese chronic kidney disease patients. Clinical &amp; Experimental Nephrology2010;14(1):28‐35. [MEDLINE: 19763743] InagumaD , TsubakiharaY , HirakataH , HiroeM , HadaY , AkizawaT , et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi352. [CENTRAL: CN‐00740573] SuzukiM , HadaY , AkaishiM , HiroeM , AonumaK , TsubakiharaY , et al. Effects of anemia correction by erythropoiesis‐stimulating agents on cardiovascular function in non‐dialysis patients with chronic kidney disease. International Heart Journal2012;53(4):238‐43. [MEDLINE: 22878802] ">Hirakata 2010</a>; <a href="./references#CD009297-bbs2-0011" title="HoriK , TsujimotoY , OhmoriH , NakamuraH , SugaA , IwasakiM , et al. Randomized, double‐blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no:F‐PO502]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00740529] ">Hori 2004</a>; <a href="./references#CD009297-bbs2-0012" title="IwasakiT , KimataN , SugiO , SawaraY , JinnaiH , KikuchiK , et al. Difference in reactivity became more evident by changing of the erythropoiesis‐stimulating agent (ESA) [abstract no: PUB462]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):914A. [CENTRAL: CN‐00792600] ">Iwasaki 2008</a>; <a href="./references#CD009297-bbs2-0015" title="LiWY , ChuTS , HuangJW , WuMS , WuKD . Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. Journal of the Formosan Medical Association2008;107(11):843‐50. [MEDLINE: 18971153] ">Li 2008</a>; <a href="./references#CD009297-bbs2-0016" title="JohnsonDW , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (darbepoetin alpha) corrects anaemia of early chronic kidney disease (CKD) at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) [abstract no: P156]. Nephrology2002;7(Suppl 3):A40. [CENTRAL: CN‐00794721] LocatelliF , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) corrects anemia of chronic renal insufficiency (CRI) at a reduced dose frequency compared with rHuEPO [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00671771] LocatelliF , OlivaresJ , WalkerR , WilkieM , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant‐human erythropoietin (r‐HuEPO) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):283A. [CENTRAL: CN‐00626023] LocatelliF , OlivaresJ , WalkerR , WilkieM , JenkinsB , DeweyC , et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International2001;60(2):741‐7. [MEDLINE: 11473657] ">Locatelli 2001</a>; <a href="./references#CD009297-bbs2-0020" title="NissensonA , KrishnanM , LiuW , McCaryL , Stehman‐BreenC , MixC . Hemoglobin (Hb) variability does not differ between hemodialysis (HD) patients treated with epoetin alfa and darbepoetin alfa [abstract no: TH‐PO360]. Journal of the American Society of Nephrology2006;17(Abstracts):183A. [CENTRAL: CN‐00740539] NissensonAR . Dosing darbepoetin alfa. American Journal of Kidney Diseases2002;40(4):872. [MEDLINE: 12324929] NissensonAR , SwanSK , LindbergJS , SorokaSD , BeateyR , WangC , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases2002;40(1):110‐8. [MEDLINE: 12087568] NissensonAR , SwanSK , LindbergJS , SorokaSD , McDermott‐VitakAD , WangC , et al. Novel Erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r‐HuEPO when administered once weekly [abstract no: A1326]. Journal of the American Society of Nephrology2000;11(Sept):252A. [CENTRAL: CN‐00794722] NissensonAR , US/Canadian NESP 980117 Study Group. Once weekly IV novel erythropoiesis stimulating protein (NESP) effectively maintains Hb in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00446969] ">Nissenson 2002</a>; <a href="./references#CD009297-bbs2-0022" title="SmythJS , MarshallW , AshfieldL , EliasL , McGinnS . Conversion from subcutaneous to intravenous erythropoietin analogues is cost neutral: results of a six month pilot study [abstract no: PUB246]. Journal of the American Society of Nephrology2004;15(Oct):814A‐5A. [CENTRAL: CN‐00792440] ">Smyth 2004</a>; <a href="./references#CD009297-bbs2-0025" title="TessitoreN , MantovaniW , BedognaV , LossR , MelilliE , PoliA , et al. Cost analysis of switching from epoetin alfa to darbepoetin alfa in chronic hemodialysis patients (HD Pts): a long‐term, randomized, open‐label, cross‐over, pilot study [abstract no: SA‐PO2645]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):706A. [CENTRAL: CN‐00740545] ">Tessitore 2008</a>; <a href="./references#CD009297-bbs2-0027" title="TolmanC , RichardsonD , BartlettC , WillE . A randomised study of weekly subcutaneous Aranesp and Neorecormon in a large unselected haemodialysis cohort, managed with computer assisted anaemia algorithms [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:229‐30. [CENTRAL: CN‐00509514] TolmanC , RichardsonD , BartlettC , WillE . Application of computer assisted anaemia management algorithms in haemodialysis patients produces predictable haemoglobin outcomes regardless of the erythropoietic agent or frequency of administration: results of a randomised study [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:110. [CENTRAL: CN‐00509513] TolmanC , RichardsonD , BartlettC , WillE . Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision‐support system: a randomized clinical study. Journal of the American Society of Nephrology2005;16(5):1463‐70. [MEDLINE: 15788469] TolmanC , RichardsonD , BartlettC , WillEJ . Dose conversion ratio (DCR) from subcutaneous epoetin‐B (EPO) to weekly darbepoetin‐A (DA) is dependent on baseline sensitivity: results from a randomised study [abstract no: SA‐PO461]. Journal of the American Society of Nephrology2004;15(Oct):404A. [CENTRAL: CN‐00583282] WestRM , HarrisK , GilthorpeMS , TolmanC , WillEJ . Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. Journal of the American Society of Nephrology2007;18(8):2371‐6. [MEDLINE: 17625113] ">Tolman 2005</a>; <a href="./references#CD009297-bbs2-0029" title="CanaudB . Darbepoetin alfa dose requirements for IV and SC administration are equivalent in anaemic dialysis patients [abstract no: M319]. Nephrology Dialysis Transplantation2002;17(Suppl 1):137. [CENTRAL: CN‐00550478] KerrPG , HarrisD , HawleyC , WalkerR , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains haemoglobin in ESRD patients with administered once weekly or once every other week [abstract no: 181]. Nephrology2000;5(3):A112. [CENTRAL: CN‐00509271] VanrenterghemY , BaranyP , MannJ , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (hgb) in ESRD patients when administered once weekly or once every other week [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):270A. [CENTRAL: CN‐00583820] VanrenterghemY , BaranyP , MannJF , KerrPG , WilsonJ , BakerNF , et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International2002;62(6):2167‐75. [MEDLINE: 12427142] ">Vanrenterghem 2002</a>; <a href="./references#CD009297-bbs2-0030" title="WaradyBA , ArarMY , LernerG , NakanishiAM , Stehman‐BreenC . Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatric Nephrology2006;21(8):1144‐52. [MEDLINE: 16724235] ">Warady 2006</a>; <a href="./references#CD009297-bbs2-0032" title="YoonSY , BangBK , KimSG , HanDC , HwangSD , ParkJS , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of renal anemia in hemodialysis patients [abstract no: MP271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:322. [CENTRAL: CN‐00509573] ">Yoon 2004</a>). Half of these studies were published in abstract form only ( <a href="./references#CD009297-bbs2-0008" title="CoyneDW , LingBN , TotoR , McDermott‐VitakAD , TrotmanML , JacksonL . Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant‐human erythropoietin (R‐HUEPO) [abstract no:1380]. Journal of the American Society of Nephrology2000;11(Sept):263A. [CENTRAL: CN‐00583382] ">Coyne 2000</a>; <a href="./references#CD009297-bbs2-0009" title="CoyneD , ZeigR , BenzR , BernsJ , VarmaN , NakanishiA , et al. A randomized, double‐blind study comparing darbepoetin alfa and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American (AA) subjects with chronic kidney disease (CKD) receiving hemodialysis (HD) [abstract no:TH‐PO365]. Journal of the American Society of Nephrology2006;17(Abstracts):184A. [CENTRAL: CN‐00740574] NCT00111995 . A randomized, double‐blind study comparing Aranesp© (darbepoetin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American subjects with chronic renal failure (CRF) receiving hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00111995 (accessed 16 January 2014). ">Coyne 2006a</a>; <a href="./references#CD009297-bbs2-0011" title="HoriK , TsujimotoY , OhmoriH , NakamuraH , SugaA , IwasakiM , et al. Randomized, double‐blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no:F‐PO502]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00740529] ">Hori 2004</a>; <a href="./references#CD009297-bbs2-0012" title="IwasakiT , KimataN , SugiO , SawaraY , JinnaiH , KikuchiK , et al. Difference in reactivity became more evident by changing of the erythropoiesis‐stimulating agent (ESA) [abstract no: PUB462]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):914A. [CENTRAL: CN‐00792600] ">Iwasaki 2008</a>; <a href="./references#CD009297-bbs2-0022" title="SmythJS , MarshallW , AshfieldL , EliasL , McGinnS . Conversion from subcutaneous to intravenous erythropoietin analogues is cost neutral: results of a six month pilot study [abstract no: PUB246]. Journal of the American Society of Nephrology2004;15(Oct):814A‐5A. [CENTRAL: CN‐00792440] ">Smyth 2004</a>; <a href="./references#CD009297-bbs2-0025" title="TessitoreN , MantovaniW , BedognaV , LossR , MelilliE , PoliA , et al. Cost analysis of switching from epoetin alfa to darbepoetin alfa in chronic hemodialysis patients (HD Pts): a long‐term, randomized, open‐label, cross‐over, pilot study [abstract no: SA‐PO2645]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):706A. [CENTRAL: CN‐00740545] ">Tessitore 2008</a>; <a href="./references#CD009297-bbs2-0032" title="YoonSY , BangBK , KimSG , HanDC , HwangSD , ParkJS , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of renal anemia in hemodialysis patients [abstract no: MP271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:322. [CENTRAL: CN‐00509573] ">Yoon 2004</a>). Three studies enrolled adults with CKD stage 3 to 5 (<a href="./references#CD009297-bbs2-0002" title="AkizawaT , GejyoF , NishiS , IinoY , WatanabeY , SuzukiM , et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Therapeutic Apheresis &amp; Dialysis2011;15(5):431‐40. [MEDLINE: 21974695] AkizawaT , TsubakiharaY . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the efficacy [abstract no: SU‐PO804]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00740554] TsubakiharaY , AkizawaT . High target hemoglobin with erythropoiesis stimulating agent (ESA) in chronic kidney disease (CKD) slows the occurrence rate of events related to decline of renal function [abstract no: SA‐FC341]. Journal of the American Society of Nephrology2009;20:79A. [CENTRAL: CN‐00793981] TsubakiharaY , AkizawaT . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the safety [abstract no: SU‐PO818]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):765A. [CENTRAL: CN‐00740542] ">Akizawa 2011</a>; <a href="./references#CD009297-bbs2-0010" title="HirakataH , GejyoF , SuzukiM , SaitoA , LinoY , WatanabeY , et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health‐related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO204]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00740524] HirakataH , TsubakiharaY , GejyoF , NishiS , IinoY , WatanabeY , et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre‐dialysis Japanese chronic kidney disease patients. Clinical &amp; Experimental Nephrology2010;14(1):28‐35. [MEDLINE: 19763743] InagumaD , TsubakiharaY , HirakataH , HiroeM , HadaY , AkizawaT , et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi352. [CENTRAL: CN‐00740573] SuzukiM , HadaY , AkaishiM , HiroeM , AonumaK , TsubakiharaY , et al. Effects of anemia correction by erythropoiesis‐stimulating agents on cardiovascular function in non‐dialysis patients with chronic kidney disease. International Heart Journal2012;53(4):238‐43. [MEDLINE: 22878802] ">Hirakata 2010</a>; <a href="./references#CD009297-bbs2-0016" title="JohnsonDW , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (darbepoetin alpha) corrects anaemia of early chronic kidney disease (CKD) at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) [abstract no: P156]. Nephrology2002;7(Suppl 3):A40. [CENTRAL: CN‐00794721] LocatelliF , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) corrects anemia of chronic renal insufficiency (CRI) at a reduced dose frequency compared with rHuEPO [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00671771] LocatelliF , OlivaresJ , WalkerR , WilkieM , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant‐human erythropoietin (r‐HuEPO) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):283A. [CENTRAL: CN‐00626023] LocatelliF , OlivaresJ , WalkerR , WilkieM , JenkinsB , DeweyC , et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International2001;60(2):741‐7. [MEDLINE: 11473657] ">Locatelli 2001</a>), one enrolled children with stage 4, 5, and 5D (<a href="./references#CD009297-bbs2-0030" title="WaradyBA , ArarMY , LernerG , NakanishiAM , Stehman‐BreenC . Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatric Nephrology2006;21(8):1144‐52. [MEDLINE: 16724235] ">Warady 2006</a>) and the remainder were in adults with CKD stage 5D (<a href="./references#CD009297-bbs2-0003" title="AllonM , KleinmanAK , WalczykM , KaupkeC , MaroniBJ , HeatheringtonA , et al. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time‐and dose‐linear [abstract no: A1308]. Journal of the American Society of Nephrology2000;11(Sept):248A. [CENTRAL: CN‐00626053] AllonM , KleinmanK , WalczykM , KaupkeC , Messer‐MannL , OlsonK , et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clinical Pharmacology &amp; Therapeutics2002;72(5):546‐55. [MEDLINE: 12426518] ">Allon 2002</a>; <a href="./references#CD009297-bbs2-0008" title="CoyneDW , LingBN , TotoR , McDermott‐VitakAD , TrotmanML , JacksonL . Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant‐human erythropoietin (R‐HUEPO) [abstract no:1380]. Journal of the American Society of Nephrology2000;11(Sept):263A. [CENTRAL: CN‐00583382] ">Coyne 2000</a>; <a href="./references#CD009297-bbs2-0009" title="CoyneD , ZeigR , BenzR , BernsJ , VarmaN , NakanishiA , et al. A randomized, double‐blind study comparing darbepoetin alfa and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American (AA) subjects with chronic kidney disease (CKD) receiving hemodialysis (HD) [abstract no:TH‐PO365]. Journal of the American Society of Nephrology2006;17(Abstracts):184A. [CENTRAL: CN‐00740574] NCT00111995 . A randomized, double‐blind study comparing Aranesp© (darbepoetin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American subjects with chronic renal failure (CRF) receiving hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00111995 (accessed 16 January 2014). ">Coyne 2006a</a>; <a href="./references#CD009297-bbs2-0011" title="HoriK , TsujimotoY , OhmoriH , NakamuraH , SugaA , IwasakiM , et al. Randomized, double‐blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no:F‐PO502]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00740529] ">Hori 2004</a>; <a href="./references#CD009297-bbs2-0012" title="IwasakiT , KimataN , SugiO , SawaraY , JinnaiH , KikuchiK , et al. Difference in reactivity became more evident by changing of the erythropoiesis‐stimulating agent (ESA) [abstract no: PUB462]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):914A. [CENTRAL: CN‐00792600] ">Iwasaki 2008</a>; <a href="./references#CD009297-bbs2-0015" title="LiWY , ChuTS , HuangJW , WuMS , WuKD . Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. Journal of the Formosan Medical Association2008;107(11):843‐50. [MEDLINE: 18971153] ">Li 2008</a>; <a href="./references#CD009297-bbs2-0020" title="NissensonA , KrishnanM , LiuW , McCaryL , Stehman‐BreenC , MixC . Hemoglobin (Hb) variability does not differ between hemodialysis (HD) patients treated with epoetin alfa and darbepoetin alfa [abstract no: TH‐PO360]. Journal of the American Society of Nephrology2006;17(Abstracts):183A. [CENTRAL: CN‐00740539] NissensonAR . Dosing darbepoetin alfa. American Journal of Kidney Diseases2002;40(4):872. [MEDLINE: 12324929] NissensonAR , SwanSK , LindbergJS , SorokaSD , BeateyR , WangC , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases2002;40(1):110‐8. [MEDLINE: 12087568] NissensonAR , SwanSK , LindbergJS , SorokaSD , McDermott‐VitakAD , WangC , et al. Novel Erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r‐HuEPO when administered once weekly [abstract no: A1326]. Journal of the American Society of Nephrology2000;11(Sept):252A. [CENTRAL: CN‐00794722] NissensonAR , US/Canadian NESP 980117 Study Group. Once weekly IV novel erythropoiesis stimulating protein (NESP) effectively maintains Hb in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00446969] ">Nissenson 2002</a>; <a href="./references#CD009297-bbs2-0022" title="SmythJS , MarshallW , AshfieldL , EliasL , McGinnS . Conversion from subcutaneous to intravenous erythropoietin analogues is cost neutral: results of a six month pilot study [abstract no: PUB246]. Journal of the American Society of Nephrology2004;15(Oct):814A‐5A. [CENTRAL: CN‐00792440] ">Smyth 2004</a>; <a href="./references#CD009297-bbs2-0025" title="TessitoreN , MantovaniW , BedognaV , LossR , MelilliE , PoliA , et al. Cost analysis of switching from epoetin alfa to darbepoetin alfa in chronic hemodialysis patients (HD Pts): a long‐term, randomized, open‐label, cross‐over, pilot study [abstract no: SA‐PO2645]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):706A. [CENTRAL: CN‐00740545] ">Tessitore 2008</a>; <a href="./references#CD009297-bbs2-0027" title="TolmanC , RichardsonD , BartlettC , WillE . A randomised study of weekly subcutaneous Aranesp and Neorecormon in a large unselected haemodialysis cohort, managed with computer assisted anaemia algorithms [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:229‐30. [CENTRAL: CN‐00509514] TolmanC , RichardsonD , BartlettC , WillE . Application of computer assisted anaemia management algorithms in haemodialysis patients produces predictable haemoglobin outcomes regardless of the erythropoietic agent or frequency of administration: results of a randomised study [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:110. [CENTRAL: CN‐00509513] TolmanC , RichardsonD , BartlettC , WillE . Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision‐support system: a randomized clinical study. Journal of the American Society of Nephrology2005;16(5):1463‐70. [MEDLINE: 15788469] TolmanC , RichardsonD , BartlettC , WillEJ . Dose conversion ratio (DCR) from subcutaneous epoetin‐B (EPO) to weekly darbepoetin‐A (DA) is dependent on baseline sensitivity: results from a randomised study [abstract no: SA‐PO461]. Journal of the American Society of Nephrology2004;15(Oct):404A. [CENTRAL: CN‐00583282] WestRM , HarrisK , GilthorpeMS , TolmanC , WillEJ . Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. Journal of the American Society of Nephrology2007;18(8):2371‐6. [MEDLINE: 17625113] ">Tolman 2005</a>; <a href="./references#CD009297-bbs2-0029" title="CanaudB . Darbepoetin alfa dose requirements for IV and SC administration are equivalent in anaemic dialysis patients [abstract no: M319]. Nephrology Dialysis Transplantation2002;17(Suppl 1):137. [CENTRAL: CN‐00550478] KerrPG , HarrisD , HawleyC , WalkerR , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains haemoglobin in ESRD patients with administered once weekly or once every other week [abstract no: 181]. Nephrology2000;5(3):A112. [CENTRAL: CN‐00509271] VanrenterghemY , BaranyP , MannJ , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (hgb) in ESRD patients when administered once weekly or once every other week [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):270A. [CENTRAL: CN‐00583820] VanrenterghemY , BaranyP , MannJF , KerrPG , WilsonJ , BakerNF , et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International2002;62(6):2167‐75. [MEDLINE: 12427142] ">Vanrenterghem 2002</a>; <a href="./references#CD009297-bbs2-0032" title="YoonSY , BangBK , KimSG , HanDC , HwangSD , ParkJS , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of renal anemia in hemodialysis patients [abstract no: MP271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:322. [CENTRAL: CN‐00509573] ">Yoon 2004</a>). No data were available for kidney transplant recipients. </p> <p>Hb levels targeted by treatment ranged between 9.0 and 13.0 g/L. Two studies reported a higher Hb level target in the darbepoetin alfa arm than in the epoetin arm (<a href="./references#CD009297-bbs2-0002" title="AkizawaT , GejyoF , NishiS , IinoY , WatanabeY , SuzukiM , et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Therapeutic Apheresis &amp; Dialysis2011;15(5):431‐40. [MEDLINE: 21974695] AkizawaT , TsubakiharaY . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the efficacy [abstract no: SU‐PO804]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00740554] TsubakiharaY , AkizawaT . High target hemoglobin with erythropoiesis stimulating agent (ESA) in chronic kidney disease (CKD) slows the occurrence rate of events related to decline of renal function [abstract no: SA‐FC341]. Journal of the American Society of Nephrology2009;20:79A. [CENTRAL: CN‐00793981] TsubakiharaY , AkizawaT . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the safety [abstract no: SU‐PO818]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):765A. [CENTRAL: CN‐00740542] ">Akizawa 2011</a>; <a href="./references#CD009297-bbs2-0010" title="HirakataH , GejyoF , SuzukiM , SaitoA , LinoY , WatanabeY , et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health‐related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO204]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00740524] HirakataH , TsubakiharaY , GejyoF , NishiS , IinoY , WatanabeY , et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre‐dialysis Japanese chronic kidney disease patients. Clinical &amp; Experimental Nephrology2010;14(1):28‐35. [MEDLINE: 19763743] InagumaD , TsubakiharaY , HirakataH , HiroeM , HadaY , AkizawaT , et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi352. [CENTRAL: CN‐00740573] SuzukiM , HadaY , AkaishiM , HiroeM , AonumaK , TsubakiharaY , et al. Effects of anemia correction by erythropoiesis‐stimulating agents on cardiovascular function in non‐dialysis patients with chronic kidney disease. International Heart Journal2012;53(4):238‐43. [MEDLINE: 22878802] ">Hirakata 2010</a>). In seven studies, Hb levels were kept within a target range based on baseline Hb levels (generally between 1.0 g/dL below to 1.0 to 1.5 g/dL above baseline values) (<a href="./references#CD009297-bbs2-0003" title="AllonM , KleinmanAK , WalczykM , KaupkeC , MaroniBJ , HeatheringtonA , et al. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time‐and dose‐linear [abstract no: A1308]. Journal of the American Society of Nephrology2000;11(Sept):248A. [CENTRAL: CN‐00626053] AllonM , KleinmanK , WalczykM , KaupkeC , Messer‐MannL , OlsonK , et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clinical Pharmacology &amp; Therapeutics2002;72(5):546‐55. [MEDLINE: 12426518] ">Allon 2002</a>; <a href="./references#CD009297-bbs2-0011" title="HoriK , TsujimotoY , OhmoriH , NakamuraH , SugaA , IwasakiM , et al. Randomized, double‐blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no:F‐PO502]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00740529] ">Hori 2004</a>; <a href="./references#CD009297-bbs2-0015" title="LiWY , ChuTS , HuangJW , WuMS , WuKD . Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. Journal of the Formosan Medical Association2008;107(11):843‐50. [MEDLINE: 18971153] ">Li 2008</a>; <a href="./references#CD009297-bbs2-0016" title="JohnsonDW , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (darbepoetin alpha) corrects anaemia of early chronic kidney disease (CKD) at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) [abstract no: P156]. Nephrology2002;7(Suppl 3):A40. [CENTRAL: CN‐00794721] LocatelliF , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) corrects anemia of chronic renal insufficiency (CRI) at a reduced dose frequency compared with rHuEPO [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00671771] LocatelliF , OlivaresJ , WalkerR , WilkieM , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant‐human erythropoietin (r‐HuEPO) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):283A. [CENTRAL: CN‐00626023] LocatelliF , OlivaresJ , WalkerR , WilkieM , JenkinsB , DeweyC , et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International2001;60(2):741‐7. [MEDLINE: 11473657] ">Locatelli 2001</a>; <a href="./references#CD009297-bbs2-0020" title="NissensonA , KrishnanM , LiuW , McCaryL , Stehman‐BreenC , MixC . Hemoglobin (Hb) variability does not differ between hemodialysis (HD) patients treated with epoetin alfa and darbepoetin alfa [abstract no: TH‐PO360]. Journal of the American Society of Nephrology2006;17(Abstracts):183A. [CENTRAL: CN‐00740539] NissensonAR . Dosing darbepoetin alfa. American Journal of Kidney Diseases2002;40(4):872. [MEDLINE: 12324929] NissensonAR , SwanSK , LindbergJS , SorokaSD , BeateyR , WangC , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases2002;40(1):110‐8. [MEDLINE: 12087568] NissensonAR , SwanSK , LindbergJS , SorokaSD , McDermott‐VitakAD , WangC , et al. Novel Erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r‐HuEPO when administered once weekly [abstract no: A1326]. Journal of the American Society of Nephrology2000;11(Sept):252A. [CENTRAL: CN‐00794722] NissensonAR , US/Canadian NESP 980117 Study Group. Once weekly IV novel erythropoiesis stimulating protein (NESP) effectively maintains Hb in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00446969] ">Nissenson 2002</a>; <a href="./references#CD009297-bbs2-0029" title="CanaudB . Darbepoetin alfa dose requirements for IV and SC administration are equivalent in anaemic dialysis patients [abstract no: M319]. Nephrology Dialysis Transplantation2002;17(Suppl 1):137. [CENTRAL: CN‐00550478] KerrPG , HarrisD , HawleyC , WalkerR , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains haemoglobin in ESRD patients with administered once weekly or once every other week [abstract no: 181]. Nephrology2000;5(3):A112. [CENTRAL: CN‐00509271] VanrenterghemY , BaranyP , MannJ , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (hgb) in ESRD patients when administered once weekly or once every other week [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):270A. [CENTRAL: CN‐00583820] VanrenterghemY , BaranyP , MannJF , KerrPG , WilsonJ , BakerNF , et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International2002;62(6):2167‐75. [MEDLINE: 12427142] ">Vanrenterghem 2002</a>; <a href="./references#CD009297-bbs2-0032" title="YoonSY , BangBK , KimSG , HanDC , HwangSD , ParkJS , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of renal anemia in hemodialysis patients [abstract no: MP271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:322. [CENTRAL: CN‐00509573] ">Yoon 2004</a>). </p> <p>Primary outcomes in the studies comparing darbepoetin alfa with epoetin alfa or beta were largely Hb levels (maintenance within a defined target, mean change during treatment, stability of Hb levels, response to treatment). In <a href="./references#CD009297-bbs2-0010" title="HirakataH , GejyoF , SuzukiM , SaitoA , LinoY , WatanabeY , et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health‐related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO204]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00740524] HirakataH , TsubakiharaY , GejyoF , NishiS , IinoY , WatanabeY , et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre‐dialysis Japanese chronic kidney disease patients. Clinical &amp; Experimental Nephrology2010;14(1):28‐35. [MEDLINE: 19763743] InagumaD , TsubakiharaY , HirakataH , HiroeM , HadaY , AkizawaT , et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi352. [CENTRAL: CN‐00740573] SuzukiM , HadaY , AkaishiM , HiroeM , AonumaK , TsubakiharaY , et al. Effects of anemia correction by erythropoiesis‐stimulating agents on cardiovascular function in non‐dialysis patients with chronic kidney disease. International Heart Journal2012;53(4):238‐43. [MEDLINE: 22878802] ">Hirakata 2010</a> (171 participants) the primary outcome included left ventricular mass index and quality of life. Treatment duration ranged between 16 and 54 weeks (median 28 weeks). The mean age of participants ranged between 48 and 60.9 years. One study evaluated darbepoetin versus epoetin in 124 children (mean age 12 years) (<a href="./references#CD009297-bbs2-0030" title="WaradyBA , ArarMY , LernerG , NakanishiAM , Stehman‐BreenC . Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatric Nephrology2006;21(8):1144‐52. [MEDLINE: 16724235] ">Warady 2006</a>). </p> <p>Of the 16 studies comparing darbepoetin alfa with epoetin alfa or beta, nine studies (2264 participants) reported sufficient data to be included in our meta‐analyses (<a href="./references#CD009297-bbs2-0009" title="CoyneD , ZeigR , BenzR , BernsJ , VarmaN , NakanishiA , et al. A randomized, double‐blind study comparing darbepoetin alfa and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American (AA) subjects with chronic kidney disease (CKD) receiving hemodialysis (HD) [abstract no:TH‐PO365]. Journal of the American Society of Nephrology2006;17(Abstracts):184A. [CENTRAL: CN‐00740574] NCT00111995 . A randomized, double‐blind study comparing Aranesp© (darbepoetin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American subjects with chronic renal failure (CRF) receiving hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00111995 (accessed 16 January 2014). ">Coyne 2006a</a>; <a href="./references#CD009297-bbs2-0010" title="HirakataH , GejyoF , SuzukiM , SaitoA , LinoY , WatanabeY , et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health‐related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO204]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00740524] HirakataH , TsubakiharaY , GejyoF , NishiS , IinoY , WatanabeY , et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre‐dialysis Japanese chronic kidney disease patients. Clinical &amp; Experimental Nephrology2010;14(1):28‐35. [MEDLINE: 19763743] InagumaD , TsubakiharaY , HirakataH , HiroeM , HadaY , AkizawaT , et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi352. [CENTRAL: CN‐00740573] SuzukiM , HadaY , AkaishiM , HiroeM , AonumaK , TsubakiharaY , et al. Effects of anemia correction by erythropoiesis‐stimulating agents on cardiovascular function in non‐dialysis patients with chronic kidney disease. International Heart Journal2012;53(4):238‐43. [MEDLINE: 22878802] ">Hirakata 2010</a>; <a href="./references#CD009297-bbs2-0011" title="HoriK , TsujimotoY , OhmoriH , NakamuraH , SugaA , IwasakiM , et al. Randomized, double‐blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no:F‐PO502]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00740529] ">Hori 2004</a>; <a href="./references#CD009297-bbs2-0016" title="JohnsonDW , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (darbepoetin alpha) corrects anaemia of early chronic kidney disease (CKD) at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) [abstract no: P156]. Nephrology2002;7(Suppl 3):A40. [CENTRAL: CN‐00794721] LocatelliF , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) corrects anemia of chronic renal insufficiency (CRI) at a reduced dose frequency compared with rHuEPO [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00671771] LocatelliF , OlivaresJ , WalkerR , WilkieM , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant‐human erythropoietin (r‐HuEPO) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):283A. [CENTRAL: CN‐00626023] LocatelliF , OlivaresJ , WalkerR , WilkieM , JenkinsB , DeweyC , et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International2001;60(2):741‐7. [MEDLINE: 11473657] ">Locatelli 2001</a>; <a href="./references#CD009297-bbs2-0020" title="NissensonA , KrishnanM , LiuW , McCaryL , Stehman‐BreenC , MixC . Hemoglobin (Hb) variability does not differ between hemodialysis (HD) patients treated with epoetin alfa and darbepoetin alfa [abstract no: TH‐PO360]. Journal of the American Society of Nephrology2006;17(Abstracts):183A. [CENTRAL: CN‐00740539] NissensonAR . Dosing darbepoetin alfa. American Journal of Kidney Diseases2002;40(4):872. [MEDLINE: 12324929] NissensonAR , SwanSK , LindbergJS , SorokaSD , BeateyR , WangC , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases2002;40(1):110‐8. [MEDLINE: 12087568] NissensonAR , SwanSK , LindbergJS , SorokaSD , McDermott‐VitakAD , WangC , et al. Novel Erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r‐HuEPO when administered once weekly [abstract no: A1326]. Journal of the American Society of Nephrology2000;11(Sept):252A. [CENTRAL: CN‐00794722] NissensonAR , US/Canadian NESP 980117 Study Group. Once weekly IV novel erythropoiesis stimulating protein (NESP) effectively maintains Hb in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00446969] ">Nissenson 2002</a>; <a href="./references#CD009297-bbs2-0022" title="SmythJS , MarshallW , AshfieldL , EliasL , McGinnS . Conversion from subcutaneous to intravenous erythropoietin analogues is cost neutral: results of a six month pilot study [abstract no: PUB246]. Journal of the American Society of Nephrology2004;15(Oct):814A‐5A. [CENTRAL: CN‐00792440] ">Smyth 2004</a>; <a href="./references#CD009297-bbs2-0027" title="TolmanC , RichardsonD , BartlettC , WillE . A randomised study of weekly subcutaneous Aranesp and Neorecormon in a large unselected haemodialysis cohort, managed with computer assisted anaemia algorithms [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:229‐30. [CENTRAL: CN‐00509514] TolmanC , RichardsonD , BartlettC , WillE . Application of computer assisted anaemia management algorithms in haemodialysis patients produces predictable haemoglobin outcomes regardless of the erythropoietic agent or frequency of administration: results of a randomised study [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:110. [CENTRAL: CN‐00509513] TolmanC , RichardsonD , BartlettC , WillE . Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision‐support system: a randomized clinical study. Journal of the American Society of Nephrology2005;16(5):1463‐70. [MEDLINE: 15788469] TolmanC , RichardsonD , BartlettC , WillEJ . Dose conversion ratio (DCR) from subcutaneous epoetin‐B (EPO) to weekly darbepoetin‐A (DA) is dependent on baseline sensitivity: results from a randomised study [abstract no: SA‐PO461]. Journal of the American Society of Nephrology2004;15(Oct):404A. [CENTRAL: CN‐00583282] WestRM , HarrisK , GilthorpeMS , TolmanC , WillEJ . Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. Journal of the American Society of Nephrology2007;18(8):2371‐6. [MEDLINE: 17625113] ">Tolman 2005</a>; <a href="./references#CD009297-bbs2-0029" title="CanaudB . Darbepoetin alfa dose requirements for IV and SC administration are equivalent in anaemic dialysis patients [abstract no: M319]. Nephrology Dialysis Transplantation2002;17(Suppl 1):137. [CENTRAL: CN‐00550478] KerrPG , HarrisD , HawleyC , WalkerR , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains haemoglobin in ESRD patients with administered once weekly or once every other week [abstract no: 181]. Nephrology2000;5(3):A112. [CENTRAL: CN‐00509271] VanrenterghemY , BaranyP , MannJ , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (hgb) in ESRD patients when administered once weekly or once every other week [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):270A. [CENTRAL: CN‐00583820] VanrenterghemY , BaranyP , MannJF , KerrPG , WilsonJ , BakerNF , et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International2002;62(6):2167‐75. [MEDLINE: 12427142] ">Vanrenterghem 2002</a>; <a href="./references#CD009297-bbs2-0030" title="WaradyBA , ArarMY , LernerG , NakanishiAM , Stehman‐BreenC . Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatric Nephrology2006;21(8):1144‐52. [MEDLINE: 16724235] ">Warady 2006</a>). </p> </section> <section id="CD009297-sec-0054"> <h5 class="title">Darbepoetin alfa versus methoxy polyethylene glycol‐epoetin beta</h5> <p>Four studies (1198 participants) compared darbepoetin alfa with methoxy polyethylene glycol‐epoetin beta (<a href="./references#CD009297-bbs2-0004" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , DeAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00644214] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009297-bbs2-0021" title="CarreraF . CERA vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009297-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>; <a href="./references#CD009297-bbs2-0026" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: 27]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of CERA once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4. ">TIVOLI Study 2011</a>). All were published in 2008 or later and one study has so far been only been reported as an abstract (<a href="./references#CD009297-bbs2-0026" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: 27]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of CERA once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4. ">TIVOLI Study 2011</a>). All studies enrolled adults. Two studies (803 participants) enrolled adults with CKD stage 5D (<a href="./references#CD009297-bbs2-0021" title="CarreraF . CERA vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009297-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>), one study evaluated treatment in 324 participants with CKD stages 3 and 4 (creatinine clearance 30 to 59 mL/min) (<a href="./references#CD009297-bbs2-0004" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , DeAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00644214] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>) and one study evaluated treatment in 71 kidney transplant recipients (<a href="./references#CD009297-bbs2-0026" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: 27]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of CERA once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4. ">TIVOLI Study 2011</a>). Treatment duration ranged between 28 and 52 weeks, although was this was unclear in one study (<a href="./references#CD009297-bbs2-0026" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: 27]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of CERA once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4. ">TIVOLI Study 2011</a>). </p> <p>Hb responses to treatment, Hb level variation, or mean change in Hb were primary outcomes. Mean age in treatment arms ranged between 61.8 and 66.9 years. The target Hb levels were 10 to 13.5 g/dL and within 1.0 g/dL of baseline (<a href="./references#CD009297-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>); 10 to 12 g/dL and within a 1.0 g/dL range (<a href="./references#CD009297-bbs2-0026" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: 27]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of CERA once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4. ">TIVOLI Study 2011</a>); 11 to 13 g/dL and not below 1.0 g/dL of baseline (<a href="./references#CD009297-bbs2-0021" title="CarreraF . CERA vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>); and ≥11 g/dL and ≥1.0 g/dL above baseline (<a href="./references#CD009297-bbs2-0004" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , DeAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00644214] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>). </p> <p>All four studies provided data that could be included in our meta‐analyses. No data comparing darbepoetin alfa with methoxy polyethylene glycol‐epoetin beta were available in children. </p> </section> <section id="CD009297-sec-0055"> <h5 class="title">Darbepoetin alfa every two weeks versus darbepoetin every four weeks</h5> <p>One study (64 participants) reported data comparing equivalent doses of darbepoetin alfa administered every four weeks compared with every two weeks in abstract format only (<a href="./references#CD009297-bbs2-0014" title="KwanBC , LeungC , SzetoC , LiPK . Efficacy of bi‐weekly versus monthly subcutaneous darbepoetin‐alpha for the maintenance treatment of anemia in peritoneal dialysis patients ‐ an open‐label randomized study [abstract no:SA‐PO805]. Journal of the American Society of Nephrology2005;16:732A. [CENTRAL: CN‐00740570] ">Kwan 2005</a>). Participants had CKD stage 5D treated with peritoneal dialysis and were treated with darbepoetin alfa over 24 weeks. The primary outcome was end of treatment Hb level. The dose of darbepoetin alfa was calculated according to epoetin dosing requirements and kept stable during treatment. Data for this comparison were available for inclusion in our meta‐analyses. No data comparing four‐weekly with two‐weekly darbepoetin alfa were available for patients with CKD stages 3 to 5, transplant recipients, or children with any stage of CKD. </p> </section> <section id="CD009297-sec-0056"> <h5 class="title">Darbepoetin alfa weekly versus darbepoetin every two weeks</h5> <p>Two studies (356 participants) compared darbepoetin alfa every two weeks versus once a week (<a href="./references#CD009297-bbs2-0017" title="LocatelliF , BacksW , delPinoMD , deMartinA , GuillaumeB , VikydalR , et al. Control of anaemia with Aranesp®: haemoglobin stability achieved with fewer patients requiring dose adjustments after switching to Aranesp® every 2‐weeks [abstract no: SP411]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv152. [CENTRAL: CN‐00740593] LocatelliF , VillaG , BacksW , delPinoMD . A phase 3, multicentre, randomised, double‐blind, non‐inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) inpatients on haemodialysis (HD) [abstract no: MP181]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v260. [CENTRAL: CN‐00740588] LocatelliF , VillaG , BacksW , delPinoMD . Aranesp® (darbepoetin alfa) maintains hemoglobin (Hb) levels in hemodialysis (HD) patients at extended dosing intervals regardless of previous recombinant human erythropoietin (rHuEPO) dosing frequency [abstract no: PUB254]. Journal of the American Society of Nephrology2004;15(Oct):816A. [CENTRAL: CN‐00740589] ">Locatelli 2004</a>; <a href="./references#CD009297-bbs2-0019" title="InagumaD , NagayaH , HamaguchiK , TatematsuM , SuzukiS , KurataK . Intravenous darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in Japanese patients on hemodialysis [abstract no: TH‐PO741]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):275A. [CENTRAL: CN‐00740572] NagayaH , InagumaD , KitagawaA , MurataM , KamimuraY , HamaguchiK , et al. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. Clinical &amp; Experimental Nephrology2010;14(2):158‐63. [MEDLINE: 19967423] ">Nagaya 2010</a>). One study was an abstract publication only (<a href="./references#CD009297-bbs2-0017" title="LocatelliF , BacksW , delPinoMD , deMartinA , GuillaumeB , VikydalR , et al. Control of anaemia with Aranesp®: haemoglobin stability achieved with fewer patients requiring dose adjustments after switching to Aranesp® every 2‐weeks [abstract no: SP411]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv152. [CENTRAL: CN‐00740593] LocatelliF , VillaG , BacksW , delPinoMD . A phase 3, multicentre, randomised, double‐blind, non‐inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) inpatients on haemodialysis (HD) [abstract no: MP181]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v260. [CENTRAL: CN‐00740588] LocatelliF , VillaG , BacksW , delPinoMD . Aranesp® (darbepoetin alfa) maintains hemoglobin (Hb) levels in hemodialysis (HD) patients at extended dosing intervals regardless of previous recombinant human erythropoietin (rHuEPO) dosing frequency [abstract no: PUB254]. Journal of the American Society of Nephrology2004;15(Oct):816A. [CENTRAL: CN‐00740589] ">Locatelli 2004</a>). Both studies evaluated treatment in participants with CKD stage 5D. Study duration was 24 weeks (<a href="./references#CD009297-bbs2-0019" title="InagumaD , NagayaH , HamaguchiK , TatematsuM , SuzukiS , KurataK . Intravenous darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in Japanese patients on hemodialysis [abstract no: TH‐PO741]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):275A. [CENTRAL: CN‐00740572] NagayaH , InagumaD , KitagawaA , MurataM , KamimuraY , HamaguchiK , et al. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. Clinical &amp; Experimental Nephrology2010;14(2):158‐63. [MEDLINE: 19967423] ">Nagaya 2010</a>) and 30 weeks (<a href="./references#CD009297-bbs2-0017" title="LocatelliF , BacksW , delPinoMD , deMartinA , GuillaumeB , VikydalR , et al. Control of anaemia with Aranesp®: haemoglobin stability achieved with fewer patients requiring dose adjustments after switching to Aranesp® every 2‐weeks [abstract no: SP411]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv152. [CENTRAL: CN‐00740593] LocatelliF , VillaG , BacksW , delPinoMD . A phase 3, multicentre, randomised, double‐blind, non‐inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) inpatients on haemodialysis (HD) [abstract no: MP181]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v260. [CENTRAL: CN‐00740588] LocatelliF , VillaG , BacksW , delPinoMD . Aranesp® (darbepoetin alfa) maintains hemoglobin (Hb) levels in hemodialysis (HD) patients at extended dosing intervals regardless of previous recombinant human erythropoietin (rHuEPO) dosing frequency [abstract no: PUB254]. Journal of the American Society of Nephrology2004;15(Oct):816A. [CENTRAL: CN‐00740589] ">Locatelli 2004</a>). Primary end points were Hb levels during treatment (<a href="./references#CD009297-bbs2-0017" title="LocatelliF , BacksW , delPinoMD , deMartinA , GuillaumeB , VikydalR , et al. Control of anaemia with Aranesp®: haemoglobin stability achieved with fewer patients requiring dose adjustments after switching to Aranesp® every 2‐weeks [abstract no: SP411]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv152. [CENTRAL: CN‐00740593] LocatelliF , VillaG , BacksW , delPinoMD . A phase 3, multicentre, randomised, double‐blind, non‐inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) inpatients on haemodialysis (HD) [abstract no: MP181]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v260. [CENTRAL: CN‐00740588] LocatelliF , VillaG , BacksW , delPinoMD . Aranesp® (darbepoetin alfa) maintains hemoglobin (Hb) levels in hemodialysis (HD) patients at extended dosing intervals regardless of previous recombinant human erythropoietin (rHuEPO) dosing frequency [abstract no: PUB254]. Journal of the American Society of Nephrology2004;15(Oct):816A. [CENTRAL: CN‐00740589] ">Locatelli 2004</a>) and weekly dose of darbepoetin alfa at end of treatment (<a href="./references#CD009297-bbs2-0019" title="InagumaD , NagayaH , HamaguchiK , TatematsuM , SuzukiS , KurataK . Intravenous darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in Japanese patients on hemodialysis [abstract no: TH‐PO741]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):275A. [CENTRAL: CN‐00740572] NagayaH , InagumaD , KitagawaA , MurataM , KamimuraY , HamaguchiK , et al. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. Clinical &amp; Experimental Nephrology2010;14(2):158‐63. [MEDLINE: 19967423] ">Nagaya 2010</a>). Treatment was targeted to achieve Hb levels between 10 and 13 g/dL and within ‐1.0 to +1.5 g/dL of baseline (<a href="./references#CD009297-bbs2-0017" title="LocatelliF , BacksW , delPinoMD , deMartinA , GuillaumeB , VikydalR , et al. Control of anaemia with Aranesp®: haemoglobin stability achieved with fewer patients requiring dose adjustments after switching to Aranesp® every 2‐weeks [abstract no: SP411]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv152. [CENTRAL: CN‐00740593] LocatelliF , VillaG , BacksW , delPinoMD . A phase 3, multicentre, randomised, double‐blind, non‐inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) inpatients on haemodialysis (HD) [abstract no: MP181]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v260. [CENTRAL: CN‐00740588] LocatelliF , VillaG , BacksW , delPinoMD . Aranesp® (darbepoetin alfa) maintains hemoglobin (Hb) levels in hemodialysis (HD) patients at extended dosing intervals regardless of previous recombinant human erythropoietin (rHuEPO) dosing frequency [abstract no: PUB254]. Journal of the American Society of Nephrology2004;15(Oct):816A. [CENTRAL: CN‐00740589] ">Locatelli 2004</a>) and between 10.5 and 11.5 g/dL (<a href="./references#CD009297-bbs2-0019" title="InagumaD , NagayaH , HamaguchiK , TatematsuM , SuzukiS , KurataK . Intravenous darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in Japanese patients on hemodialysis [abstract no: TH‐PO741]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):275A. [CENTRAL: CN‐00740572] NagayaH , InagumaD , KitagawaA , MurataM , KamimuraY , HamaguchiK , et al. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. Clinical &amp; Experimental Nephrology2010;14(2):158‐63. [MEDLINE: 19967423] ">Nagaya 2010</a>). One study provided data extractable for meta‐analysis (<a href="./references#CD009297-bbs2-0019" title="InagumaD , NagayaH , HamaguchiK , TatematsuM , SuzukiS , KurataK . Intravenous darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in Japanese patients on hemodialysis [abstract no: TH‐PO741]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):275A. [CENTRAL: CN‐00740572] NagayaH , InagumaD , KitagawaA , MurataM , KamimuraY , HamaguchiK , et al. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. Clinical &amp; Experimental Nephrology2010;14(2):158‐63. [MEDLINE: 19967423] ">Nagaya 2010</a>). </p> <p>No data comparing darbepoetin alfa treatment every two weeks compared to once a week were available for patients with CKD stage 3 to 5, transplant recipients, or children with any stage of CKD. </p> </section> <section id="CD009297-sec-0057"> <h5 class="title">Darbepoetin alfa intravenous versus subcutaneous administration</h5> <p>Four studies (303 participants) compared IV administration with SC administration (<a href="./references#CD009297-bbs2-0001" title="AarupM , BryndumJ , DieperinkH , JoffeP . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrology Dialysis Transplantation2006;21(5):1312‐6. [MEDLINE: 16396971] AarupM , BryndumJ , JoffeP , DieperinkH . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of Aranesp® (darbepoetin alfa) [abstract no: PUB278]. Journal of the American Society of Nephrology2004;15(Oct):821A. [CENTRAL: CN‐00583657] ">Aarup 2004</a>; <a href="./references#CD009297-bbs2-0005" title="BommerJ , AsmusG , WenningM , BommerG . A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study. Nephrology Dialysis Transplantation2008;23(12):4002‐8. [MEDLINE: 18676350] BommerJ , AsmusH , BommerG , WenningM . Efficacy of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: W‐PO40135]. Nephrology2005;10(Suppl 1):A315. [CENTRAL: CN‐00602087] BommerJ , AssmusH , BommerG , WenningM . Comparison of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: F‐PO499]. Journal of the American Society of Nephrology2004;15(Oct):176A. [CENTRAL: CN‐00583725] BommerJ , WenningM , BommerG . Comparison of IV or SC darbepoetin in hemodialysis patients [abstract no: F‐PO676]. Journal of the American Society of Nephrology2005;16:482A. [CENTRAL: CN‐00583778] ">Bommer 2004</a>; <a href="./references#CD009297-bbs2-0006" title="CervelliMJ , DisneyAPS , GrayN , McDonaldSP . Randomised, single blinded, cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients [abstract]. Nephrology2004;9(Suppl 1):A28. [CENTRAL: CN‐00509125] CervelliMJ , GrayN , McDonaldS , GentgallMG , DisneyAP . Randomized cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology2005;10(2):129‐35. [MEDLINE: 15877671] ">Cervelli 2005</a>; <a href="./references#CD009297-bbs2-0013" title="KimCD , ParkSH , KimDJ , DoJY , ShinSK , KimBS , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in hemodialysis patient [abstract no: TH‐PO370]. Journal of the American Society of Nephrology2006;17(Abstracts):185A. [CENTRAL: CN‐00740537] KimCD , ParkSH , KimDJ , ParkJW , DoJY , ShinSK , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. Nephrology2009;14(5):482‐7. [MEDLINE: 19298639] ">Kim 2009a</a>). One study compared darbepoetin alfa IV administration compared with initial SC administration followed by delayed IV administration in 154 participants (<a href="./references#CD009297-bbs2-0007" title="ChazotC , DumoulinA , AngKS , PaulGJ , BernardC , Conference Medicale Group. Haemodialysis patients under subcutaneous recombinant human erythropoietin can be directly switched to intravenous Aranesp® [abstract no: F‐PO682]. Journal of the American Society of Nephrology2005;16:483A. [CENTRAL: CN‐00740583] ChazotC , TerratJC , AngK , GassiaJP , ChedidK , MauriceF , et al. Intravenous darbepoetin A maintains hemoglobin level in hemodialysis patients converting from subcutaneous recombinant human erythropoietin. [abstract no: F‐PO501]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00583168] ChazotC , TerratJC , DumoulinA , AngKS , GassiaJP , ChedidK , et al. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa. Annals of Pharmacotherapy2009;43(2):228‐34. [MEDLINE: 19407262] ">Chazot 2009</a>). Study duration ranged between 20 and 52 weeks. Administration frequency ranged between once a week and every two weeks. All studies evaluated treatment in adults treated with haemodialysis. Primary outcomes included darbepoetin alfa dose necessary to maintain the Hb level within the defined range (<a href="./references#CD009297-bbs2-0001" title="AarupM , BryndumJ , DieperinkH , JoffeP . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrology Dialysis Transplantation2006;21(5):1312‐6. [MEDLINE: 16396971] AarupM , BryndumJ , JoffeP , DieperinkH . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of Aranesp® (darbepoetin alfa) [abstract no: PUB278]. Journal of the American Society of Nephrology2004;15(Oct):821A. [CENTRAL: CN‐00583657] ">Aarup 2004</a>; <a href="./references#CD009297-bbs2-0005" title="BommerJ , AsmusG , WenningM , BommerG . A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study. Nephrology Dialysis Transplantation2008;23(12):4002‐8. [MEDLINE: 18676350] BommerJ , AsmusH , BommerG , WenningM . Efficacy of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: W‐PO40135]. Nephrology2005;10(Suppl 1):A315. [CENTRAL: CN‐00602087] BommerJ , AssmusH , BommerG , WenningM . Comparison of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: F‐PO499]. Journal of the American Society of Nephrology2004;15(Oct):176A. [CENTRAL: CN‐00583725] BommerJ , WenningM , BommerG . Comparison of IV or SC darbepoetin in hemodialysis patients [abstract no: F‐PO676]. Journal of the American Society of Nephrology2005;16:482A. [CENTRAL: CN‐00583778] ">Bommer 2004</a>; <a href="./references#CD009297-bbs2-0013" title="KimCD , ParkSH , KimDJ , DoJY , ShinSK , KimBS , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in hemodialysis patient [abstract no: TH‐PO370]. Journal of the American Society of Nephrology2006;17(Abstracts):185A. [CENTRAL: CN‐00740537] KimCD , ParkSH , KimDJ , ParkJW , DoJY , ShinSK , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. Nephrology2009;14(5):482‐7. [MEDLINE: 19298639] ">Kim 2009a</a>) and variation in Hb levels (<a href="./references#CD009297-bbs2-0006" title="CervelliMJ , DisneyAPS , GrayN , McDonaldSP . Randomised, single blinded, cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients [abstract]. Nephrology2004;9(Suppl 1):A28. [CENTRAL: CN‐00509125] CervelliMJ , GrayN , McDonaldS , GentgallMG , DisneyAP . Randomized cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology2005;10(2):129‐35. [MEDLINE: 15877671] ">Cervelli 2005</a>). Hb levels were maintained between 6.8 and 8.5 mmol/L and within a target range of ‐0.8 to +0.8 mmol/L of the baseline value (<a href="./references#CD009297-bbs2-0001" title="AarupM , BryndumJ , DieperinkH , JoffeP . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrology Dialysis Transplantation2006;21(5):1312‐6. [MEDLINE: 16396971] AarupM , BryndumJ , JoffeP , DieperinkH . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of Aranesp® (darbepoetin alfa) [abstract no: PUB278]. Journal of the American Society of Nephrology2004;15(Oct):821A. [CENTRAL: CN‐00583657] ">Aarup 2004</a>); 10 to 13 g/dL (<a href="./references#CD009297-bbs2-0005" title="BommerJ , AsmusG , WenningM , BommerG . A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study. Nephrology Dialysis Transplantation2008;23(12):4002‐8. [MEDLINE: 18676350] BommerJ , AsmusH , BommerG , WenningM . Efficacy of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: W‐PO40135]. Nephrology2005;10(Suppl 1):A315. [CENTRAL: CN‐00602087] BommerJ , AssmusH , BommerG , WenningM . Comparison of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: F‐PO499]. Journal of the American Society of Nephrology2004;15(Oct):176A. [CENTRAL: CN‐00583725] BommerJ , WenningM , BommerG . Comparison of IV or SC darbepoetin in hemodialysis patients [abstract no: F‐PO676]. Journal of the American Society of Nephrology2005;16:482A. [CENTRAL: CN‐00583778] ">Bommer 2004</a>); 11 to 13 g/dL and within ‐1.0 and +1.0 g/dL of evaluation phase level (<a href="./references#CD009297-bbs2-0006" title="CervelliMJ , DisneyAPS , GrayN , McDonaldSP . Randomised, single blinded, cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients [abstract]. Nephrology2004;9(Suppl 1):A28. [CENTRAL: CN‐00509125] CervelliMJ , GrayN , McDonaldS , GentgallMG , DisneyAP . Randomized cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology2005;10(2):129‐35. [MEDLINE: 15877671] ">Cervelli 2005</a>); and 8.0 to 11.0 g/dL (<a href="./references#CD009297-bbs2-0013" title="KimCD , ParkSH , KimDJ , DoJY , ShinSK , KimBS , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in hemodialysis patient [abstract no: TH‐PO370]. Journal of the American Society of Nephrology2006;17(Abstracts):185A. [CENTRAL: CN‐00740537] KimCD , ParkSH , KimDJ , ParkJW , DoJY , ShinSK , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. Nephrology2009;14(5):482‐7. [MEDLINE: 19298639] ">Kim 2009a</a>). Three studies provided data in a format extractable for meta‐analysis (<a href="./references#CD009297-bbs2-0001" title="AarupM , BryndumJ , DieperinkH , JoffeP . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrology Dialysis Transplantation2006;21(5):1312‐6. [MEDLINE: 16396971] AarupM , BryndumJ , JoffeP , DieperinkH . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of Aranesp® (darbepoetin alfa) [abstract no: PUB278]. Journal of the American Society of Nephrology2004;15(Oct):821A. [CENTRAL: CN‐00583657] ">Aarup 2004</a>; <a href="./references#CD009297-bbs2-0005" title="BommerJ , AsmusG , WenningM , BommerG . A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study. Nephrology Dialysis Transplantation2008;23(12):4002‐8. [MEDLINE: 18676350] BommerJ , AsmusH , BommerG , WenningM . Efficacy of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: W‐PO40135]. Nephrology2005;10(Suppl 1):A315. [CENTRAL: CN‐00602087] BommerJ , AssmusH , BommerG , WenningM . Comparison of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: F‐PO499]. Journal of the American Society of Nephrology2004;15(Oct):176A. [CENTRAL: CN‐00583725] BommerJ , WenningM , BommerG . Comparison of IV or SC darbepoetin in hemodialysis patients [abstract no: F‐PO676]. Journal of the American Society of Nephrology2005;16:482A. [CENTRAL: CN‐00583778] ">Bommer 2004</a>; <a href="./references#CD009297-bbs2-0013" title="KimCD , ParkSH , KimDJ , DoJY , ShinSK , KimBS , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in hemodialysis patient [abstract no: TH‐PO370]. Journal of the American Society of Nephrology2006;17(Abstracts):185A. [CENTRAL: CN‐00740537] KimCD , ParkSH , KimDJ , ParkJW , DoJY , ShinSK , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. Nephrology2009;14(5):482‐7. [MEDLINE: 19298639] ">Kim 2009a</a>). </p> <p>No data comparing darbepoetin alfa administered IV versus SC were available for patients with CKD stages 3 to 5, transplant recipients, or children with any stage of CKD. </p> </section> <section id="CD009297-sec-0058"> <h5 class="title">Other comparisons</h5> <p>One study compared darbepoetin alfa administered every two, three and four weeks with every two weekly dosing in 25 participants with CKD stage 3 to 5 (mean eGFR 30.6 mL/min) (<a href="./references#CD009297-bbs2-0024" title="SvarstadE , ForslundT . Nurse assisted nine months darbepoetin (D) treatment with fix dose and variable dosing interval in an outpatient clinic is cost effective in predialytic CKD patients [abstract no: SU‐PO800]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00740562] ">Svarstad 2007</a>). Target Hb ranged between 12 to 14 g/dL and treatment duration was three months. Data were available in an abstract publication only. One study (289 participants) compared darbepoetin or epoetin given IV compared to once a week IV epoetin to maintain Hb levels at 11.0 to 13.0 g/dL for 28 weeks (<a href="./references#CD009297-bbs2-0018" title="LocatelliF , VillaG , MessaP , FilippiniA , CannellaG , DeFerrariG , et al. Efficacy and safety of once‐weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. Journal of Nephrology2008;21(3):412‐20. [MEDLINE: 18587731] ">Locatelli 2008</a>). Primary end points were the changes in Hb levels and weekly dose between baseline and assessment phase. In one study, darbepoetin alfa was administered either every two weeks or every four weeks at initial doses of 30 or 60 μg/kg body weight in 32 participants with CKD stage 3 to 5 (<a href="./references#CD009297-bbs2-0031" title="WatanabeY , GejyoF , ShigematsuT , IinoY , HosoyaT , ShojiT , et al. KRN321 (darbepoetin alfa) administered once every other week (Q2W) and once every four weeks (Q4W) in predialysis chronic renal failure (CRF) patients in Japan [abstract no: SU‐PO053]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00740541] ">Watanabe 2004</a>). The randomised comparison in this study was unclear. </p> </section> </section> </section> <section id="CD009297-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>Studies included in this review were generally at high or unclear risk of bias for all items (random sequence generation, allocation concealment, incomplete outcome data, blinding of participants and personnel, blinding of outcome assessment, selective outcome reporting, intention to treat analysis and other sources of bias (<a href="#CD009297-fig-0002">Figure 2</a>; <a href="#CD009297-fig-0003">Figure 3</a>). One large study comparing darbepoetin alfa with placebo was at low risk for most items assessed (<a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>). </p> <div class="figure" id="CD009297-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009297-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009297-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009297-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009297-sec-0060"> <h4 class="title">Allocation</h4> <section id="CD009297-sec-0061"> <h5 class="title">Random sequence generation</h5> <p>Seven of 32 studies (22%) were at low risk of selection bias due to appropriate random sequence generation (<a href="./references#CD009297-bbs2-0006" title="CervelliMJ , DisneyAPS , GrayN , McDonaldSP . Randomised, single blinded, cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients [abstract]. Nephrology2004;9(Suppl 1):A28. [CENTRAL: CN‐00509125] CervelliMJ , GrayN , McDonaldS , GentgallMG , DisneyAP . Randomized cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology2005;10(2):129‐35. [MEDLINE: 15877671] ">Cervelli 2005</a>; <a href="./references#CD009297-bbs2-0013" title="KimCD , ParkSH , KimDJ , DoJY , ShinSK , KimBS , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in hemodialysis patient [abstract no: TH‐PO370]. Journal of the American Society of Nephrology2006;17(Abstracts):185A. [CENTRAL: CN‐00740537] KimCD , ParkSH , KimDJ , ParkJW , DoJY , ShinSK , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. Nephrology2009;14(5):482‐7. [MEDLINE: 19298639] ">Kim 2009a</a>; <a href="./references#CD009297-bbs2-0020" title="NissensonA , KrishnanM , LiuW , McCaryL , Stehman‐BreenC , MixC . Hemoglobin (Hb) variability does not differ between hemodialysis (HD) patients treated with epoetin alfa and darbepoetin alfa [abstract no: TH‐PO360]. Journal of the American Society of Nephrology2006;17(Abstracts):183A. [CENTRAL: CN‐00740539] NissensonAR . Dosing darbepoetin alfa. American Journal of Kidney Diseases2002;40(4):872. [MEDLINE: 12324929] NissensonAR , SwanSK , LindbergJS , SorokaSD , BeateyR , WangC , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases2002;40(1):110‐8. [MEDLINE: 12087568] NissensonAR , SwanSK , LindbergJS , SorokaSD , McDermott‐VitakAD , WangC , et al. Novel Erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r‐HuEPO when administered once weekly [abstract no: A1326]. Journal of the American Society of Nephrology2000;11(Sept):252A. [CENTRAL: CN‐00794722] NissensonAR , US/Canadian NESP 980117 Study Group. Once weekly IV novel erythropoiesis stimulating protein (NESP) effectively maintains Hb in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00446969] ">Nissenson 2002</a>; <a href="./references#CD009297-bbs2-0021" title="CarreraF . CERA vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>; <a href="./references#CD009297-bbs2-0029" title="CanaudB . Darbepoetin alfa dose requirements for IV and SC administration are equivalent in anaemic dialysis patients [abstract no: M319]. Nephrology Dialysis Transplantation2002;17(Suppl 1):137. [CENTRAL: CN‐00550478] KerrPG , HarrisD , HawleyC , WalkerR , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains haemoglobin in ESRD patients with administered once weekly or once every other week [abstract no: 181]. Nephrology2000;5(3):A112. [CENTRAL: CN‐00509271] VanrenterghemY , BaranyP , MannJ , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (hgb) in ESRD patients when administered once weekly or once every other week [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):270A. [CENTRAL: CN‐00583820] VanrenterghemY , BaranyP , MannJF , KerrPG , WilsonJ , BakerNF , et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International2002;62(6):2167‐75. [MEDLINE: 12427142] ">Vanrenterghem 2002</a>; <a href="./references#CD009297-bbs2-0030" title="WaradyBA , ArarMY , LernerG , NakanishiAM , Stehman‐BreenC . Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatric Nephrology2006;21(8):1144‐52. [MEDLINE: 16724235] ">Warady 2006</a>) and one was at high risk (<a href="./references#CD009297-bbs2-0025" title="TessitoreN , MantovaniW , BedognaV , LossR , MelilliE , PoliA , et al. Cost analysis of switching from epoetin alfa to darbepoetin alfa in chronic hemodialysis patients (HD Pts): a long‐term, randomized, open‐label, cross‐over, pilot study [abstract no: SA‐PO2645]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):706A. [CENTRAL: CN‐00740545] ">Tessitore 2008</a>). For random sequence generation in each treatment comparison, the only study comparing darbepoetin with placebo (<a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>), three studies comparing darbepoetin with epoetin (<a href="./references#CD009297-bbs2-0020" title="NissensonA , KrishnanM , LiuW , McCaryL , Stehman‐BreenC , MixC . Hemoglobin (Hb) variability does not differ between hemodialysis (HD) patients treated with epoetin alfa and darbepoetin alfa [abstract no: TH‐PO360]. Journal of the American Society of Nephrology2006;17(Abstracts):183A. [CENTRAL: CN‐00740539] NissensonAR . Dosing darbepoetin alfa. American Journal of Kidney Diseases2002;40(4):872. [MEDLINE: 12324929] NissensonAR , SwanSK , LindbergJS , SorokaSD , BeateyR , WangC , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases2002;40(1):110‐8. [MEDLINE: 12087568] NissensonAR , SwanSK , LindbergJS , SorokaSD , McDermott‐VitakAD , WangC , et al. Novel Erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r‐HuEPO when administered once weekly [abstract no: A1326]. Journal of the American Society of Nephrology2000;11(Sept):252A. [CENTRAL: CN‐00794722] NissensonAR , US/Canadian NESP 980117 Study Group. Once weekly IV novel erythropoiesis stimulating protein (NESP) effectively maintains Hb in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00446969] ">Nissenson 2002</a>; <a href="./references#CD009297-bbs2-0029" title="CanaudB . Darbepoetin alfa dose requirements for IV and SC administration are equivalent in anaemic dialysis patients [abstract no: M319]. Nephrology Dialysis Transplantation2002;17(Suppl 1):137. [CENTRAL: CN‐00550478] KerrPG , HarrisD , HawleyC , WalkerR , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains haemoglobin in ESRD patients with administered once weekly or once every other week [abstract no: 181]. Nephrology2000;5(3):A112. [CENTRAL: CN‐00509271] VanrenterghemY , BaranyP , MannJ , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (hgb) in ESRD patients when administered once weekly or once every other week [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):270A. [CENTRAL: CN‐00583820] VanrenterghemY , BaranyP , MannJF , KerrPG , WilsonJ , BakerNF , et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International2002;62(6):2167‐75. [MEDLINE: 12427142] ">Vanrenterghem 2002</a>; <a href="./references#CD009297-bbs2-0030" title="WaradyBA , ArarMY , LernerG , NakanishiAM , Stehman‐BreenC . Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatric Nephrology2006;21(8):1144‐52. [MEDLINE: 16724235] ">Warady 2006</a>), one study comparing darbepoetin with methoxy polyethylene glycol‐epoetin beta (<a href="./references#CD009297-bbs2-0021" title="CarreraF . CERA vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>), none of the three studies comparing differing dosing frequencies (<a href="./references#CD009297-bbs2-0019" title="InagumaD , NagayaH , HamaguchiK , TatematsuM , SuzukiS , KurataK . Intravenous darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in Japanese patients on hemodialysis [abstract no: TH‐PO741]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):275A. [CENTRAL: CN‐00740572] NagayaH , InagumaD , KitagawaA , MurataM , KamimuraY , HamaguchiK , et al. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. Clinical &amp; Experimental Nephrology2010;14(2):158‐63. [MEDLINE: 19967423] ">Nagaya 2010</a>; <a href="./references#CD009297-bbs2-0014" title="KwanBC , LeungC , SzetoC , LiPK . Efficacy of bi‐weekly versus monthly subcutaneous darbepoetin‐alpha for the maintenance treatment of anemia in peritoneal dialysis patients ‐ an open‐label randomized study [abstract no:SA‐PO805]. Journal of the American Society of Nephrology2005;16:732A. [CENTRAL: CN‐00740570] ">Kwan 2005</a>; <a href="./references#CD009297-bbs2-0017" title="LocatelliF , BacksW , delPinoMD , deMartinA , GuillaumeB , VikydalR , et al. Control of anaemia with Aranesp®: haemoglobin stability achieved with fewer patients requiring dose adjustments after switching to Aranesp® every 2‐weeks [abstract no: SP411]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv152. [CENTRAL: CN‐00740593] LocatelliF , VillaG , BacksW , delPinoMD . A phase 3, multicentre, randomised, double‐blind, non‐inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) inpatients on haemodialysis (HD) [abstract no: MP181]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v260. [CENTRAL: CN‐00740588] LocatelliF , VillaG , BacksW , delPinoMD . Aranesp® (darbepoetin alfa) maintains hemoglobin (Hb) levels in hemodialysis (HD) patients at extended dosing intervals regardless of previous recombinant human erythropoietin (rHuEPO) dosing frequency [abstract no: PUB254]. Journal of the American Society of Nephrology2004;15(Oct):816A. [CENTRAL: CN‐00740589] ">Locatelli 2004</a>), and two studies comparing IV with SC administration (<a href="./references#CD009297-bbs2-0006" title="CervelliMJ , DisneyAPS , GrayN , McDonaldSP . Randomised, single blinded, cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients [abstract]. Nephrology2004;9(Suppl 1):A28. [CENTRAL: CN‐00509125] CervelliMJ , GrayN , McDonaldS , GentgallMG , DisneyAP . Randomized cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology2005;10(2):129‐35. [MEDLINE: 15877671] ">Cervelli 2005</a>; <a href="./references#CD009297-bbs2-0013" title="KimCD , ParkSH , KimDJ , DoJY , ShinSK , KimBS , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in hemodialysis patient [abstract no: TH‐PO370]. Journal of the American Society of Nephrology2006;17(Abstracts):185A. [CENTRAL: CN‐00740537] KimCD , ParkSH , KimDJ , ParkJW , DoJY , ShinSK , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. Nephrology2009;14(5):482‐7. [MEDLINE: 19298639] ">Kim 2009a</a>) were at low risk of bias. </p> </section> <section id="CD009297-sec-0062"> <h5 class="title">Allocation concealment</h5> <p>Six of 32 studies (19%) were at low risk due to adequate allocation concealment (<a href="./references#CD009297-bbs2-0004" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , DeAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00644214] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009297-bbs2-0005" title="BommerJ , AsmusG , WenningM , BommerG . A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study. Nephrology Dialysis Transplantation2008;23(12):4002‐8. [MEDLINE: 18676350] BommerJ , AsmusH , BommerG , WenningM . Efficacy of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: W‐PO40135]. Nephrology2005;10(Suppl 1):A315. [CENTRAL: CN‐00602087] BommerJ , AssmusH , BommerG , WenningM . Comparison of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: F‐PO499]. Journal of the American Society of Nephrology2004;15(Oct):176A. [CENTRAL: CN‐00583725] BommerJ , WenningM , BommerG . Comparison of IV or SC darbepoetin in hemodialysis patients [abstract no: F‐PO676]. Journal of the American Society of Nephrology2005;16:482A. [CENTRAL: CN‐00583778] ">Bommer 2004</a>; <a href="./references#CD009297-bbs2-0010" title="HirakataH , GejyoF , SuzukiM , SaitoA , LinoY , WatanabeY , et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health‐related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO204]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00740524] HirakataH , TsubakiharaY , GejyoF , NishiS , IinoY , WatanabeY , et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre‐dialysis Japanese chronic kidney disease patients. Clinical &amp; Experimental Nephrology2010;14(1):28‐35. [MEDLINE: 19763743] InagumaD , TsubakiharaY , HirakataH , HiroeM , HadaY , AkizawaT , et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi352. [CENTRAL: CN‐00740573] SuzukiM , HadaY , AkaishiM , HiroeM , AonumaK , TsubakiharaY , et al. Effects of anemia correction by erythropoiesis‐stimulating agents on cardiovascular function in non‐dialysis patients with chronic kidney disease. International Heart Journal2012;53(4):238‐43. [MEDLINE: 22878802] ">Hirakata 2010</a>; <a href="./references#CD009297-bbs2-0021" title="CarreraF . CERA vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009297-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>; <a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>). In each treatment comparison, the only study comparing darbepoetin with placebo (<a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>), one study comparing darbepoetin with epoetin (<a href="./references#CD009297-bbs2-0010" title="HirakataH , GejyoF , SuzukiM , SaitoA , LinoY , WatanabeY , et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health‐related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO204]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00740524] HirakataH , TsubakiharaY , GejyoF , NishiS , IinoY , WatanabeY , et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre‐dialysis Japanese chronic kidney disease patients. Clinical &amp; Experimental Nephrology2010;14(1):28‐35. [MEDLINE: 19763743] InagumaD , TsubakiharaY , HirakataH , HiroeM , HadaY , AkizawaT , et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi352. [CENTRAL: CN‐00740573] SuzukiM , HadaY , AkaishiM , HiroeM , AonumaK , TsubakiharaY , et al. Effects of anemia correction by erythropoiesis‐stimulating agents on cardiovascular function in non‐dialysis patients with chronic kidney disease. International Heart Journal2012;53(4):238‐43. [MEDLINE: 22878802] ">Hirakata 2010</a>), three studies of studies comparing darbepoetin with methoxy polyethylene glycol‐epoetin beta (<a href="./references#CD009297-bbs2-0004" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , DeAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00644214] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009297-bbs2-0021" title="CarreraF . CERA vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009297-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>), none of the three studies comparing differing dosing frequencies, and one study comparing IV with SC administration (<a href="./references#CD009297-bbs2-0005" title="BommerJ , AsmusG , WenningM , BommerG . A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study. Nephrology Dialysis Transplantation2008;23(12):4002‐8. [MEDLINE: 18676350] BommerJ , AsmusH , BommerG , WenningM . Efficacy of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: W‐PO40135]. Nephrology2005;10(Suppl 1):A315. [CENTRAL: CN‐00602087] BommerJ , AssmusH , BommerG , WenningM . Comparison of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: F‐PO499]. Journal of the American Society of Nephrology2004;15(Oct):176A. [CENTRAL: CN‐00583725] BommerJ , WenningM , BommerG . Comparison of IV or SC darbepoetin in hemodialysis patients [abstract no: F‐PO676]. Journal of the American Society of Nephrology2005;16:482A. [CENTRAL: CN‐00583778] ">Bommer 2004</a>) were at low risk of bias. </p> </section> </section> <section id="CD009297-sec-0063"> <h4 class="title">Blinding</h4> <p>Overall, 5/32 (16%) were at low risk due to blinding of study personnel and patients (<a href="./references#CD009297-bbs2-0009" title="CoyneD , ZeigR , BenzR , BernsJ , VarmaN , NakanishiA , et al. A randomized, double‐blind study comparing darbepoetin alfa and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American (AA) subjects with chronic kidney disease (CKD) receiving hemodialysis (HD) [abstract no:TH‐PO365]. Journal of the American Society of Nephrology2006;17(Abstracts):184A. [CENTRAL: CN‐00740574] NCT00111995 . A randomized, double‐blind study comparing Aranesp© (darbepoetin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American subjects with chronic renal failure (CRF) receiving hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00111995 (accessed 16 January 2014). ">Coyne 2006a</a>; <a href="./references#CD009297-bbs2-0011" title="HoriK , TsujimotoY , OhmoriH , NakamuraH , SugaA , IwasakiM , et al. Randomized, double‐blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no:F‐PO502]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00740529] ">Hori 2004</a>; <a href="./references#CD009297-bbs2-0017" title="LocatelliF , BacksW , delPinoMD , deMartinA , GuillaumeB , VikydalR , et al. Control of anaemia with Aranesp®: haemoglobin stability achieved with fewer patients requiring dose adjustments after switching to Aranesp® every 2‐weeks [abstract no: SP411]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv152. [CENTRAL: CN‐00740593] LocatelliF , VillaG , BacksW , delPinoMD . A phase 3, multicentre, randomised, double‐blind, non‐inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) inpatients on haemodialysis (HD) [abstract no: MP181]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v260. [CENTRAL: CN‐00740588] LocatelliF , VillaG , BacksW , delPinoMD . Aranesp® (darbepoetin alfa) maintains hemoglobin (Hb) levels in hemodialysis (HD) patients at extended dosing intervals regardless of previous recombinant human erythropoietin (rHuEPO) dosing frequency [abstract no: PUB254]. Journal of the American Society of Nephrology2004;15(Oct):816A. [CENTRAL: CN‐00740589] ">Locatelli 2004</a>; <a href="./references#CD009297-bbs2-0020" title="NissensonA , KrishnanM , LiuW , McCaryL , Stehman‐BreenC , MixC . Hemoglobin (Hb) variability does not differ between hemodialysis (HD) patients treated with epoetin alfa and darbepoetin alfa [abstract no: TH‐PO360]. Journal of the American Society of Nephrology2006;17(Abstracts):183A. [CENTRAL: CN‐00740539] NissensonAR . Dosing darbepoetin alfa. American Journal of Kidney Diseases2002;40(4):872. [MEDLINE: 12324929] NissensonAR , SwanSK , LindbergJS , SorokaSD , BeateyR , WangC , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases2002;40(1):110‐8. [MEDLINE: 12087568] NissensonAR , SwanSK , LindbergJS , SorokaSD , McDermott‐VitakAD , WangC , et al. Novel Erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r‐HuEPO when administered once weekly [abstract no: A1326]. Journal of the American Society of Nephrology2000;11(Sept):252A. [CENTRAL: CN‐00794722] NissensonAR , US/Canadian NESP 980117 Study Group. Once weekly IV novel erythropoiesis stimulating protein (NESP) effectively maintains Hb in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00446969] ">Nissenson 2002</a>; <a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>) and 17 studies were at high risk (<a href="./references#CD009297-bbs2-0001" title="AarupM , BryndumJ , DieperinkH , JoffeP . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrology Dialysis Transplantation2006;21(5):1312‐6. [MEDLINE: 16396971] AarupM , BryndumJ , JoffeP , DieperinkH . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of Aranesp® (darbepoetin alfa) [abstract no: PUB278]. Journal of the American Society of Nephrology2004;15(Oct):821A. [CENTRAL: CN‐00583657] ">Aarup 2004</a>; <a href="./references#CD009297-bbs2-0003" title="AllonM , KleinmanAK , WalczykM , KaupkeC , MaroniBJ , HeatheringtonA , et al. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time‐and dose‐linear [abstract no: A1308]. Journal of the American Society of Nephrology2000;11(Sept):248A. [CENTRAL: CN‐00626053] AllonM , KleinmanK , WalczykM , KaupkeC , Messer‐MannL , OlsonK , et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clinical Pharmacology &amp; Therapeutics2002;72(5):546‐55. [MEDLINE: 12426518] ">Allon 2002</a>; <a href="./references#CD009297-bbs2-0004" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , DeAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00644214] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009297-bbs2-0007" title="ChazotC , DumoulinA , AngKS , PaulGJ , BernardC , Conference Medicale Group. Haemodialysis patients under subcutaneous recombinant human erythropoietin can be directly switched to intravenous Aranesp® [abstract no: F‐PO682]. Journal of the American Society of Nephrology2005;16:483A. [CENTRAL: CN‐00740583] ChazotC , TerratJC , AngK , GassiaJP , ChedidK , MauriceF , et al. Intravenous darbepoetin A maintains hemoglobin level in hemodialysis patients converting from subcutaneous recombinant human erythropoietin. [abstract no: F‐PO501]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00583168] ChazotC , TerratJC , DumoulinA , AngKS , GassiaJP , ChedidK , et al. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa. Annals of Pharmacotherapy2009;43(2):228‐34. [MEDLINE: 19407262] ">Chazot 2009</a>; <a href="./references#CD009297-bbs2-0010" title="HirakataH , GejyoF , SuzukiM , SaitoA , LinoY , WatanabeY , et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health‐related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO204]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00740524] HirakataH , TsubakiharaY , GejyoF , NishiS , IinoY , WatanabeY , et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre‐dialysis Japanese chronic kidney disease patients. Clinical &amp; Experimental Nephrology2010;14(1):28‐35. [MEDLINE: 19763743] InagumaD , TsubakiharaY , HirakataH , HiroeM , HadaY , AkizawaT , et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi352. [CENTRAL: CN‐00740573] SuzukiM , HadaY , AkaishiM , HiroeM , AonumaK , TsubakiharaY , et al. Effects of anemia correction by erythropoiesis‐stimulating agents on cardiovascular function in non‐dialysis patients with chronic kidney disease. International Heart Journal2012;53(4):238‐43. [MEDLINE: 22878802] ">Hirakata 2010</a>; <a href="./references#CD009297-bbs2-0013" title="KimCD , ParkSH , KimDJ , DoJY , ShinSK , KimBS , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in hemodialysis patient [abstract no: TH‐PO370]. Journal of the American Society of Nephrology2006;17(Abstracts):185A. [CENTRAL: CN‐00740537] KimCD , ParkSH , KimDJ , ParkJW , DoJY , ShinSK , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. Nephrology2009;14(5):482‐7. [MEDLINE: 19298639] ">Kim 2009a</a>; <a href="./references#CD009297-bbs2-0014" title="KwanBC , LeungC , SzetoC , LiPK . Efficacy of bi‐weekly versus monthly subcutaneous darbepoetin‐alpha for the maintenance treatment of anemia in peritoneal dialysis patients ‐ an open‐label randomized study [abstract no:SA‐PO805]. Journal of the American Society of Nephrology2005;16:732A. [CENTRAL: CN‐00740570] ">Kwan 2005</a>; <a href="./references#CD009297-bbs2-0015" title="LiWY , ChuTS , HuangJW , WuMS , WuKD . Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. Journal of the Formosan Medical Association2008;107(11):843‐50. [MEDLINE: 18971153] ">Li 2008</a>; <a href="./references#CD009297-bbs2-0016" title="JohnsonDW , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (darbepoetin alpha) corrects anaemia of early chronic kidney disease (CKD) at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) [abstract no: P156]. Nephrology2002;7(Suppl 3):A40. [CENTRAL: CN‐00794721] LocatelliF , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) corrects anemia of chronic renal insufficiency (CRI) at a reduced dose frequency compared with rHuEPO [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00671771] LocatelliF , OlivaresJ , WalkerR , WilkieM , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant‐human erythropoietin (r‐HuEPO) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):283A. [CENTRAL: CN‐00626023] LocatelliF , OlivaresJ , WalkerR , WilkieM , JenkinsB , DeweyC , et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International2001;60(2):741‐7. [MEDLINE: 11473657] ">Locatelli 2001</a>; <a href="./references#CD009297-bbs2-0018" title="LocatelliF , VillaG , MessaP , FilippiniA , CannellaG , DeFerrariG , et al. Efficacy and safety of once‐weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. Journal of Nephrology2008;21(3):412‐20. [MEDLINE: 18587731] ">Locatelli 2008</a>; <a href="./references#CD009297-bbs2-0021" title="CarreraF . CERA vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009297-bbs2-0025" title="TessitoreN , MantovaniW , BedognaV , LossR , MelilliE , PoliA , et al. Cost analysis of switching from epoetin alfa to darbepoetin alfa in chronic hemodialysis patients (HD Pts): a long‐term, randomized, open‐label, cross‐over, pilot study [abstract no: SA‐PO2645]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):706A. [CENTRAL: CN‐00740545] ">Tessitore 2008</a>; <a href="./references#CD009297-bbs2-0026" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: 27]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of CERA once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4. ">TIVOLI Study 2011</a>; <a href="./references#CD009297-bbs2-0027" title="TolmanC , RichardsonD , BartlettC , WillE . A randomised study of weekly subcutaneous Aranesp and Neorecormon in a large unselected haemodialysis cohort, managed with computer assisted anaemia algorithms [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:229‐30. [CENTRAL: CN‐00509514] TolmanC , RichardsonD , BartlettC , WillE . Application of computer assisted anaemia management algorithms in haemodialysis patients produces predictable haemoglobin outcomes regardless of the erythropoietic agent or frequency of administration: results of a randomised study [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:110. [CENTRAL: CN‐00509513] TolmanC , RichardsonD , BartlettC , WillE . Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision‐support system: a randomized clinical study. Journal of the American Society of Nephrology2005;16(5):1463‐70. [MEDLINE: 15788469] TolmanC , RichardsonD , BartlettC , WillEJ . Dose conversion ratio (DCR) from subcutaneous epoetin‐B (EPO) to weekly darbepoetin‐A (DA) is dependent on baseline sensitivity: results from a randomised study [abstract no: SA‐PO461]. Journal of the American Society of Nephrology2004;15(Oct):404A. [CENTRAL: CN‐00583282] WestRM , HarrisK , GilthorpeMS , TolmanC , WillEJ . Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. Journal of the American Society of Nephrology2007;18(8):2371‐6. [MEDLINE: 17625113] ">Tolman 2005</a>; <a href="./references#CD009297-bbs2-0029" title="CanaudB . Darbepoetin alfa dose requirements for IV and SC administration are equivalent in anaemic dialysis patients [abstract no: M319]. Nephrology Dialysis Transplantation2002;17(Suppl 1):137. [CENTRAL: CN‐00550478] KerrPG , HarrisD , HawleyC , WalkerR , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains haemoglobin in ESRD patients with administered once weekly or once every other week [abstract no: 181]. Nephrology2000;5(3):A112. [CENTRAL: CN‐00509271] VanrenterghemY , BaranyP , MannJ , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (hgb) in ESRD patients when administered once weekly or once every other week [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):270A. [CENTRAL: CN‐00583820] VanrenterghemY , BaranyP , MannJF , KerrPG , WilsonJ , BakerNF , et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International2002;62(6):2167‐75. [MEDLINE: 12427142] ">Vanrenterghem 2002</a>; <a href="./references#CD009297-bbs2-0030" title="WaradyBA , ArarMY , LernerG , NakanishiAM , Stehman‐BreenC . Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatric Nephrology2006;21(8):1144‐52. [MEDLINE: 16724235] ">Warady 2006</a>). </p> <p>In each treatment comparison, the only study comparing darbepoetin with placebo (<a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>), three studies comparing darbepoetin with epoetin (<a href="./references#CD009297-bbs2-0009" title="CoyneD , ZeigR , BenzR , BernsJ , VarmaN , NakanishiA , et al. A randomized, double‐blind study comparing darbepoetin alfa and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American (AA) subjects with chronic kidney disease (CKD) receiving hemodialysis (HD) [abstract no:TH‐PO365]. Journal of the American Society of Nephrology2006;17(Abstracts):184A. [CENTRAL: CN‐00740574] NCT00111995 . A randomized, double‐blind study comparing Aranesp© (darbepoetin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American subjects with chronic renal failure (CRF) receiving hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00111995 (accessed 16 January 2014). ">Coyne 2006a</a>; <a href="./references#CD009297-bbs2-0011" title="HoriK , TsujimotoY , OhmoriH , NakamuraH , SugaA , IwasakiM , et al. Randomized, double‐blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no:F‐PO502]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00740529] ">Hori 2004</a>; <a href="./references#CD009297-bbs2-0020" title="NissensonA , KrishnanM , LiuW , McCaryL , Stehman‐BreenC , MixC . Hemoglobin (Hb) variability does not differ between hemodialysis (HD) patients treated with epoetin alfa and darbepoetin alfa [abstract no: TH‐PO360]. Journal of the American Society of Nephrology2006;17(Abstracts):183A. [CENTRAL: CN‐00740539] NissensonAR . Dosing darbepoetin alfa. American Journal of Kidney Diseases2002;40(4):872. [MEDLINE: 12324929] NissensonAR , SwanSK , LindbergJS , SorokaSD , BeateyR , WangC , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases2002;40(1):110‐8. [MEDLINE: 12087568] NissensonAR , SwanSK , LindbergJS , SorokaSD , McDermott‐VitakAD , WangC , et al. Novel Erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r‐HuEPO when administered once weekly [abstract no: A1326]. Journal of the American Society of Nephrology2000;11(Sept):252A. [CENTRAL: CN‐00794722] NissensonAR , US/Canadian NESP 980117 Study Group. Once weekly IV novel erythropoiesis stimulating protein (NESP) effectively maintains Hb in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00446969] ">Nissenson 2002</a>), no studies comparing darbepoetin with methoxy polyethylene glycol‐epoetin beta, one study comparing differing dosing frequencies (<a href="./references#CD009297-bbs2-0017" title="LocatelliF , BacksW , delPinoMD , deMartinA , GuillaumeB , VikydalR , et al. Control of anaemia with Aranesp®: haemoglobin stability achieved with fewer patients requiring dose adjustments after switching to Aranesp® every 2‐weeks [abstract no: SP411]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv152. [CENTRAL: CN‐00740593] LocatelliF , VillaG , BacksW , delPinoMD . A phase 3, multicentre, randomised, double‐blind, non‐inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) inpatients on haemodialysis (HD) [abstract no: MP181]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v260. [CENTRAL: CN‐00740588] LocatelliF , VillaG , BacksW , delPinoMD . Aranesp® (darbepoetin alfa) maintains hemoglobin (Hb) levels in hemodialysis (HD) patients at extended dosing intervals regardless of previous recombinant human erythropoietin (rHuEPO) dosing frequency [abstract no: PUB254]. Journal of the American Society of Nephrology2004;15(Oct):816A. [CENTRAL: CN‐00740589] ">Locatelli 2004</a>), and no study comparing IV with SC administration were at low risk of bias due to blinding of study personnel or patients. </p> <p>One study (3%) was at low risk due to blinding of outcomes assessment (<a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>) and 16 were at high risk (<a href="./references#CD009297-bbs2-0001" title="AarupM , BryndumJ , DieperinkH , JoffeP . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrology Dialysis Transplantation2006;21(5):1312‐6. [MEDLINE: 16396971] AarupM , BryndumJ , JoffeP , DieperinkH . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of Aranesp® (darbepoetin alfa) [abstract no: PUB278]. Journal of the American Society of Nephrology2004;15(Oct):821A. [CENTRAL: CN‐00583657] ">Aarup 2004</a>; <a href="./references#CD009297-bbs2-0003" title="AllonM , KleinmanAK , WalczykM , KaupkeC , MaroniBJ , HeatheringtonA , et al. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time‐and dose‐linear [abstract no: A1308]. Journal of the American Society of Nephrology2000;11(Sept):248A. [CENTRAL: CN‐00626053] AllonM , KleinmanK , WalczykM , KaupkeC , Messer‐MannL , OlsonK , et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clinical Pharmacology &amp; Therapeutics2002;72(5):546‐55. [MEDLINE: 12426518] ">Allon 2002</a>; <a href="./references#CD009297-bbs2-0004" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , DeAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00644214] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009297-bbs2-0007" title="ChazotC , DumoulinA , AngKS , PaulGJ , BernardC , Conference Medicale Group. Haemodialysis patients under subcutaneous recombinant human erythropoietin can be directly switched to intravenous Aranesp® [abstract no: F‐PO682]. Journal of the American Society of Nephrology2005;16:483A. [CENTRAL: CN‐00740583] ChazotC , TerratJC , AngK , GassiaJP , ChedidK , MauriceF , et al. Intravenous darbepoetin A maintains hemoglobin level in hemodialysis patients converting from subcutaneous recombinant human erythropoietin. [abstract no: F‐PO501]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00583168] ChazotC , TerratJC , DumoulinA , AngKS , GassiaJP , ChedidK , et al. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa. Annals of Pharmacotherapy2009;43(2):228‐34. [MEDLINE: 19407262] ">Chazot 2009</a>; <a href="./references#CD009297-bbs2-0010" title="HirakataH , GejyoF , SuzukiM , SaitoA , LinoY , WatanabeY , et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health‐related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO204]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00740524] HirakataH , TsubakiharaY , GejyoF , NishiS , IinoY , WatanabeY , et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre‐dialysis Japanese chronic kidney disease patients. Clinical &amp; Experimental Nephrology2010;14(1):28‐35. [MEDLINE: 19763743] InagumaD , TsubakiharaY , HirakataH , HiroeM , HadaY , AkizawaT , et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi352. [CENTRAL: CN‐00740573] SuzukiM , HadaY , AkaishiM , HiroeM , AonumaK , TsubakiharaY , et al. Effects of anemia correction by erythropoiesis‐stimulating agents on cardiovascular function in non‐dialysis patients with chronic kidney disease. International Heart Journal2012;53(4):238‐43. [MEDLINE: 22878802] ">Hirakata 2010</a>; <a href="./references#CD009297-bbs2-0013" title="KimCD , ParkSH , KimDJ , DoJY , ShinSK , KimBS , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in hemodialysis patient [abstract no: TH‐PO370]. Journal of the American Society of Nephrology2006;17(Abstracts):185A. [CENTRAL: CN‐00740537] KimCD , ParkSH , KimDJ , ParkJW , DoJY , ShinSK , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. Nephrology2009;14(5):482‐7. [MEDLINE: 19298639] ">Kim 2009a</a>; <a href="./references#CD009297-bbs2-0014" title="KwanBC , LeungC , SzetoC , LiPK . Efficacy of bi‐weekly versus monthly subcutaneous darbepoetin‐alpha for the maintenance treatment of anemia in peritoneal dialysis patients ‐ an open‐label randomized study [abstract no:SA‐PO805]. Journal of the American Society of Nephrology2005;16:732A. [CENTRAL: CN‐00740570] ">Kwan 2005</a>; <a href="./references#CD009297-bbs2-0015" title="LiWY , ChuTS , HuangJW , WuMS , WuKD . Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. Journal of the Formosan Medical Association2008;107(11):843‐50. [MEDLINE: 18971153] ">Li 2008</a>; <a href="./references#CD009297-bbs2-0016" title="JohnsonDW , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (darbepoetin alpha) corrects anaemia of early chronic kidney disease (CKD) at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) [abstract no: P156]. Nephrology2002;7(Suppl 3):A40. [CENTRAL: CN‐00794721] LocatelliF , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) corrects anemia of chronic renal insufficiency (CRI) at a reduced dose frequency compared with rHuEPO [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00671771] LocatelliF , OlivaresJ , WalkerR , WilkieM , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant‐human erythropoietin (r‐HuEPO) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):283A. [CENTRAL: CN‐00626023] LocatelliF , OlivaresJ , WalkerR , WilkieM , JenkinsB , DeweyC , et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International2001;60(2):741‐7. [MEDLINE: 11473657] ">Locatelli 2001</a>; <a href="./references#CD009297-bbs2-0018" title="LocatelliF , VillaG , MessaP , FilippiniA , CannellaG , DeFerrariG , et al. Efficacy and safety of once‐weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. Journal of Nephrology2008;21(3):412‐20. [MEDLINE: 18587731] ">Locatelli 2008</a>; <a href="./references#CD009297-bbs2-0021" title="CarreraF . CERA vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009297-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>; <a href="./references#CD009297-bbs2-0025" title="TessitoreN , MantovaniW , BedognaV , LossR , MelilliE , PoliA , et al. Cost analysis of switching from epoetin alfa to darbepoetin alfa in chronic hemodialysis patients (HD Pts): a long‐term, randomized, open‐label, cross‐over, pilot study [abstract no: SA‐PO2645]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):706A. [CENTRAL: CN‐00740545] ">Tessitore 2008</a>; <a href="./references#CD009297-bbs2-0026" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: 27]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of CERA once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4. ">TIVOLI Study 2011</a>; <a href="./references#CD009297-bbs2-0027" title="TolmanC , RichardsonD , BartlettC , WillE . A randomised study of weekly subcutaneous Aranesp and Neorecormon in a large unselected haemodialysis cohort, managed with computer assisted anaemia algorithms [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:229‐30. [CENTRAL: CN‐00509514] TolmanC , RichardsonD , BartlettC , WillE . Application of computer assisted anaemia management algorithms in haemodialysis patients produces predictable haemoglobin outcomes regardless of the erythropoietic agent or frequency of administration: results of a randomised study [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:110. [CENTRAL: CN‐00509513] TolmanC , RichardsonD , BartlettC , WillE . Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision‐support system: a randomized clinical study. Journal of the American Society of Nephrology2005;16(5):1463‐70. [MEDLINE: 15788469] TolmanC , RichardsonD , BartlettC , WillEJ . Dose conversion ratio (DCR) from subcutaneous epoetin‐B (EPO) to weekly darbepoetin‐A (DA) is dependent on baseline sensitivity: results from a randomised study [abstract no: SA‐PO461]. Journal of the American Society of Nephrology2004;15(Oct):404A. [CENTRAL: CN‐00583282] WestRM , HarrisK , GilthorpeMS , TolmanC , WillEJ . Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. Journal of the American Society of Nephrology2007;18(8):2371‐6. [MEDLINE: 17625113] ">Tolman 2005</a>; <a href="./references#CD009297-bbs2-0029" title="CanaudB . Darbepoetin alfa dose requirements for IV and SC administration are equivalent in anaemic dialysis patients [abstract no: M319]. Nephrology Dialysis Transplantation2002;17(Suppl 1):137. [CENTRAL: CN‐00550478] KerrPG , HarrisD , HawleyC , WalkerR , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains haemoglobin in ESRD patients with administered once weekly or once every other week [abstract no: 181]. Nephrology2000;5(3):A112. [CENTRAL: CN‐00509271] VanrenterghemY , BaranyP , MannJ , European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (hgb) in ESRD patients when administered once weekly or once every other week [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):270A. [CENTRAL: CN‐00583820] VanrenterghemY , BaranyP , MannJF , KerrPG , WilsonJ , BakerNF , et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International2002;62(6):2167‐75. [MEDLINE: 12427142] ">Vanrenterghem 2002</a>; <a href="./references#CD009297-bbs2-0030" title="WaradyBA , ArarMY , LernerG , NakanishiAM , Stehman‐BreenC . Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatric Nephrology2006;21(8):1144‐52. [MEDLINE: 16724235] ">Warady 2006</a>). </p> </section> <section id="CD009297-sec-0064"> <h4 class="title">Incomplete outcome data</h4> <p>Between 0% and 83% (median of randomised participants) could not be included in analyses within the included studies. In 8/32 studies, data to identify loss to follow‐up were not provided (<a href="./references#CD009297-bbs2-0002" title="AkizawaT , GejyoF , NishiS , IinoY , WatanabeY , SuzukiM , et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Therapeutic Apheresis &amp; Dialysis2011;15(5):431‐40. [MEDLINE: 21974695] AkizawaT , TsubakiharaY . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the efficacy [abstract no: SU‐PO804]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00740554] TsubakiharaY , AkizawaT . High target hemoglobin with erythropoiesis stimulating agent (ESA) in chronic kidney disease (CKD) slows the occurrence rate of events related to decline of renal function [abstract no: SA‐FC341]. Journal of the American Society of Nephrology2009;20:79A. [CENTRAL: CN‐00793981] TsubakiharaY , AkizawaT . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the safety [abstract no: SU‐PO818]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):765A. [CENTRAL: CN‐00740542] ">Akizawa 2011</a>; <a href="./references#CD009297-bbs2-0008" title="CoyneDW , LingBN , TotoR , McDermott‐VitakAD , TrotmanML , JacksonL . Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant‐human erythropoietin (R‐HUEPO) [abstract no:1380]. Journal of the American Society of Nephrology2000;11(Sept):263A. [CENTRAL: CN‐00583382] ">Coyne 2000</a>; <a href="./references#CD009297-bbs2-0011" title="HoriK , TsujimotoY , OhmoriH , NakamuraH , SugaA , IwasakiM , et al. Randomized, double‐blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no:F‐PO502]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00740529] ">Hori 2004</a>; <a href="./references#CD009297-bbs2-0012" title="IwasakiT , KimataN , SugiO , SawaraY , JinnaiH , KikuchiK , et al. Difference in reactivity became more evident by changing of the erythropoiesis‐stimulating agent (ESA) [abstract no: PUB462]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):914A. [CENTRAL: CN‐00792600] ">Iwasaki 2008</a>; <a href="./references#CD009297-bbs2-0025" title="TessitoreN , MantovaniW , BedognaV , LossR , MelilliE , PoliA , et al. Cost analysis of switching from epoetin alfa to darbepoetin alfa in chronic hemodialysis patients (HD Pts): a long‐term, randomized, open‐label, cross‐over, pilot study [abstract no: SA‐PO2645]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):706A. [CENTRAL: CN‐00740545] ">Tessitore 2008</a>; <a href="./references#CD009297-bbs2-0026" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: 27]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of CERA once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4. ">TIVOLI Study 2011</a>; <a href="./references#CD009297-bbs2-0031" title="WatanabeY , GejyoF , ShigematsuT , IinoY , HosoyaT , ShojiT , et al. KRN321 (darbepoetin alfa) administered once every other week (Q2W) and once every four weeks (Q4W) in predialysis chronic renal failure (CRF) patients in Japan [abstract no: SU‐PO053]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00740541] ">Watanabe 2004</a>; <a href="./references#CD009297-bbs2-0032" title="YoonSY , BangBK , KimSG , HanDC , HwangSD , ParkJS , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of renal anemia in hemodialysis patients [abstract no: MP271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:322. [CENTRAL: CN‐00509573] ">Yoon 2004</a>). </p> <p>Four of 32 studies (13%) were at low risk of bias due to attrition (below 10% of randomised patients not available for inclusion in analyses) (<a href="./references#CD009297-bbs2-0004" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , DeAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00644214] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009297-bbs2-0016" title="JohnsonDW , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (darbepoetin alpha) corrects anaemia of early chronic kidney disease (CKD) at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) [abstract no: P156]. Nephrology2002;7(Suppl 3):A40. [CENTRAL: CN‐00794721] LocatelliF , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) corrects anemia of chronic renal insufficiency (CRI) at a reduced dose frequency compared with rHuEPO [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00671771] LocatelliF , OlivaresJ , WalkerR , WilkieM , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant‐human erythropoietin (r‐HuEPO) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):283A. [CENTRAL: CN‐00626023] LocatelliF , OlivaresJ , WalkerR , WilkieM , JenkinsB , DeweyC , et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International2001;60(2):741‐7. [MEDLINE: 11473657] ">Locatelli 2001</a>; <a href="./references#CD009297-bbs2-0017" title="LocatelliF , BacksW , delPinoMD , deMartinA , GuillaumeB , VikydalR , et al. Control of anaemia with Aranesp®: haemoglobin stability achieved with fewer patients requiring dose adjustments after switching to Aranesp® every 2‐weeks [abstract no: SP411]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv152. [CENTRAL: CN‐00740593] LocatelliF , VillaG , BacksW , delPinoMD . A phase 3, multicentre, randomised, double‐blind, non‐inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) inpatients on haemodialysis (HD) [abstract no: MP181]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v260. [CENTRAL: CN‐00740588] LocatelliF , VillaG , BacksW , delPinoMD . Aranesp® (darbepoetin alfa) maintains hemoglobin (Hb) levels in hemodialysis (HD) patients at extended dosing intervals regardless of previous recombinant human erythropoietin (rHuEPO) dosing frequency [abstract no: PUB254]. Journal of the American Society of Nephrology2004;15(Oct):816A. [CENTRAL: CN‐00740589] ">Locatelli 2004</a>; <a href="./references#CD009297-bbs2-0024" title="SvarstadE , ForslundT . Nurse assisted nine months darbepoetin (D) treatment with fix dose and variable dosing interval in an outpatient clinic is cost effective in predialytic CKD patients [abstract no: SU‐PO800]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00740562] ">Svarstad 2007</a>). No studies comparing darbepoetin with placebo, one study comparing darbepoetin with epoetin (<a href="./references#CD009297-bbs2-0016" title="JohnsonDW , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (darbepoetin alpha) corrects anaemia of early chronic kidney disease (CKD) at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) [abstract no: P156]. Nephrology2002;7(Suppl 3):A40. [CENTRAL: CN‐00794721] LocatelliF , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) corrects anemia of chronic renal insufficiency (CRI) at a reduced dose frequency compared with rHuEPO [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00671771] LocatelliF , OlivaresJ , WalkerR , WilkieM , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant‐human erythropoietin (r‐HuEPO) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):283A. [CENTRAL: CN‐00626023] LocatelliF , OlivaresJ , WalkerR , WilkieM , JenkinsB , DeweyC , et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International2001;60(2):741‐7. [MEDLINE: 11473657] ">Locatelli 2001</a>), one study comparing darbepoetin with methoxy polyethylene glycol‐epoetin beta (<a href="./references#CD009297-bbs2-0004" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , DeAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00644214] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>), and no studies comparing differing treatment frequencies or IV with SC administration were at low risk. </p> </section> <section id="CD009297-sec-0065"> <h4 class="title">Selective reporting</h4> <p>In eight studies (25%), published reports included all expected outcomes and were considered at low risk of bias (<a href="./references#CD009297-bbs2-0004" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , DeAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00644214] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009297-bbs2-0016" title="JohnsonDW , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (darbepoetin alpha) corrects anaemia of early chronic kidney disease (CKD) at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) [abstract no: P156]. Nephrology2002;7(Suppl 3):A40. [CENTRAL: CN‐00794721] LocatelliF , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) corrects anemia of chronic renal insufficiency (CRI) at a reduced dose frequency compared with rHuEPO [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00671771] LocatelliF , OlivaresJ , WalkerR , WilkieM , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant‐human erythropoietin (r‐HuEPO) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):283A. [CENTRAL: CN‐00626023] LocatelliF , OlivaresJ , WalkerR , WilkieM , JenkinsB , DeweyC , et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International2001;60(2):741‐7. [MEDLINE: 11473657] ">Locatelli 2001</a>; <a href="./references#CD009297-bbs2-0020" title="NissensonA , KrishnanM , LiuW , McCaryL , Stehman‐BreenC , MixC . Hemoglobin (Hb) variability does not differ between hemodialysis (HD) patients treated with epoetin alfa and darbepoetin alfa [abstract no: TH‐PO360]. Journal of the American Society of Nephrology2006;17(Abstracts):183A. [CENTRAL: CN‐00740539] NissensonAR . Dosing darbepoetin alfa. American Journal of Kidney Diseases2002;40(4):872. [MEDLINE: 12324929] NissensonAR , SwanSK , LindbergJS , SorokaSD , BeateyR , WangC , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases2002;40(1):110‐8. [MEDLINE: 12087568] NissensonAR , SwanSK , LindbergJS , SorokaSD , McDermott‐VitakAD , WangC , et al. Novel Erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r‐HuEPO when administered once weekly [abstract no: A1326]. Journal of the American Society of Nephrology2000;11(Sept):252A. [CENTRAL: CN‐00794722] NissensonAR , US/Canadian NESP 980117 Study Group. Once weekly IV novel erythropoiesis stimulating protein (NESP) effectively maintains Hb in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00446969] ">Nissenson 2002</a>; <a href="./references#CD009297-bbs2-0021" title="CarreraF . CERA vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009297-bbs2-0022" title="SmythJS , MarshallW , AshfieldL , EliasL , McGinnS . Conversion from subcutaneous to intravenous erythropoietin analogues is cost neutral: results of a six month pilot study [abstract no: PUB246]. Journal of the American Society of Nephrology2004;15(Oct):814A‐5A. [CENTRAL: CN‐00792440] ">Smyth 2004</a>; <a href="./references#CD009297-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>; <a href="./references#CD009297-bbs2-0027" title="TolmanC , RichardsonD , BartlettC , WillE . A randomised study of weekly subcutaneous Aranesp and Neorecormon in a large unselected haemodialysis cohort, managed with computer assisted anaemia algorithms [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:229‐30. [CENTRAL: CN‐00509514] TolmanC , RichardsonD , BartlettC , WillE . Application of computer assisted anaemia management algorithms in haemodialysis patients produces predictable haemoglobin outcomes regardless of the erythropoietic agent or frequency of administration: results of a randomised study [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:110. [CENTRAL: CN‐00509513] TolmanC , RichardsonD , BartlettC , WillE . Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision‐support system: a randomized clinical study. Journal of the American Society of Nephrology2005;16(5):1463‐70. [MEDLINE: 15788469] TolmanC , RichardsonD , BartlettC , WillEJ . Dose conversion ratio (DCR) from subcutaneous epoetin‐B (EPO) to weekly darbepoetin‐A (DA) is dependent on baseline sensitivity: results from a randomised study [abstract no: SA‐PO461]. Journal of the American Society of Nephrology2004;15(Oct):404A. [CENTRAL: CN‐00583282] WestRM , HarrisK , GilthorpeMS , TolmanC , WillEJ . Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. Journal of the American Society of Nephrology2007;18(8):2371‐6. [MEDLINE: 17625113] ">Tolman 2005</a>; <a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>) while 22 were considered at high risk due to potential selective reporting of outcomes (<a href="./references#CD009297-bbs2-0001" title="AarupM , BryndumJ , DieperinkH , JoffeP . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrology Dialysis Transplantation2006;21(5):1312‐6. [MEDLINE: 16396971] AarupM , BryndumJ , JoffeP , DieperinkH . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of Aranesp® (darbepoetin alfa) [abstract no: PUB278]. Journal of the American Society of Nephrology2004;15(Oct):821A. [CENTRAL: CN‐00583657] ">Aarup 2004</a>; <a href="./references#CD009297-bbs2-0002" title="AkizawaT , GejyoF , NishiS , IinoY , WatanabeY , SuzukiM , et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Therapeutic Apheresis &amp; Dialysis2011;15(5):431‐40. [MEDLINE: 21974695] AkizawaT , TsubakiharaY . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the efficacy [abstract no: SU‐PO804]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00740554] TsubakiharaY , AkizawaT . High target hemoglobin with erythropoiesis stimulating agent (ESA) in chronic kidney disease (CKD) slows the occurrence rate of events related to decline of renal function [abstract no: SA‐FC341]. Journal of the American Society of Nephrology2009;20:79A. [CENTRAL: CN‐00793981] TsubakiharaY , AkizawaT . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the safety [abstract no: SU‐PO818]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):765A. [CENTRAL: CN‐00740542] ">Akizawa 2011</a>; <a href="./references#CD009297-bbs2-0003" title="AllonM , KleinmanAK , WalczykM , KaupkeC , MaroniBJ , HeatheringtonA , et al. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time‐and dose‐linear [abstract no: A1308]. Journal of the American Society of Nephrology2000;11(Sept):248A. [CENTRAL: CN‐00626053] AllonM , KleinmanK , WalczykM , KaupkeC , Messer‐MannL , OlsonK , et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clinical Pharmacology &amp; Therapeutics2002;72(5):546‐55. [MEDLINE: 12426518] ">Allon 2002</a>; <a href="./references#CD009297-bbs2-0005" title="BommerJ , AsmusG , WenningM , BommerG . A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study. Nephrology Dialysis Transplantation2008;23(12):4002‐8. [MEDLINE: 18676350] BommerJ , AsmusH , BommerG , WenningM . Efficacy of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: W‐PO40135]. Nephrology2005;10(Suppl 1):A315. [CENTRAL: CN‐00602087] BommerJ , AssmusH , BommerG , WenningM . Comparison of IV or SC darbepoetin alfa in hemodialysis patients [abstract no: F‐PO499]. Journal of the American Society of Nephrology2004;15(Oct):176A. [CENTRAL: CN‐00583725] BommerJ , WenningM , BommerG . Comparison of IV or SC darbepoetin in hemodialysis patients [abstract no: F‐PO676]. Journal of the American Society of Nephrology2005;16:482A. [CENTRAL: CN‐00583778] ">Bommer 2004</a>; <a href="./references#CD009297-bbs2-0006" title="CervelliMJ , DisneyAPS , GrayN , McDonaldSP . Randomised, single blinded, cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients [abstract]. Nephrology2004;9(Suppl 1):A28. [CENTRAL: CN‐00509125] CervelliMJ , GrayN , McDonaldS , GentgallMG , DisneyAP . Randomized cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology2005;10(2):129‐35. [MEDLINE: 15877671] ">Cervelli 2005</a>; <a href="./references#CD009297-bbs2-0007" title="ChazotC , DumoulinA , AngKS , PaulGJ , BernardC , Conference Medicale Group. Haemodialysis patients under subcutaneous recombinant human erythropoietin can be directly switched to intravenous Aranesp® [abstract no: F‐PO682]. Journal of the American Society of Nephrology2005;16:483A. [CENTRAL: CN‐00740583] ChazotC , TerratJC , AngK , GassiaJP , ChedidK , MauriceF , et al. Intravenous darbepoetin A maintains hemoglobin level in hemodialysis patients converting from subcutaneous recombinant human erythropoietin. [abstract no: F‐PO501]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00583168] ChazotC , TerratJC , DumoulinA , AngKS , GassiaJP , ChedidK , et al. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa. Annals of Pharmacotherapy2009;43(2):228‐34. [MEDLINE: 19407262] ">Chazot 2009</a>; <a href="./references#CD009297-bbs2-0008" title="CoyneDW , LingBN , TotoR , McDermott‐VitakAD , TrotmanML , JacksonL . Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant‐human erythropoietin (R‐HUEPO) [abstract no:1380]. Journal of the American Society of Nephrology2000;11(Sept):263A. [CENTRAL: CN‐00583382] ">Coyne 2000</a>; <a href="./references#CD009297-bbs2-0009" title="CoyneD , ZeigR , BenzR , BernsJ , VarmaN , NakanishiA , et al. A randomized, double‐blind study comparing darbepoetin alfa and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American (AA) subjects with chronic kidney disease (CKD) receiving hemodialysis (HD) [abstract no:TH‐PO365]. Journal of the American Society of Nephrology2006;17(Abstracts):184A. [CENTRAL: CN‐00740574] NCT00111995 . A randomized, double‐blind study comparing Aranesp© (darbepoetin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American subjects with chronic renal failure (CRF) receiving hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00111995 (accessed 16 January 2014). ">Coyne 2006a</a>; <a href="./references#CD009297-bbs2-0010" title="HirakataH , GejyoF , SuzukiM , SaitoA , LinoY , WatanabeY , et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health‐related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO204]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00740524] HirakataH , TsubakiharaY , GejyoF , NishiS , IinoY , WatanabeY , et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre‐dialysis Japanese chronic kidney disease patients. Clinical &amp; Experimental Nephrology2010;14(1):28‐35. [MEDLINE: 19763743] InagumaD , TsubakiharaY , HirakataH , HiroeM , HadaY , AkizawaT , et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi352. [CENTRAL: CN‐00740573] SuzukiM , HadaY , AkaishiM , HiroeM , AonumaK , TsubakiharaY , et al. Effects of anemia correction by erythropoiesis‐stimulating agents on cardiovascular function in non‐dialysis patients with chronic kidney disease. International Heart Journal2012;53(4):238‐43. [MEDLINE: 22878802] ">Hirakata 2010</a>; <a href="./references#CD009297-bbs2-0011" title="HoriK , TsujimotoY , OhmoriH , NakamuraH , SugaA , IwasakiM , et al. Randomized, double‐blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no:F‐PO502]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00740529] ">Hori 2004</a>; <a href="./references#CD009297-bbs2-0012" title="IwasakiT , KimataN , SugiO , SawaraY , JinnaiH , KikuchiK , et al. Difference in reactivity became more evident by changing of the erythropoiesis‐stimulating agent (ESA) [abstract no: PUB462]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):914A. [CENTRAL: CN‐00792600] ">Iwasaki 2008</a>; <a href="./references#CD009297-bbs2-0013" title="KimCD , ParkSH , KimDJ , DoJY , ShinSK , KimBS , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in hemodialysis patient [abstract no: TH‐PO370]. Journal of the American Society of Nephrology2006;17(Abstracts):185A. [CENTRAL: CN‐00740537] KimCD , ParkSH , KimDJ , ParkJW , DoJY , ShinSK , et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. Nephrology2009;14(5):482‐7. [MEDLINE: 19298639] ">Kim 2009a</a>; <a href="./references#CD009297-bbs2-0014" title="KwanBC , LeungC , SzetoC , LiPK . Efficacy of bi‐weekly versus monthly subcutaneous darbepoetin‐alpha for the maintenance treatment of anemia in peritoneal dialysis patients ‐ an open‐label randomized study [abstract no:SA‐PO805]. Journal of the American Society of Nephrology2005;16:732A. [CENTRAL: CN‐00740570] ">Kwan 2005</a>; <a href="./references#CD009297-bbs2-0015" title="LiWY , ChuTS , HuangJW , WuMS , WuKD . Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. Journal of the Formosan Medical Association2008;107(11):843‐50. [MEDLINE: 18971153] ">Li 2008</a>; <a href="./references#CD009297-bbs2-0017" title="LocatelliF , BacksW , delPinoMD , deMartinA , GuillaumeB , VikydalR , et al. Control of anaemia with Aranesp®: haemoglobin stability achieved with fewer patients requiring dose adjustments after switching to Aranesp® every 2‐weeks [abstract no: SP411]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv152. [CENTRAL: CN‐00740593] LocatelliF , VillaG , BacksW , delPinoMD . A phase 3, multicentre, randomised, double‐blind, non‐inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) inpatients on haemodialysis (HD) [abstract no: MP181]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v260. [CENTRAL: CN‐00740588] LocatelliF , VillaG , BacksW , delPinoMD . Aranesp® (darbepoetin alfa) maintains hemoglobin (Hb) levels in hemodialysis (HD) patients at extended dosing intervals regardless of previous recombinant human erythropoietin (rHuEPO) dosing frequency [abstract no: PUB254]. Journal of the American Society of Nephrology2004;15(Oct):816A. [CENTRAL: CN‐00740589] ">Locatelli 2004</a>; <a href="./references#CD009297-bbs2-0018" title="LocatelliF , VillaG , MessaP , FilippiniA , CannellaG , DeFerrariG , et al. Efficacy and safety of once‐weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. Journal of Nephrology2008;21(3):412‐20. [MEDLINE: 18587731] ">Locatelli 2008</a>; <a href="./references#CD009297-bbs2-0019" title="InagumaD , NagayaH , HamaguchiK , TatematsuM , SuzukiS , KurataK . Intravenous darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in Japanese patients on hemodialysis [abstract no: TH‐PO741]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):275A. [CENTRAL: CN‐00740572] NagayaH , InagumaD , KitagawaA , MurataM , KamimuraY , HamaguchiK , et al. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. Clinical &amp; Experimental Nephrology2010;14(2):158‐63. [MEDLINE: 19967423] ">Nagaya 2010</a>; <a href="./references#CD009297-bbs2-0024" title="SvarstadE , ForslundT . Nurse assisted nine months darbepoetin (D) treatment with fix dose and variable dosing interval in an outpatient clinic is cost effective in predialytic CKD patients [abstract no: SU‐PO800]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00740562] ">Svarstad 2007</a>; <a href="./references#CD009297-bbs2-0025" title="TessitoreN , MantovaniW , BedognaV , LossR , MelilliE , PoliA , et al. Cost analysis of switching from epoetin alfa to darbepoetin alfa in chronic hemodialysis patients (HD Pts): a long‐term, randomized, open‐label, cross‐over, pilot study [abstract no: SA‐PO2645]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):706A. [CENTRAL: CN‐00740545] ">Tessitore 2008</a>; <a href="./references#CD009297-bbs2-0026" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: 27]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of CERA once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4. ">TIVOLI Study 2011</a>; <a href="./references#CD009297-bbs2-0031" title="WatanabeY , GejyoF , ShigematsuT , IinoY , HosoyaT , ShojiT , et al. KRN321 (darbepoetin alfa) administered once every other week (Q2W) and once every four weeks (Q4W) in predialysis chronic renal failure (CRF) patients in Japan [abstract no: SU‐PO053]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00740541] ">Watanabe 2004</a>; <a href="./references#CD009297-bbs2-0032" title="YoonSY , BangBK , KimSG , HanDC , HwangSD , ParkJS , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of renal anemia in hemodialysis patients [abstract no: MP271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:322. [CENTRAL: CN‐00509573] ">Yoon 2004</a>). </p> <p>In each treatment comparison, the only study comparing darbepoetin with placebo (<a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>), four studies comparing darbepoetin with epoetin (<a href="./references#CD009297-bbs2-0016" title="JohnsonDW , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (darbepoetin alpha) corrects anaemia of early chronic kidney disease (CKD) at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) [abstract no: P156]. Nephrology2002;7(Suppl 3):A40. [CENTRAL: CN‐00794721] LocatelliF , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) corrects anemia of chronic renal insufficiency (CRI) at a reduced dose frequency compared with rHuEPO [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00671771] LocatelliF , OlivaresJ , WalkerR , WilkieM , European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant‐human erythropoietin (r‐HuEPO) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):283A. [CENTRAL: CN‐00626023] LocatelliF , OlivaresJ , WalkerR , WilkieM , JenkinsB , DeweyC , et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International2001;60(2):741‐7. [MEDLINE: 11473657] ">Locatelli 2001</a>; <a href="./references#CD009297-bbs2-0020" title="NissensonA , KrishnanM , LiuW , McCaryL , Stehman‐BreenC , MixC . Hemoglobin (Hb) variability does not differ between hemodialysis (HD) patients treated with epoetin alfa and darbepoetin alfa [abstract no: TH‐PO360]. Journal of the American Society of Nephrology2006;17(Abstracts):183A. [CENTRAL: CN‐00740539] NissensonAR . Dosing darbepoetin alfa. American Journal of Kidney Diseases2002;40(4):872. [MEDLINE: 12324929] NissensonAR , SwanSK , LindbergJS , SorokaSD , BeateyR , WangC , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases2002;40(1):110‐8. [MEDLINE: 12087568] NissensonAR , SwanSK , LindbergJS , SorokaSD , McDermott‐VitakAD , WangC , et al. Novel Erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r‐HuEPO when administered once weekly [abstract no: A1326]. Journal of the American Society of Nephrology2000;11(Sept):252A. [CENTRAL: CN‐00794722] NissensonAR , US/Canadian NESP 980117 Study Group. Once weekly IV novel erythropoiesis stimulating protein (NESP) effectively maintains Hb in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2001;16(6):A92. [CENTRAL: CN‐00446969] ">Nissenson 2002</a>; <a href="./references#CD009297-bbs2-0022" title="SmythJS , MarshallW , AshfieldL , EliasL , McGinnS . Conversion from subcutaneous to intravenous erythropoietin analogues is cost neutral: results of a six month pilot study [abstract no: PUB246]. Journal of the American Society of Nephrology2004;15(Oct):814A‐5A. [CENTRAL: CN‐00792440] ">Smyth 2004</a>; <a href="./references#CD009297-bbs2-0027" title="TolmanC , RichardsonD , BartlettC , WillE . A randomised study of weekly subcutaneous Aranesp and Neorecormon in a large unselected haemodialysis cohort, managed with computer assisted anaemia algorithms [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:229‐30. [CENTRAL: CN‐00509514] TolmanC , RichardsonD , BartlettC , WillE . Application of computer assisted anaemia management algorithms in haemodialysis patients produces predictable haemoglobin outcomes regardless of the erythropoietic agent or frequency of administration: results of a randomised study [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:110. [CENTRAL: CN‐00509513] TolmanC , RichardsonD , BartlettC , WillE . Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision‐support system: a randomized clinical study. Journal of the American Society of Nephrology2005;16(5):1463‐70. [MEDLINE: 15788469] TolmanC , RichardsonD , BartlettC , WillEJ . Dose conversion ratio (DCR) from subcutaneous epoetin‐B (EPO) to weekly darbepoetin‐A (DA) is dependent on baseline sensitivity: results from a randomised study [abstract no: SA‐PO461]. Journal of the American Society of Nephrology2004;15(Oct):404A. [CENTRAL: CN‐00583282] WestRM , HarrisK , GilthorpeMS , TolmanC , WillEJ . Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. Journal of the American Society of Nephrology2007;18(8):2371‐6. [MEDLINE: 17625113] ">Tolman 2005</a>), three studies comparing darbepoetin with methoxy polyethylene glycol‐epoetin beta (<a href="./references#CD009297-bbs2-0004" title="FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] KesslerM , Martinez‐CastelaoA , SiamopoulosKC , VillaG , SpinowitzB , DoughertyFC , et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International2010;14(2):233‐9. [MEDLINE: 19888948] MacdougallIC , WalkerR , ProvenzanoR , DeAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN2008;3(2):337‐47. [MEDLINE: 18287255] MacdougallIC , WalkerR , ProvenzanoR , deAlvaroF , LocayHR , NaderPC , et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA‐PO208]. Journal of the American Society of Nephrology2006;17(Abstracts):619A. [CENTRAL: CN‐00644214] ProvenzanoR , MacdougallIC , LawA , OuyangY , BexonM . Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU‐PO796]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00747311] WalkerR , MacdougallIC , LevinA , KesslerM , NobleS , Burgos‐CalderonR , et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52‐week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi412. [CENTRAL: CN‐00644215] ">ARCTOS Study 2008</a>; <a href="./references#CD009297-bbs2-0021" title="CarreraF . CERA vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CarreraF , LokCE , deFranciscoA , LocatelliF , MannJF , CanaudB , et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation2010;25(12):4009‐17. [MEDLINE: 20522670] LocatelliF , PATRONUS Study Group. Once‐monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA‐PO2412]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747328] MannJF , PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving once‐monthly C.E.R.A. or once‐monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology2009;20:921A. [CENTRAL: CN‐00747329] deFranciscoAL , PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once‐monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SA‐PO2411]. Journal of the American Society of Nephrology2009;20:663A. [CENTRAL: CN‐00747327] ">PATRONUS Study 2010</a>; <a href="./references#CD009297-bbs2-0023" title="BaranyP , BesarabA , MacdougallIC , LawA , OuyangY , HeifetsM . Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SU‐PO795]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):760A. [CENTRAL: CN‐00794522] CanaudB , BraunJ , LocatelliF , VillaG , VanVlemB , Sanz GuajardoD , et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv157. [CENTRAL: CN‐00690645] CanaudB , MingardiG , BraunJ , AljamaP , KerrPG , LocatelliF , et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation2008;23(11):3654‐61. [MEDLINE: 18586762] FishbaneS , DaltonC , BeswickR , DutkaP , SchmidtR . Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases2007;49(4):A39. [CENTRAL: CN‐00756571] ">STRIATA Study 2008</a>), no studies comparing differing dosing frequencies, and no studies comparing IV with SC administration were at low risk of bias due to complete reporting of outcomes. </p> </section> <section id="CD009297-sec-0066"> <h4 class="title">Other potential sources of bias</h4> <p>Other potential sources of bias included abstract‐only publication (13/32 studies (41%)) (<a href="./references#CD009297-bbs2-0002" title="AkizawaT , GejyoF , NishiS , IinoY , WatanabeY , SuzukiM , et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Therapeutic Apheresis &amp; Dialysis2011;15(5):431‐40. [MEDLINE: 21974695] AkizawaT , TsubakiharaY . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the efficacy [abstract no: SU‐PO804]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00740554] TsubakiharaY , AkizawaT . High target hemoglobin with erythropoiesis stimulating agent (ESA) in chronic kidney disease (CKD) slows the occurrence rate of events related to decline of renal function [abstract no: SA‐FC341]. Journal of the American Society of Nephrology2009;20:79A. [CENTRAL: CN‐00793981] TsubakiharaY , AkizawaT . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the safety [abstract no: SU‐PO818]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):765A. [CENTRAL: CN‐00740542] ">Akizawa 2011</a>; <a href="./references#CD009297-bbs2-0008" title="CoyneDW , LingBN , TotoR , McDermott‐VitakAD , TrotmanML , JacksonL . Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant‐human erythropoietin (R‐HUEPO) [abstract no:1380]. Journal of the American Society of Nephrology2000;11(Sept):263A. [CENTRAL: CN‐00583382] ">Coyne 2000</a>; <a href="./references#CD009297-bbs2-0009" title="CoyneD , ZeigR , BenzR , BernsJ , VarmaN , NakanishiA , et al. A randomized, double‐blind study comparing darbepoetin alfa and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American (AA) subjects with chronic kidney disease (CKD) receiving hemodialysis (HD) [abstract no:TH‐PO365]. Journal of the American Society of Nephrology2006;17(Abstracts):184A. [CENTRAL: CN‐00740574] NCT00111995 . A randomized, double‐blind study comparing Aranesp© (darbepoetin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African‐American subjects with chronic renal failure (CRF) receiving hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00111995 (accessed 16 January 2014). ">Coyne 2006a</a>; <a href="./references#CD009297-bbs2-0011" title="HoriK , TsujimotoY , OhmoriH , NakamuraH , SugaA , IwasakiM , et al. Randomized, double‐blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no:F‐PO502]. Journal of the American Society of Nephrology2004;15(Oct):177A. [CENTRAL: CN‐00740529] ">Hori 2004</a>; <a href="./references#CD009297-bbs2-0014" title="KwanBC , LeungC , SzetoC , LiPK . Efficacy of bi‐weekly versus monthly subcutaneous darbepoetin‐alpha for the maintenance treatment of anemia in peritoneal dialysis patients ‐ an open‐label randomized study [abstract no:SA‐PO805]. Journal of the American Society of Nephrology2005;16:732A. [CENTRAL: CN‐00740570] ">Kwan 2005</a>; <a href="./references#CD009297-bbs2-0017" title="LocatelliF , BacksW , delPinoMD , deMartinA , GuillaumeB , VikydalR , et al. Control of anaemia with Aranesp®: haemoglobin stability achieved with fewer patients requiring dose adjustments after switching to Aranesp® every 2‐weeks [abstract no: SP411]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv152. [CENTRAL: CN‐00740593] LocatelliF , VillaG , BacksW , delPinoMD . A phase 3, multicentre, randomised, double‐blind, non‐inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) inpatients on haemodialysis (HD) [abstract no: MP181]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v260. [CENTRAL: CN‐00740588] LocatelliF , VillaG , BacksW , delPinoMD . Aranesp® (darbepoetin alfa) maintains hemoglobin (Hb) levels in hemodialysis (HD) patients at extended dosing intervals regardless of previous recombinant human erythropoietin (rHuEPO) dosing frequency [abstract no: PUB254]. Journal of the American Society of Nephrology2004;15(Oct):816A. [CENTRAL: CN‐00740589] ">Locatelli 2004</a>; <a href="./references#CD009297-bbs2-0019" title="InagumaD , NagayaH , HamaguchiK , TatematsuM , SuzukiS , KurataK . Intravenous darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in Japanese patients on hemodialysis [abstract no: TH‐PO741]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):275A. [CENTRAL: CN‐00740572] NagayaH , InagumaD , KitagawaA , MurataM , KamimuraY , HamaguchiK , et al. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. Clinical &amp; Experimental Nephrology2010;14(2):158‐63. [MEDLINE: 19967423] ">Nagaya 2010</a>; <a href="./references#CD009297-bbs2-0022" title="SmythJS , MarshallW , AshfieldL , EliasL , McGinnS . Conversion from subcutaneous to intravenous erythropoietin analogues is cost neutral: results of a six month pilot study [abstract no: PUB246]. Journal of the American Society of Nephrology2004;15(Oct):814A‐5A. [CENTRAL: CN‐00792440] ">Smyth 2004</a>; <a href="./references#CD009297-bbs2-0024" title="SvarstadE , ForslundT . Nurse assisted nine months darbepoetin (D) treatment with fix dose and variable dosing interval in an outpatient clinic is cost effective in predialytic CKD patients [abstract no: SU‐PO800]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00740562] ">Svarstad 2007</a>; <a href="./references#CD009297-bbs2-0025" title="TessitoreN , MantovaniW , BedognaV , LossR , MelilliE , PoliA , et al. Cost analysis of switching from epoetin alfa to darbepoetin alfa in chronic hemodialysis patients (HD Pts): a long‐term, randomized, open‐label, cross‐over, pilot study [abstract no: SA‐PO2645]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):706A. [CENTRAL: CN‐00740545] ">Tessitore 2008</a>; <a href="./references#CD009297-bbs2-0026" title="CampistolJM , CarrenoA , MoralesJM , PallardoL , FrancoA , NavarroD , et al. Once‐monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation2013;95(2):e6‐e10. [MEDLINE: 23325012] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: 27]. American Journal of Transplantation2011;11:36. [EMBASE: 70405062] CarrenoA , CampistolJM , AriasM , MoralesJM , PallardoL , FrancoA . A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of CERA once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus2011;4(Suppl 2):4. ">TIVOLI Study 2011</a>; <a href="./references#CD009297-bbs2-0031" title="WatanabeY , GejyoF , ShigematsuT , IinoY , HosoyaT , ShojiT , et al. KRN321 (darbepoetin alfa) administered once every other week (Q2W) and once every four weeks (Q4W) in predialysis chronic renal failure (CRF) patients in Japan [abstract no: SU‐PO053]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00740541] ">Watanabe 2004</a>; <a href="./references#CD009297-bbs2-0032" title="YoonSY , BangBK , KimSG , HanDC , HwangSD , ParkJS , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of renal anemia in hemodialysis patients [abstract no: MP271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:322. [CENTRAL: CN‐00509573] ">Yoon 2004</a>), data not sufficient for inclusion in meta‐analysis (12/32 studies (38%)) (<a href="./references#CD009297-bbs2-0002" title="AkizawaT , GejyoF , NishiS , IinoY , WatanabeY , SuzukiM , et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Therapeutic Apheresis &amp; Dialysis2011;15(5):431‐40. [MEDLINE: 21974695] AkizawaT , TsubakiharaY . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the efficacy [abstract no: SU‐PO804]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00740554] TsubakiharaY , AkizawaT . High target hemoglobin with erythropoiesis stimulating agent (ESA) in chronic kidney disease (CKD) slows the occurrence rate of events related to decline of renal function [abstract no: SA‐FC341]. Journal of the American Society of Nephrology2009;20:79A. [CENTRAL: CN‐00793981] TsubakiharaY , AkizawaT . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the safety [abstract no: SU‐PO818]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):765A. [CENTRAL: CN‐00740542] ">Akizawa 2011</a>; <a href="./references#CD009297-bbs2-0003" title="AllonM , KleinmanAK , WalczykM , KaupkeC , MaroniBJ , HeatheringtonA , et al. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time‐and dose‐linear [abstract no: A1308]. Journal of the American Society of Nephrology2000;11(Sept):248A. [CENTRAL: CN‐00626053] AllonM , KleinmanK , WalczykM , KaupkeC , Messer‐MannL , OlsonK , et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clinical Pharmacology &amp; Therapeutics2002;72(5):546‐55. [MEDLINE: 12426518] ">Allon 2002</a>; <a href="./references#CD009297-bbs2-0006" title="CervelliMJ , DisneyAPS , GrayN , McDonaldSP . Randomised, single blinded, cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients [abstract]. Nephrology2004;9(Suppl 1):A28. [CENTRAL: CN‐00509125] CervelliMJ , GrayN , McDonaldS , GentgallMG , DisneyAP . Randomized cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology2005;10(2):129‐35. [MEDLINE: 15877671] ">Cervelli 2005</a>; <a href="./references#CD009297-bbs2-0008" title="CoyneDW , LingBN , TotoR , McDermott‐VitakAD , TrotmanML , JacksonL . Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant‐human erythropoietin (R‐HUEPO) [abstract no:1380]. Journal of the American Society of Nephrology2000;11(Sept):263A. [CENTRAL: CN‐00583382] ">Coyne 2000</a>; <a href="./references#CD009297-bbs2-0012" title="IwasakiT , KimataN , SugiO , SawaraY , JinnaiH , KikuchiK , et al. Difference in reactivity became more evident by changing of the erythropoiesis‐stimulating agent (ESA) [abstract no: PUB462]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):914A. [CENTRAL: CN‐00792600] ">Iwasaki 2008</a>; <a href="./references#CD009297-bbs2-0015" title="LiWY , ChuTS , HuangJW , WuMS , WuKD . Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. Journal of the Formosan Medical Association2008;107(11):843‐50. [MEDLINE: 18971153] ">Li 2008</a>; <a href="./references#CD009297-bbs2-0017" title="LocatelliF , BacksW , delPinoMD , deMartinA , GuillaumeB , VikydalR , et al. Control of anaemia with Aranesp®: haemoglobin stability achieved with fewer patients requiring dose adjustments after switching to Aranesp® every 2‐weeks [abstract no: SP411]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv152. [CENTRAL: CN‐00740593] LocatelliF , VillaG , BacksW , delPinoMD . A phase 3, multicentre, randomised, double‐blind, non‐inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) inpatients on haemodialysis (HD) [abstract no: MP181]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v260. [CENTRAL: CN‐00740588] LocatelliF , VillaG , BacksW , delPinoMD . Aranesp® (darbepoetin alfa) maintains hemoglobin (Hb) levels in hemodialysis (HD) patients at extended dosing intervals regardless of previous recombinant human erythropoietin (rHuEPO) dosing frequency [abstract no: PUB254]. Journal of the American Society of Nephrology2004;15(Oct):816A. [CENTRAL: CN‐00740589] ">Locatelli 2004</a>; <a href="./references#CD009297-bbs2-0018" title="LocatelliF , VillaG , MessaP , FilippiniA , CannellaG , DeFerrariG , et al. Efficacy and safety of once‐weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. Journal of Nephrology2008;21(3):412‐20. [MEDLINE: 18587731] ">Locatelli 2008</a>; <a href="./references#CD009297-bbs2-0024" title="SvarstadE , ForslundT . Nurse assisted nine months darbepoetin (D) treatment with fix dose and variable dosing interval in an outpatient clinic is cost effective in predialytic CKD patients [abstract no: SU‐PO800]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00740562] ">Svarstad 2007</a>; <a href="./references#CD009297-bbs2-0025" title="TessitoreN , MantovaniW , BedognaV , LossR , MelilliE , PoliA , et al. Cost analysis of switching from epoetin alfa to darbepoetin alfa in chronic hemodialysis patients (HD Pts): a long‐term, randomized, open‐label, cross‐over, pilot study [abstract no: SA‐PO2645]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):706A. [CENTRAL: CN‐00740545] ">Tessitore 2008</a>; <a href="./references#CD009297-bbs2-0031" title="WatanabeY , GejyoF , ShigematsuT , IinoY , HosoyaT , ShojiT , et al. KRN321 (darbepoetin alfa) administered once every other week (Q2W) and once every four weeks (Q4W) in predialysis chronic renal failure (CRF) patients in Japan [abstract no: SU‐PO053]. Journal of the American Society of Nephrology2004;15(Oct):544A. [CENTRAL: CN‐00740541] ">Watanabe 2004</a>; <a href="./references#CD009297-bbs2-0032" title="YoonSY , BangBK , KimSG , HanDC , HwangSD , ParkJS , et al. Randomized, controlled trial of darbepoetin alfa for the treatment of renal anemia in hemodialysis patients [abstract no: MP271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:322. [CENTRAL: CN‐00509573] ">Yoon 2004</a>) data not available for end of first phase of treatment in cross‐over studies (2/32 studies (6%)) (<a href="./references#CD009297-bbs2-0001" title="AarupM , BryndumJ , DieperinkH , JoffeP . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrology Dialysis Transplantation2006;21(5):1312‐6. [MEDLINE: 16396971] AarupM , BryndumJ , JoffeP , DieperinkH . Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of Aranesp® (darbepoetin alfa) [abstract no: PUB278]. Journal of the American Society of Nephrology2004;15(Oct):821A. [CENTRAL: CN‐00583657] ">Aarup 2004</a>; <a href="./references#CD009297-bbs2-0006" title="CervelliMJ , DisneyAPS , GrayN , McDonaldSP . Randomised, single blinded, cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients [abstract]. Nephrology2004;9(Suppl 1):A28. [CENTRAL: CN‐00509125] CervelliMJ , GrayN , McDonaldS , GentgallMG , DisneyAP . Randomized cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology2005;10(2):129‐35. [MEDLINE: 15877671] ">Cervelli 2005</a>) and unequal treatment comparisons or baseline characteristics (3/32 studies (9%)) (<a href="./references#CD009297-bbs2-0002" title="AkizawaT , GejyoF , NishiS , IinoY , WatanabeY , SuzukiM , et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Therapeutic Apheresis &amp; Dialysis2011;15(5):431‐40. [MEDLINE: 21974695] AkizawaT , TsubakiharaY . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the efficacy [abstract no: SU‐PO804]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00740554] TsubakiharaY , AkizawaT . High target hemoglobin with erythropoiesis stimulating agent (ESA) in chronic kidney disease (CKD) slows the occurrence rate of events related to decline of renal function [abstract no: SA‐FC341]. Journal of the American Society of Nephrology2009;20:79A. [CENTRAL: CN‐00793981] TsubakiharaY , AkizawaT . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the safety [abstract no: SU‐PO818]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):765A. [CENTRAL: CN‐00740542] ">Akizawa 2011</a>; <a href="./references#CD009297-bbs2-0006" title="CervelliMJ , DisneyAPS , GrayN , McDonaldSP . Randomised, single blinded, cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients [abstract]. Nephrology2004;9(Suppl 1):A28. [CENTRAL: CN‐00509125] CervelliMJ , GrayN , McDonaldS , GentgallMG , DisneyAP . Randomized cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology2005;10(2):129‐35. [MEDLINE: 15877671] ">Cervelli 2005</a>; <a href="./references#CD009297-bbs2-0010" title="HirakataH , GejyoF , SuzukiM , SaitoA , LinoY , WatanabeY , et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health‐related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA‐PO204]. Journal of the American Society of Nephrology2006;17(Abstracts):618A. [CENTRAL: CN‐00740524] HirakataH , TsubakiharaY , GejyoF , NishiS , IinoY , WatanabeY , et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre‐dialysis Japanese chronic kidney disease patients. Clinical &amp; Experimental Nephrology2010;14(1):28‐35. [MEDLINE: 19763743] InagumaD , TsubakiharaY , HirakataH , HiroeM , HadaY , AkizawaT , et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi352. [CENTRAL: CN‐00740573] SuzukiM , HadaY , AkaishiM , HiroeM , AonumaK , TsubakiharaY , et al. Effects of anemia correction by erythropoiesis‐stimulating agents on cardiovascular function in non‐dialysis patients with chronic kidney disease. International Heart Journal2012;53(4):238‐43. [MEDLINE: 22878802] ">Hirakata 2010</a>). </p> </section> </section> <section id="CD009297-sec-0067"> <h3 class="title" id="CD009297-sec-0067">Effects of interventions</h3> <section id="CD009297-sec-0068"> <h4 class="title">Darbepoetin alfa versus placebo</h4> <p>One large study at generally low risk of bias compared darbepoetin alfa with placebo in 4038 participants with CKD stages 3 to 4. Compared to placebo, darbepoetin alfa reduced need for one or more blood transfusions (<a href="./references#CD009297-fig-0004" title="">Analysis 1.1</a>: RR 0.60, 95% CI 0.53 to 0.69) and need for iron therapy (<a href="./references#CD009297-fig-0005" title="">Analysis 1.2</a>: RR 0.75, 95% CI 0.73 to 0.78) but had little or no effect on need for RRT (<a href="./references#CD009297-fig-0006" title="">Analysis 1.3</a>: RR 1.03, 95% CI 0.90 to 1.18). Darbepoetin alfa had little or no effect on all‐cause mortality (<a href="./references#CD009297-fig-0007" title="">Analysis 1.4</a>: RR 1.05, 95% CI 0.93 to 1.19) or cardiovascular mortality (<a href="./references#CD009297-fig-0008" title="">Analysis 1.5</a>: RR 1.04, 95% CI 0.89 to 1.23) and uncertain effects on cancer (<a href="./references#CD009297-fig-0009" title="">Analysis 1.6</a>: RR 1.08, 95% CI 0.85 to 1.36). Darbepoetin alfa may increase risk of hypertension (<a href="./references#CD009297-fig-0010" title="">Analysis 1.7</a>: RR 1.11, 95% CI 0.99 to 1.24) but has uncertain effects on seizure risk (<a href="./references#CD009297-fig-0011" title="">Analysis 1.8</a>: RR 2.27, 95% CI 0.70 to 7.35). Darbepoetin alfa increased the Functional Assessment of Cancer Therapy (FACT) fatigue score (<a href="./references#CD009297-fig-0012" title="">Analysis 1.9</a>: MD 1.40, 95% CI 0.71 to 2.09) but had little or no effect on the SF‐36 energy score (<a href="./references#CD009297-fig-0013" title="">Analysis 1.10</a>: MD 0.50, 95% CI ‐0.15 to 1.15) or physical functioning score (<a href="./references#CD009297-fig-0014" title="">Analysis 1.11</a>: MD 0.20, 95% CI ‐0.39 to 0.79). </p> </section> <section id="CD009297-sec-0069"> <h4 class="title">Darbepoetin alfa versus epoetin</h4> <p>In both adults (<a href="./references#CD009297-fig-0015" title="">Analysis 2.1</a>.1 (2 studies, 483 participants): RR 0.80, 95% CI 0.35 to 1.83; I² = 0%)) and children (<a href="./references#CD009297-fig-0015" title="">Analysis 2.1</a>.2 (1 study, 123 participants): RR 0.43, 95% CI 0.14 to 1.33), darbepoetin alfa had uncertain effects on need for blood transfusions compared to epoetin. No data were available for need for iron treatment. In children, darbepoetin alfa had uncertain effects on risk of RRT (<a href="./references#CD009297-fig-0016" title="">Analysis 2.2</a> (1 study, 123 participants): RR 0.67, 95% CI 0.27 to 1.66) compared with epoetin. No data were available for adults. </p> <p>Compared to epoetin, darbepoetin alfa had uncertain effects on all‐cause mortality for both adults (<a href="./references#CD009297-fig-0017" title="">Analysis 2.3</a>.1 (6 studies, 1657 participants): RR 1.35, 95% CI 0.84 to 2.15; I² = 0%) and children (<a href="./references#CD009297-fig-0017" title="">Analysis 2.3</a>.2 (1 study, 123 participants): RR 0.52, 95% CI 0.03 to 8.08). Darbepoetin alfa had uncertain effects on cardiovascular mortality in adults (<a href="./references#CD009297-fig-0018" title="">Analysis 2.4</a> (2 studies, 487 participants): RR 0.47, 95% CI 0.07 to 3.17; I² = 0%). No data were available for children. In adults, darbepoetin alfa had uncertain effects on risk of major cardiovascular events compared to epoetin (<a href="./references#CD009297-fig-0019" title="">Analysis 2.5</a> (2 studies, 840 participants): RR 0.88, 95% CI 0.06 to 12.69; I² = 63%) with substantial heterogeneity in the analysis. No data were available for children. </p> <p>Darbepoetin alfa had similar effects on risk of hypertension compared to epoetin in adults (<a href="./references#CD009297-fig-0020" title="">Analysis 2.6</a>.1 (4 studies, 1412 participants): RR 1.17, 95% CI 0.93 to 1.49; I² = 0%) and had uncertain effects in children (<a href="./references#CD009297-fig-0020" title="">Analysis 2.6</a>.2 (1 study, 123 participants): RR 0.96, 95% CI 0.43 to 2.23). Darbepoetin alfa also had uncertain effects on risk of seizures in adults (<a href="./references#CD009297-fig-0021" title="">Analysis 2.7</a> (1 study, 519 participants): RR 1.17, 95% CI 0.31 to 4.46). No data were available for children. Darbepoetin alfa had similar effects on vascular access thrombosis in adults (<a href="./references#CD009297-fig-0022" title="">Analysis 2.8</a>.1 (2 studies, 925 participants): RR 1.06, 95% CI 0.63 to 1.79; I² = 0%) and uncertain effects in children (<a href="./references#CD009297-fig-0022" title="">Analysis 2.8</a>.2 (1 study, 123 participants): RR 0.17, 95% CI 0.01 to 4.20). Darbepoetin alfa had similar effects on risk of children exceeding the Hb target range (<a href="./references#CD009297-fig-0023" title="">Analysis 2.9</a> (1 study, 123 participants): RR 1.09, 95% CI 0.57 to 2.09) and uncertain risks of injection site pain (<a href="./references#CD009297-fig-0024" title="">Analysis 2.10</a> (1 study, 123 participants): RR 1.21, 95% CI 0.50 to 2.92). </p> <p>In one study in which the Hb target in the darbepoetin alfa arm was higher than in the epoetin arm, darbepoetin alfa increased Hb levels at the end of treatment (<a href="./references#CD009297-fig-0025" title="">Analysis 2.11</a>.1 (1 study, 84 participants): MD 1.33 g/dL, 95% CI 0.84 to 1.82) whereas in the study reporting treatment effects on end of treatment Hb values in which target values were similar for both darbepoetin alfa and darbepoetin alfa arms, end of treatment values were similar (<a href="./references#CD009297-fig-0025" title="">Analysis 2.11</a>.2 (1 study, 363 participants): MD ‐0.07 g/dL, 95% CI ‐0.27 to 0.13). The mean change in Hb was similar for darbepoetin alfa and epoetin treatment in both adults (<a href="./references#CD009297-fig-0026" title="">Analysis 2.12</a> (3 studies, 1060 participants): MD 0.06 g/dL, 95% CI ‐0.08 to 0.19; I² = 0%) and children (<a href="./references#CD009297-fig-0026" title="">Analysis 2.12</a>.3 (1 study, 123 participants): MD 0.22 g/dL, 95% CI ‐0.47 to 0.91). </p> </section> <section id="CD009297-sec-0070"> <h4 class="title">Darbepoetin alfa versus methoxy polyethylene glycol‐epoetin beta</h4> <p>In studies comparing darbepoetin alfa with methoxy polyethylene glycol‐epoetin beta, darbepoetin alfa had inconclusive effects on need for blood transfusion therapy (<a href="./references#CD009297-fig-0027" title="">Analysis 3.1</a> (2 studies, 799 participants): RR 0.82, 95% CI 0.58 to 1.17; I² = 0%) and similar effects on need for iron treatment (<a href="./references#CD009297-fig-0028" title="">Analysis 3.2</a> (2 studies, 799 participants): RR 1.01, 95% CI 0.97 to 1.05; I² = 0%). Darbepoetin alfa had uncertain effects on all‐cause mortality (<a href="./references#CD009297-fig-0029" title="">Analysis 3.3</a> (3 studies, 1122 participants): RR 0.89, 95% CI 0.53 to 1.51; I² = 3%) and cardiovascular mortality (<a href="./references#CD009297-fig-0030" title="">Analysis 3.4</a> (1 study, 309 participants): RR 0.56, 95% CI 0.17 to 1.88). Compared to methoxy polyethylene glycol‐epoetin beta, darbepoetin alfa had uncertain effects on vascular access thrombosis (<a href="./references#CD009297-fig-0031" title="">Analysis 3.5</a> (1 study, 309 participants): RR 0.91, 95% CI 0.43 to 1.92) and hypertension (<a href="./references#CD009297-fig-0032" title="">Analysis 3.6</a> (3 studies, 869 participants): RR 0.77, 95% CI 0.52 to 1.13; I² = 0%). One study reported patients receiving methoxy polyethylene glycol‐epoetin beta were more likely than those receiving darbepoetin alfa to achieve the Hb target (<a href="./references#CD009297-fig-0033" title="">Analysis 3.7</a> (1 study, 450 participants): RR 1.59, 95% CI 1.33 to 1.90). One study reported darbepoetin alfa had similar effects to methoxy polyethylene glycol‐epoetin beta on end of treatment Hb (<a href="./references#CD009297-fig-0034" title="">Analysis 3.8</a> (1 study, 313 participants): MD 0.00 g/dL, 95% CI ‐0.23 to 0.23). </p> </section> <section id="CD009297-sec-0071"> <h4 class="title">Darbepoetin alfa every two weeks versus darbepoetin alfa every four weeks</h4> <p>Darbepoetin alfa administered every two weeks compared to once every four weeks may reduce need for blood transfusions (<a href="./references#CD009297-fig-0035" title="">Analysis 4.1</a> (1 study, 64 participants): RR 0.33, 95% CI 0.10 to 1.14) and iron therapy (<a href="./references#CD009297-fig-0036" title="">Analysis 4.2</a> (1 study, 64 participants): RR 0.39, 95% CI 0.13 to 1.14). Treatment every two weeks had similar effects on end of treatment Hb levels (<a href="./references#CD009297-fig-0037" title="">Analysis 4.3</a> (1 study, 64 participants): MD 0.40 g/dL, 95% CI ‐0.37 to 1.17). </p> </section> <section id="CD009297-sec-0072"> <h4 class="title">Darbepoetin alfa weekly versus every two weeks</h4> <p>One study reported darbepoetin alfa administered every week had similar effects on end of treatment Hb compared to treatment given every two weeks (<a href="./references#CD009297-fig-0038" title="">Analysis 5.1</a> (1 study, 39 participants): MD ‐0.30 g/dL, 95% CI ‐0.87 to 0.27). </p> </section> <section id="CD009297-sec-0073"> <h4 class="title">Intravenous versus subcutaneous treatment</h4> <p>IV darbepoetin alfa therapy had uncertain effects on need for blood transfusions (<a href="./references#CD009297-fig-0039" title="">Analysis 6.1</a> (2 studies, 183 participants): RR 1.15, 95% CI 0.30 to 4.38), all‐cause mortality (<a href="./references#CD009297-fig-0040" title="">Analysis 6.2</a> (2 studies, 183 participants): RR 1.28, 95% CI 0.32 to 5.06; I² = 0%), cardiovascular mortality (<a href="./references#CD009297-fig-0041" title="">Analysis 6.3</a> (2 studies, 183 participants): RR 1.15, 95% CI 0.30 to 4.38) and major cardiovascular events (<a href="./references#CD009297-fig-0042" title="">Analysis 6.4</a> (1 study, 105 participants): RR 1.31, 95% CI 0.23 to 7.54) compared to SC administration. IV and SC darbepoetin alfa therapy had similar effects on end of treatment Hb levels (<a href="./references#CD009297-fig-0043" title="">Analysis 6.5</a> (3 studies, 284 participants): MD ‐0.10 g/dL, 95% CI ‐0.34 to 0.14; I² = 0%) and change in Hb levels during treatment (<a href="./references#CD009297-fig-0044" title="">Analysis 6.6</a> (1 study, 65 participants): MD 0.23 g/dL, 95% CI ‐0.32 to 0.78). </p> </section> <section id="CD009297-sec-0074"> <h4 class="title">Stratified analyses and meta‐regression</h4> <p>There was no heterogeneity in treatment effects between studies in which two or more studies were included except for the effects of darbepoetin alfa versus epoetin on major cardiovascular events. Insufficient data were available for stratified or meta‐regression analyses or random effects meta‐regression. When we excluded <a href="./references#CD009297-bbs2-0002" title="AkizawaT , GejyoF , NishiS , IinoY , WatanabeY , SuzukiM , et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Therapeutic Apheresis &amp; Dialysis2011;15(5):431‐40. [MEDLINE: 21974695] AkizawaT , TsubakiharaY . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the efficacy [abstract no: SU‐PO804]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00740554] TsubakiharaY , AkizawaT . High target hemoglobin with erythropoiesis stimulating agent (ESA) in chronic kidney disease (CKD) slows the occurrence rate of events related to decline of renal function [abstract no: SA‐FC341]. Journal of the American Society of Nephrology2009;20:79A. [CENTRAL: CN‐00793981] TsubakiharaY , AkizawaT . Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the safety [abstract no: SU‐PO818]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):765A. [CENTRAL: CN‐00740542] ">Akizawa 2011</a> from analyses as this study had differing haemoglobin targets for the darbepoetin alfa and the epoetin arms, the meta‐analyses results were substantively similar. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009297-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009297-sec-0075"></div> <section id="CD009297-sec-0076"> <h3 class="title" id="CD009297-sec-0076">Summary of main results</h3> <p>In high‐quality evidence, data from one large study involving 4038 adults with diabetes and CKD stage 3 to 4 indicated that, compared to placebo, darbepoetin alfa reduced the need for blood transfusions and iron therapy but had small or uncertain effects on mortality and need for dialysis treatment. Darbepoetin alfa did not clearly increase risk of cancer or seizures, but may have worsened hypertension. Placebo‐controlled RCTs to guide darbepoetin alfa treatment in children and adults with CKD stage 5 or kidney transplantation were not available. </p> <p>Compared to epoetin, darbepoetin alfa had uncertain effects on need for blood transfusions, all‐cause and cardiovascular mortality, major cardiovascular events, hypertension, seizures and had comparable effects to epoetin for risk of dialysis vascular access thrombosis and end of treatment Hb levels. Data comparing darbepoetin alfa with epoetin on need for iron therapy and cancer were absent for adults. In children with CKD stages 4 and 5, compared to epoetin, darbepoetin alfa treatment had uncertain effects on need for blood transfusion and risk of progression to RRT, all‐cause mortality, hypertension, dialysis vascular access thrombosis, exceeding Hb target level and injection site pain as well as Hb levels during treatment. Compared with methoxy polyethylene glycol‐epoetin beta, darbepoetin alfa had similar effects on need for blood transfusions and iron therapy and uncertain effects on all‐cause and cardiovascular mortality, dialysis vascular access thrombosis and hypertension in adults. In one study, adults treated with darbepoetin alfa were less likely to achieve a prespecified Hb target than those treated with methoxy polyethylene glycol‐epoetin beta. </p> <p>In studies comparing differing dosing frequencies or routes of administration of darbepoetin alfa, compared to treatment every four weeks, darbepoetin alfa administered every two weeks in adults with CKD stage 5D had uncertain effects on need for blood transfusion and iron therapy and end of treatment Hb levels, while administration every two weeks had uncertain effects on Hb levels compared with weekly treatment. Data for patient‐level outcomes (e.g. mortality) comparing differing dosing frequencies were largely absent. Treatment effects for IV compared to SC darbepoetin alfa in adults with CKD stage 5D were inconclusive for the need for blood transfusions, as well as risks of all‐cause and cardiovascular mortality and major cardiovascular events; effects on Hb levels were similar between treatment groups. </p> </section> <section id="CD009297-sec-0077"> <h3 class="title" id="CD009297-sec-0077">Overall completeness and applicability of evidence</h3> <p>Overall, data for effectiveness of darbepoetin alfa therapy compared to placebo or other ESAs on patient‐relevant outcomes were dominated by a single placebo‐controlled study in adults with CKD stage 3 to 5 (<a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>). Evidence comparing darbepoetin alfa against placebo were not available for adults with CKD stage 5D and kidney transplant recipients as well as children with all stages of CKD. Information directly comparing darbepoetin alfa with epoetin was largely restricted to adults with CKD stage 5D and treatment effects for risks of most patient‐relevant outcomes including mortality and major cardiovascular events were uncertain. Similarly, data directly comparing treatment effects of darbepoetin alfa with the longer‐acting methoxy polyethylene glycol‐epoetin beta were limited to adults with CKD. Evidence of the effectiveness of differing dosing frequencies and routes of administration for darbepoetin alfa were restricted to adults with CKD stage 5D, with largely inconclusive results. </p> </section> <section id="CD009297-sec-0078"> <h3 class="title" id="CD009297-sec-0078">Quality of the evidence</h3> <p>Data comparing darbepoetin alfa against placebo were generally at low risk of bias within a single well‐conducted study (<a href="./references#CD009297-bbs2-0028" title="DesaiAS , TotoR , JarolimP , UnoH , EckardtKU , KewalramaniR , et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of Kidney Diseases2011;58(5):717‐28. [MEDLINE: 21820220] LewisEF , PfefferMA , FengA , UnoH , McMurrayJJ , TotoR , et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2011;6(4):845‐55. [MEDLINE: 21212421] McMurrayJJ , UnoH , JarolimP , DesaiAS , deZeeuwD , EckardtKU , et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy (TREAT). American Heart Journal2011;162(4):748‐55. [MEDLINE: 21982669] MixTC , BrennerRM , CooperME , deZeeuwD , IvanovichP , LeveyAS , et al. Rationale‐‐Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal2005;149(3):408‐13. [MEDLINE: 15864229] PfefferMA , BurdmannEA , ChenC , CooperME , deZeeuwD , EckardtK , et al. Trial to reduce cardiovascular events with Aranesp Therapy [abstract]. Circulation2010;120(21):2154‐5. [EMBASE: 70089295] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine2009;361(21):2019‐32. [MEDLINE: 19880844] PfefferMA , BurdmannEA , ChenCY , CooperME , deZeeuwD , EckardtKU , et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases2009;54(1):59‐69. [MEDLINE: 19501439] PfefferMA , TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine2007;356(9):959‐61. [MEDLINE: 17329707] SkaliH , LinJ , PfefferMA , ChenCY , CooperME , McMurrayJJ , et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases2013;61(2):238‐46. [MEDLINE: 23159232] SkaliH , ParvingHH , ParfreyPS , BurdmannEA , LewisEF , IvanovichP , et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation2011;124(25):2903‐8. [MEDLINE: 22104547] SolomonSD , UnoH , LewisEF , EckardtKU , LinJ , BurdmannEA , et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine2010;363(12):1146‐55. [MEDLINE: 20843249] ThomasMC , CooperME , RossingK , ParvingHH . Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia2006;49(6):1151‐7. [MEDLINE: 16586069] TotoR , IvanovichP , LeveyA , ParfreyPS , PereiraBJG , RemuzziG , et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU‐PO239]. Journal of the American Society of Nephrology2004;15(Oct):584A. [CENTRAL: CN‐00550766] ">TREAT Study 2005</a>) although treatment effects may not be widely applicable to patients not included in the study population (adults with diabetes and CKD stages 3 to 5). Data to assess effectiveness of darbepoetin alfa compared with epoetin or methoxy polyethylene glycol‐epoetin beta were at higher risk of bias, providing treatment effects with confidence intervals that included a range of plausible values below clinical significance or that included harm. Data comparing darbepoetin alfa with epoetin or methoxy polyethylene glycol‐epoetin beta were limited frequently by studies that selectively reported clinical outcomes, provided incomplete data during follow‐up for many patients, and did not clearly blind study personnel and patients to assigned treatment. Similarly, data comparing more versus less frequent darbepoetin alfa administration and IV with SC therapy were at generally high risk of bias, suggesting that treatment summary effects for these treatment comparisons may be less reliable. </p> </section> <section id="CD009297-sec-0079"> <h3 class="title" id="CD009297-sec-0079">Potential biases in the review process</h3> <p>While this review was conducted according to rigorous methods developed by the Cochrane Collaboration, residual bias within the review process were inevitably present. While we searched the Cochrane Renal Group's Specialised Register of studies that included grey literature sources obtained by systematic handsearching of relevant renal conference proceedings and journals, it is possible that relevant but unpublished data (those studies with neutral or negative effects) may have been missed. Analysis for evidence of such publication bias was not possible due to the small number of studies available in each meta‐analysis. Second, many studies did not prospectively and systematically collect data for patient‐relevant outcomes including mortality, need for blood transfusions, and major cardiovascular events; we cannot be sure that the outcomes in these studies were the same or similar to those in the studies that did report these outcomes and which could be included in meta‐analyses. Finally, few studies included children or kidney transplant recipients. Treatment estimates derived from studies in adults with CKD may not be applicable to these other specific populations. </p> </section> <section id="CD009297-sec-0080"> <h3 class="title" id="CD009297-sec-0080">Agreements and disagreements with other studies or reviews</h3> <p>An earlier updated systematic review published in 2010 evaluated treatment effects for epoetin alfa or beta or darbepoetin alfa versus placebo or different doses of ESAs as needed to achieve higher versus lower target Hb levels (<a href="./references#CD009297-bbs2-0093" title="PalmerSC , NavaneethanSD , CraigJC , JohnsonDW , TonelliM , GargAX , et al. Meta‐analysis: erythropoiesis‐stimulating agents in patients with chronic kidney disease. Annals of Internal Medicine2010;153(1):23‐33. [MEDLINE: 20439566] ">Palmer 2010</a>). Indirect comparisons of treatment effects for darbepoetin alfa compared with either epoetin or methoxy polyethylene glycol‐epoetin beta were not possible in this review due to insufficient data. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009297-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow chart showing number of reports retrieved by database searching and the number of studies included in this review" data-id="CD009297-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow chart showing number of reports retrieved by database searching and the number of studies included in this review </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/full#CD009297-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009297-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/full#CD009297-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009297-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/full#CD009297-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Darbepoetin versus placebo, Outcome 1 One or more blood transfusions." data-id="CD009297-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Darbepoetin versus placebo, Outcome 1 One or more blood transfusions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Darbepoetin versus placebo, Outcome 2 Need for iron therapy." data-id="CD009297-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Darbepoetin versus placebo, Outcome 2 Need for iron therapy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Darbepoetin versus placebo, Outcome 3 Progression to RRT." data-id="CD009297-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Darbepoetin versus placebo, Outcome 3 Progression to RRT.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Darbepoetin versus placebo, Outcome 4 All‐cause mortality." data-id="CD009297-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Darbepoetin versus placebo, Outcome 4 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Darbepoetin versus placebo, Outcome 5 Cardiovascular mortality." data-id="CD009297-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Darbepoetin versus placebo, Outcome 5 Cardiovascular mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Darbepoetin versus placebo, Outcome 6 Cancer." data-id="CD009297-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Darbepoetin versus placebo, Outcome 6 Cancer.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Darbepoetin versus placebo, Outcome 7 Hypertension." data-id="CD009297-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Darbepoetin versus placebo, Outcome 7 Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Darbepoetin versus placebo, Outcome 8 Seizures." data-id="CD009297-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Darbepoetin versus placebo, Outcome 8 Seizures.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Darbepoetin versus placebo, Outcome 9 Mean change in FACT‐Fatigue score." data-id="CD009297-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Darbepoetin versus placebo, Outcome 9 Mean change in FACT‐Fatigue score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Darbepoetin versus placebo, Outcome 10 Mean change in SF‐36 energy score." data-id="CD009297-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Darbepoetin versus placebo, Outcome 10 Mean change in SF‐36 energy score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Darbepoetin versus placebo, Outcome 11 Mean change in SF‐36 physical functioning score." data-id="CD009297-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Darbepoetin versus placebo, Outcome 11 Mean change in SF‐36 physical functioning score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin versus epoetin, Outcome 1 One or more blood transfusions." data-id="CD009297-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin versus epoetin, Outcome 1 One or more blood transfusions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin versus epoetin, Outcome 2 Progression to renal replacement therapy." data-id="CD009297-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin versus epoetin, Outcome 2 Progression to renal replacement therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin versus epoetin, Outcome 3 All‐cause mortality." data-id="CD009297-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin versus epoetin, Outcome 3 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin versus epoetin, Outcome 4 Cardiovascular mortality." data-id="CD009297-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin versus epoetin, Outcome 4 Cardiovascular mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin versus epoetin, Outcome 5 Major cardiovascular events." data-id="CD009297-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin versus epoetin, Outcome 5 Major cardiovascular events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin versus epoetin, Outcome 6 Hypertension." data-id="CD009297-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin versus epoetin, Outcome 6 Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin versus epoetin, Outcome 7 Seizures." data-id="CD009297-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin versus epoetin, Outcome 7 Seizures.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin versus epoetin, Outcome 8 Vascular access thrombosis." data-id="CD009297-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin versus epoetin, Outcome 8 Vascular access thrombosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin versus epoetin, Outcome 9 Exceeded Hb target ≥1 episodes." data-id="CD009297-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin versus epoetin, Outcome 9 Exceeded Hb target ≥1 episodes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin versus epoetin, Outcome 10 Injection site pain." data-id="CD009297-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin versus epoetin, Outcome 10 Injection site pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin versus epoetin, Outcome 11 End of treatment Hb." data-id="CD009297-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin versus epoetin, Outcome 11 End of treatment Hb.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin versus epoetin, Outcome 12 Mean change in Hb." data-id="CD009297-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin versus epoetin, Outcome 12 Mean change in Hb.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 1 One or more blood transfusions." data-id="CD009297-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 1 One or more blood transfusions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 2 Need for iron therapy." data-id="CD009297-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 2 Need for iron therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 3 All‐cause mortality." data-id="CD009297-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 3 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 4 Cardiovascular mortality." data-id="CD009297-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 4 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 5 Vascular access thrombosis." data-id="CD009297-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 5 Vascular access thrombosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 6 Hypertension." data-id="CD009297-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 6 Hypertension. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 7 Achieved Hb target." data-id="CD009297-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 7 Achieved Hb target. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 8 End of treatment Hb." data-id="CD009297-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin versus methoxy polyethylene glycol‐epoetin beta, Outcome 8 End of treatment Hb. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Darbepoetin every 2 weeks versus every 4 weeks, Outcome 1 One or more blood transfusions." data-id="CD009297-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Darbepoetin every 2 weeks versus every 4 weeks, Outcome 1 One or more blood transfusions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Darbepoetin every 2 weeks versus every 4 weeks, Outcome 2 Need for iron therapy." data-id="CD009297-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Darbepoetin every 2 weeks versus every 4 weeks, Outcome 2 Need for iron therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Darbepoetin every 2 weeks versus every 4 weeks, Outcome 3 End of treatment Hb." data-id="CD009297-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Darbepoetin every 2 weeks versus every 4 weeks, Outcome 3 End of treatment Hb. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Darbepoetin weekly versus every 2 weeks, Outcome 1 End of treatment Hb." data-id="CD009297-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Darbepoetin weekly versus every 2 weeks, Outcome 1 End of treatment Hb.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Darbepoetin intravenous versus subcutaneous administration, Outcome 1 One or more blood transfusions." data-id="CD009297-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Darbepoetin intravenous versus subcutaneous administration, Outcome 1 One or more blood transfusions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Darbepoetin intravenous versus subcutaneous administration, Outcome 2 All‐cause mortality." data-id="CD009297-fig-0040" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Darbepoetin intravenous versus subcutaneous administration, Outcome 2 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Darbepoetin intravenous versus subcutaneous administration, Outcome 3 Cardiovascular mortality." data-id="CD009297-fig-0041" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Darbepoetin intravenous versus subcutaneous administration, Outcome 3 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Darbepoetin intravenous versus subcutaneous administration, Outcome 4 Major cardiovascular events." data-id="CD009297-fig-0042" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Darbepoetin intravenous versus subcutaneous administration, Outcome 4 Major cardiovascular events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Darbepoetin intravenous versus subcutaneous administration, Outcome 5 End of treatment Hb." data-id="CD009297-fig-0043" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Darbepoetin intravenous versus subcutaneous administration, Outcome 5 End of treatment Hb. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009297-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/urn:x-wiley:14651858:media:CD009297:CD009297-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_t/tCD009297-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Darbepoetin intravenous versus subcutaneous administration, Outcome 6 Mean change in Hb." data-id="CD009297-fig-0044" src="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Darbepoetin intravenous versus subcutaneous administration, Outcome 6 Mean change in Hb. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/media/CDSR/CD009297/image_n/nCD009297-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD009297-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Darbepoetin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 One or more blood transfusions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Need for iron therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Progression to RRT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mean change in FACT‐Fatigue score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mean change in SF‐36 energy score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mean change in SF‐36 physical functioning score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Darbepoetin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009297-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Darbepoetin versus epoetin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 One or more blood transfusions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.35, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.14, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression to renal replacement therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.27, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.84, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.03, 8.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.07, 3.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Major cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.06, 12.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.93, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.42, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.31, 4.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Vascular access thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.63, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 4.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Exceeded Hb target ≥1 episodes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.57, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Injection site pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.50, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 End of treatment Hb <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Adults ‐ different haemoglobin target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.84, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Adults ‐ same haemoglobin target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.27, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mean change in Hb <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.08, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [‐0.47, 0.91]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Darbepoetin versus epoetin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009297-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Darbepoetin versus methoxy polyethylene glycol‐epoetin beta</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 One or more blood transfusions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.58, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Need for iron therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.97, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.53, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.17, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Vascular access thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.43, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.52, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Achieved Hb target <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.33, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 End of treatment Hb <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.23, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Darbepoetin versus methoxy polyethylene glycol‐epoetin beta</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009297-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Darbepoetin every 2 weeks versus every 4 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 One or more blood transfusions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Need for iron therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 End of treatment Hb <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Darbepoetin every 2 weeks versus every 4 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009297-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Darbepoetin weekly versus every 2 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 End of treatment Hb <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Darbepoetin weekly versus every 2 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009297-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Darbepoetin intravenous versus subcutaneous administration</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 One or more blood transfusions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.30, 4.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.32, 5.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.30, 4.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Major cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.23, 7.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 End of treatment Hb <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.34, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mean change in Hb <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.32, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Darbepoetin intravenous versus subcutaneous administration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009297.pub2/references#CD009297-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009297.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009297-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009297-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009297-note-0001">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009297\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009297\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009297\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009297\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009297\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009297.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009297.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009297.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009297.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009297.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728481034"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009297.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728481038"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009297.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec5869e6f9367',t:'MTc0MDcyODQ4MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 